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Zusammenfassung 
Chronische Nierenerkrankungen sind mit steigender Morbidität und Mortalität weltweit verbunden. 
Unabhängig von der Ätiologie sind alle Nierenschädigungen, die zu irreversiblen Nephronverlusten 
führen, mit Nierenfibrose assoziiert. Das NLRP3 Inflammasom ist ein Multiprotein-Komplex, der 
die Erkennung von Selbst- und Nicht-Selbst-Gefahrensignale vermittelt und diese in die Freisetzung 
von Interleukinen übersetzt, was wesentlich zu entzündungs Reaktionen beiträgt. Allerdings haben 
neuere Studien gezeigt, dass die NLRP3 Komponente auch andere Inflammasom-unabhängige (d.h. 
nicht IL-1β- oder IL-18-abhängige) Funktionen ausüben kann, insbesondere bei der Regulierung des 
TGF-β Signalwegs. Wir postulierten, dass NLRP3 eine wichtige Rolle bei der Entwicklung der 
renalen interstitiellen Fibrose spielt, indem es den TGF-β Signalweg reguliert. 
Unsere in vivo Experimente im Modell der einseitigen Ureterobstruktion (UUO) zeigten, dass die 
Caspase-1 (Casp-1) Inhibition die Mäuse vor der renalen interstitiellen Fibrose im Vergleich zu 
Nlrp-3-defizienten Mäusen nicht schützt. Eine zweite in vivo Studie mit Hyperoxalurie-induzierter 
chronischer Niereninsuffizienz verdeutlichte, dass die Hemmung des IL-1 Rezeptors mit Anakinra 
keine große Bedeutung bei der Oxalat-induzierten Nephropathie spielt. Die genaue Rolle des NLRP3 
oder ASC in diesem Model konnte nur eingeschränkt beurteilt werden, da Nlrp-3- sowie Asc-
defiziente Mäuse keine intrarenalen Kalziumoxalat Kristalle entwickelten. Zusätzlich zeigte das 
UUO in vivo Modell eine reduzierte Phosphorylierung von Smad 2/3 bei Nlrp3 Defizienz, was 
darauf hindeutet, dass NLRP3 die Signalübertragung des TGF Rezeptors durch Regulierung der 
Smad 2/3 Phosphorylierung erhöht. Ferner konnten in vitro Experimente mit embryonalen Maus 
Fibroblasten verdeutlichen, dass NLRP3 die Proliferation und Aktivität dieser Zellen stark reguliert, 
dies allerdings unabhängig von der Sekretion von Interleukinen erfolgt.  
Diese Arbeit zeigt, dass NLRP3 die renale interstitielle Fibrose beim renalen Gewebsumbau und  
chronischer Niereninsuffizienz durch die Verstärkung des TGF Rezeptor Signalwegs unabhängig 
von Casp-1-vermittelter IL-1β Freisetzung fördert. 
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Summary 
Chronic kidney disease (CKD) is associated with increasing morbidity and mortality worldwide. 
Regardless of the etiology, all kidney injuries that lead to irreversible nephron loss are associated 
with renal fibrosis. The NLRP3 inflammasome is a multiprotein-complex, which translates self and 
non-self danger signals for the activation and release of IL-1β and IL-18, contributing significantly to 
inflammatory responses. However, recent studies have shown that the NLRP3 component also exerts 
other inflammasome-independent (i.e. IL-1β- or IL-18-independent) functions, especially in 
regulating TGF-β signaling. We postulated that NLRP3 plays an important role in the development 
of renal interstitial fibrosis by regulating TGF-β signaling in an inflammasome-independent manner.  
Our in vivo experiments using the unilateral ureteral obstruction (UUO) mouse model showed that 
Caspase-1 (Casp-1) inhibition does not protect mice from renal interstitial fibrosis compared to Nlrp-
3-deficient mice. A second in vivo study using a chronic hyperoxaluria-induced CKD model showed 
that inhibition of the IL-1 receptor with anakinra does not protect mice from nephrocalcinosis-
induced CKD, whereas Nlrp-3- and Asc-null mice were unable to develop intrarenal calcium oxalate 
crystals, compromising any conclusions regarding the role of NLRP3 in nephrocalcinosis-induced 
CKD. The UUO in vivo model showed a reduced phosphorylation of SMAD 2/3 upon Nlrp-3 
deficiency, suggesting that NLRP3 augments TGF-β receptor signaling by regulating SMAD 2/3 
phosphorylation. Furthermore, in vitro studies using mouse embryonic fibroblasts revealed that the 
inflammasome component NLRP3 regulates fibroblast activation, function and proliferation, and that 
this is independent of the release and activation of IL-1β.  
Taken together, this thesis demonstrates that the inflammasome component NLRP3 drives renal 
fibrogenesis and tissue remodeling in CKD by augmenting TGF receptor signaling independent of a 
Casp-1-mediated interleukin release.  
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1. Introduction  
1.1 Chronic Kidney Disease 
 
1.1.1 Definition and epidemiology   
Definition: Kidney Disease: Improving Global Outcomes (KDIGO) defines chronic kidney disease 
as abnormalities of kidney structure or function present for over three months with implications for 
health [4]. These abnormalities encompass increased albuminuria, urine sediment or histological 
irregularities, electrolyte and acid-base disorders, imaging abnormalities (as marker of kidney 
damage) or decreased Glomerular Filtration Rate (GFR) (< 60 ml/min/1.73m2). The latter is the best-
known parameter for estimating kidney function. It declines from 125 ml/min/1.73m2 starting from 
the third decade of age at an approximate of 1 ml/min/1.73m2 per year in healthy adults, thus leading 
to CKD stage G1 or G2 in the older population. KDIGO refers to a GFR under 60 ml/min/1,73m2 as 
decreased, whereas a GFR under 15 ml/min/1,73m2 is considered as kidney failure, reflecting a state 
of End Stage Renal Disease (ESRD) [4].  
Epidemiology: CKD and its complications have increasingly contributed to the morbidity and 
mortality in industrialized and developing countries. In the U.S. 4 to 5% of the adult population has 
CKD stages G4 to G5 [3]. Between 2007 and 2012 a study called NHANES was performed in the 
U.S., which revealed a total of 13.6% prevalence of CKD in patients with 20 years of age and older. 
Also, the number of patients with CKD stage G3 increased from 4.5% to 6.0% in 10 years [5]. In 
Germany, 175 out of one million people have ESRD and the incidence increases 3 to 5% every year 
[6]. It is also one of the most expensive diseases for the health-care system with costs of up to 500 
million Euros (2002) for patients between 65 and 85 years of age. This number significantly 
expanded in 2008 to an approximate of 724 million Euros [7], defining CKD as one of the most 
expensive non-communicable chronic diseases that involve a significant reduction of lifespan. The 
increased incidence of CKD in industrialized countries is mainly a result of improved 
cardiovascular-disease management and survival rates of the population [3]. On the other hand, 
ESRD has not changed its incidence in these countries, probably because of the improved 
management possibilities. However, developing countries show a rising trend in the development of 
both CKD and ESRD. This is expected to increase dramatically in the next two decades [8]. Overall, 
epidemiological studies signalize the growing importance of CKD worldwide and the need for 
improved and more economical strategies in the management of the disease.   
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1.1.2 Etiology and Classification  
Etiology: Diabetic nephropathy, glomerulonephritis, hypertensive nephropathy (as primary 
glomerulonephritis with hypertension or vascular and ischemic renal disease), diverse congenital 
anomalies of the kidney and urinary tract (CAKUT) and tubulointerstitial nephropathies are the most 
frequent causes of CKD in Germany (Figure 1). This distribution varies worldwide depending on the 
geographic region. Still, diabetic nephropathy remains the leading cause in both industrialized and 
developing countries, mainly secondary to type 2 diabetes mellitus [3].  However, the number of 
people with CKD not secondary to diabetes or hypertension is significantly higher in developing 
countries, especially in younger patients. One study from 2007 revealed 43% of CKD patients in 
China, Mongolia, and Nepal did not have diabetes or hypertension [9]. Other factors affecting 
developing countries such as poor nutrition during pregnancy, result in low nephron number in the 
fetus, increasing the risk for CKD development later in life [10]. 
Among the highest risk factors for the development, progression and worsening of CKD today are 
hypertension, diabetes mellitus, older age, smoking, metabolic syndrome, prolonged treatment with 
nephrotoxic drugs, family history for CKD and acute kidney injury (AKI) in the past medical history 
[11]. Genetic factors like the presence of the APOL1 gene in CKD patients with African ancestries 
have shown higher rates for progression of kidney disease and development of ESRD [12].  
 
 
 
 Figure 1: Adapted from Daten und Fakten zur Nephrolgie (DGFN) [6] 
Etiology of CKD in Germany 
Diabetic nephropathy  (40%)
Glomerulonephritis (13%)
congenital anomalies of the kidney and 
urinary tract  (CAKUT)(6%)
Vascular (hypertensive) nephropathy 
(20%)
Chronic tubulointerstitial disease 
(10%)
Others (10%)
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Classification: The CKD classification is based on cause, GFR category (G1 to G5) and albuminuria 
category (A1 to A3). Due to recent evidence, both categories were combined and used for the 
prediction of disease progression and prognosis [4].  
 
1.1.3 Clinical features and complications  
Kidneys are multifunctional organs, responsible for the elimination of metabolites and toxins, water 
and electrolyte balance, acid-base homeostasis, regulation of the hematopoietic (erythropoietin 
secretion) and cardiovascular system (angiotensin II and prostaglandin regulation), bone-
mineralization homeostasis (calcitriol formation) and arterial blood pressure control, taking a pivotal 
role in the function of almost every organ system in the body [3, 13]. 
Interestingly, patients with an early stage of the disease (CKD G1 to 3) are generally asymptomatic. 
They may present with unspecific symptoms such as fatigue, sleep disturbances, hypertension or 
decreased urine output. In most cases, the underlying pathology is the key symptomatic feature (e.g. 
systemic manifestations of type 2 diabetes mellitus, arterial hypertension or lupus erythematosus). 
Patients with advanced stages of CKD (G4 to 5) may present with diverse signs and symptoms 
including metabolic or endocrine derangements (e.g. anemia), signs of acid-base dysbalance (e.g. 
malnutrition and muscle weakness), water and electrolyte disturbances (e.g. edema and hypertension 
due to fluid overload), and many others. Patients with kidney failure or ESRD present with a wide 
group of symptoms that reflect the presence of uremia. It results mostly from the accumulation of 
internal and external toxins, the inability to regulate the endocrine system, acid-base and fluid 
homeostasis disturbances, and the progressive and systemic inflammation with subsequent vascular 
and nutritional consequences. Table 1 shows clinical manifestations of this syndrome in different 
organ systems [3]. The clinical manifestations of uremia have almost disappeared among European 
countries mainly due to the growing implementation of renal replacement therapies such as chronic 
dialysis and renal transplantation. Nevertheless, not all symptoms are ameliorated by dialysis.  Many 
of them persist and worsen during this procedure, while others appear as a consequence of the 
treatment itself.   
Conceptual model of CKD: For a better understanding of CKD with its risk factors, progression 
and complications, a conceptual model was developed by the KDOQI in 2002, later modified by 
KDIGO 2012. This displays in a simplified diagram the continuous development, progression and 
complications of CKD, which serves as a guideline in disease prevention programs of the public 
health care system (Figure 2). 
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Complications of CKD: Kidney malfunction implies systemic complications. Commonly, patients 
with advanced stages of CKD present with metabolic acidosis, hyperkalemia, calcium and phosphate 
disturbances and respective bone and cardiovascular complications, including low turnover and high 
turnover hyperparathyroidism (starting from a GFR < 60 ml/min/1.73m2). The cardiovascular 
complications as well the significantly higher risk for infections are the leading causes of morbidity 
and mortality in patients with CKD [14]. 
  
         
Figure 2: Conceptual model of CKD. Adapted from KDIGO 2012 [4].  Blue: potential antecedents of CKD; red: stages 
of CKD; purple: consequences of CKD; thick arrows: left to right: development and progression of CKD, white right to 
left arrows: remission (less frequent than progression). Abb.: GFR: Glomerular filtration rate.  
 
 
 
Table 1: Clinical manifestations of uremia 
Organ system Symptoms 
Fluid, electrolyte, 
and acid-base Volume expansion, hyperkalemia, hyperphosphatemia. 
Endocrine – 
metabolic 
Secondary hyperparathyroidism, a-dynamic bone, Vitamin-D deficient osteomalacia, 
carbohydrate resistance, hyperuricemia, hypertriglyceridemia, decreased HDL, 
protein-energy malnutrition, infertility and sexual dysfunction, amenorrhea, 
amyloidosis. 
Cardiovascular Arterial hypertension, pericarditis, uremic lung, accelerated atherosclerosis, hypotension and vascular calcifications. 
Hematologic and 
immunologic 
Anemia, lymphocytopenia, bleeding diathesis, increased susceptibility to infection, 
thrombocytopenia. 
Gastrointestinal and 
nutritional Nausea, vomiting, peptic ulcer and gastrointestinal bleeding, ascites, peritonitis. 
Neuromuscular 
 Fatigue, sleep disorders, lethargy, muscular irritability, myopathy. 
Dermatological Pallor, hyperpigmentation, pruritus, uremic frost. 
Adapted from Harrisons: Principles of Internal Medicine [3] 
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1.2 Pathophysiology  
 
Nephrons are the functional units of the kidney and work in a defined and organized manner. Neal 
Bricker’s 1969 intact nephron hypothesis describes from a functional perspective, how surviving 
nephrons either function normally or do not function at all [15]. When an injurious trigger causes 
relevant damage to the kidney parenchyma with significant nephron loss, adaptive mechanisms of 
the remaining nephrons activate and lead to their “hyperfunction” and progressive hypertrophy with 
the aim of compensating the lost functionality. Such mechanism can be observed in patients who 
undergo unilateral nephrectomy, where the remaining kidney is able to regain the function by rising 
the GFR up to 80% of the normal population with two kidneys and show a hypertrophic parenchyma 
[15]. This initial adaptive response involving nephron hyperfunction and hypertrophy can become 
from a certain point maladaptive, leading to disease progression and CKD, especially with ongoing 
kidney injury like in chronic glomerulonephritis or with persistent proteinuria. 
From a molecular perspective, CKD pathology is mostly a product of the deregulation of the four 
“danger response programs”; these include hemostasis, inflammation, epithelial- and mesenchymal 
healing [16]. They are responsible for regaining tissue structure and function after any kind of injury. 
In most cases, nature has achieved an adequate balance between these mechanisms. Occasionally 
these act in a dysregulated manner, being either insufficient or overshooting [16, 17].  
Certainly, whether glomerular, vascular or tubulointerstitial, continuous injury to the kidney will 
almost always lead to interstitial nephritis, a product of overshooting inflammation. In diabetic and 
hypertensive nephropathy, for example, the intraglomerular capillary pressure rises, increasing the 
single nephron GFR. The activated renin-angiotensin-aldosteron system also known as RAAS, and 
concomitant elevation of angiotensin II further worsen the scenario by constricting the efferent 
arteriole, reducing glomerular filtration selectivity, inducing protein ultrafiltration and increasing 
shear stress for podocytes. The elevated concentration of proteins in the ultrafiltrate induces its 
uptake in the proximal convoluted tubule cells via megalin/cubulin into the lysosomes [18], 
disturbing cell homeostasis and activating them to secrete proinflammatory cytokines such as 
interleukin 6 (IL-6), IL-8, among others [18, 19]. The released cytokines stimulate resident immune 
cells such as macrophages and dendritic cells (DCs), which in turn augment the reaction by 
recruiting additional mononuclear cells, sustaining the inflammatory process [20]. The exaggerated 
and continuous inflammation persists as long as the injurious trigger is not removed. Interstitial 
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nephritis, oxidative stress, and cytokines damage tubular cells, resulting in an epithelial imperfection 
that hardly recovers, especially under these conditions.  
Mesenchymal cells, namely activated fibroblasts from the interstitial compartment, will then try to 
cover up the defect by producing extracellular matrix (ECM) components such as collagen I and III, 
leaving eventually an acellular scar, which when overshooting results in interstitial fibrosis [21]. This 
pathological feature is the hallmark of advanced CKD, which further aggravates the organ 
architecture destruction and function impairment, and is thus thought to worsen the prognostic 
outcome of the disease [22]. Figure 3 displays a schematic presentation of the pathomechanisms 
leading to CKD. The following chapters will carefully describe the molecular mechanisms regarding 
interstitial nephritis and mesenchymal healing leading to CKD. 
  
15 
 
                
 
 
 
Figure 3: Pathomechanisms leading to CKD. Glomerular, vascular and tubulointerstitial injuries lead to interstitial 
nephritis. Damaged tubular cells (green) release cytokines, activating resident immune cells (DCs, neutrophils and 
macrophages) who recruit additional immune cells and release proinflammatory (IL-6, IL-1) and profibrotic cytokines 
(TGF-β). Disease chronification enhances progressive nephron loss and leads to overshooting activation of fibroblasts 
and therefore the mesenchymal healing process, leading to renal interstitial fibrosis. Abb.: DCs: dendritic cells; IL-1, 
IL-6: interleukin 1 and 6; TGF-β: transforming growth factor β, TNF: tumor necrosis factor, MCP1: monocyte 
chemoattractant protein 1.  
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1.3 The innate immune system  
 
Humans possess two types of immune system: the innate or unspecific and the adaptive or specific 
immunity. Both systems consist of soluble molecules and cells that act against invading 
microorganisms. The innate immunity is found in both vertebrates and invertebrates, and it is 
characterized as a rather unspecific and ancient defense system. The adaptive system, on the other 
hand, is only found in more evolved organisms such as jawed fish and mammals and is characterized 
for being a rather specific and more evolutionary recent mechanism [23]. In vivo, both systems act 
together in the immune response. The following mechanisms are required for a proper and accurate 
response: (1) recognition of the danger signal/microorganism, (2) elimination of the injurious agent, 
(3) regulation of the immune response and (4) gain of memory. The regulatory and memory 
functions are mainly achieved by the adaptive immunity [24]. Innate immunity recognizes a large 
number of pathogens but not in a specific manner like the adaptive immune response does. 
Nevertheless, specific recognition requires more time and implies a delayed response. This is 
counteracted by the innate immune system, which is capable of acting instantly against entering 
invaders. Table 2 shows some of the principal differences between innate and adaptive immunity. 
 
Table 2: Main differences between innate and adaptive immunity 
 Innate Adaptive 
Specificity Limited Same response for a variety of agents 
Wide 
Response only to stimulating agent 
Protagonists Mononuclear phagocytic  system Granulocytes (neutrophils, basophils) T- and B-lymphocytes  
Reaction Immediate Delayed 
Immune 
response 
Phagocytosis  
Co-stimulating molecules: cytokines IL-6, IL-1 
Clonal expansion (IL-2) 
Effector cytokines (IFN-γ, IL-4) 
Receptors PRRs, invariant, germline encoded 
T-cell receptor, B-cell receptor, 
somatic gene encoded; rearrangement, 
diversity extended to a wide range of 
receptors 
Recognition Conserved molecular patterns (LPS) Structural unities (peptides, carbohydrates) 
Memory Absent, same response for subsequent exposure. Non-anticipatory 
Present, amplified responses for 
subsequent exposure.  
Anticipatory 
Adapted from Janeway, C.A, et al. Abb.: PRRs: pattern recognition receptors, LPS: lipopolysaccharide, IL: interleukin, 
IFN: interferon   [25] 
  
17 
 
After pathogens cross the physical barriers (skin, epithelial respiratory, gastrointestinal and 
urogenital tract), chemical barriers (gastric acid with low pH and vaginal secretions) and biological 
defense barriers (bactericide lysozyme in mucosal secretion), innate immunity awaits as first line 
host defense to prevent their further propagation [26, 27]. Cells of the innate immunity include 
monocytes, tissue macrophages and their precursors (Langerhans cells, mesangium cells of the 
kidney and microglia) [28], recognize pathogens via specific molecular patterns named Pathogen-
associated molecular patterns or PAMPs using specific receptors called Pattern recognition 
receptors or PRRs. Upon recognition, cells eliminate the invading agent through instant mechanisms 
such as phagocytosis, where pathogens are “eaten” by neutrophils or monocytes/macrophages and 
killed in endosomes with the help of nitric oxide (NO), oxygen radicals (O2-), hydrogen peroxide 
(H2O2) and other toxic agents. Following activation, these cells induce the recruitment of further 
inflammatory cells by secreting proinflammatory cytokines (IL-1β, IL-6, monocyte chemotactic 
protein 1 (MCP-1)), chemokines, complement factors and antimicrobial peptides, thus amplifying the 
immune response [29, 30]. Furthermore, antigen presenting cells (APC) such as DCs introduce the 
pathogen to T-lymphocytes and thereby, activating the adaptive immune system [27]. Table 3 
describes the main components of the innate immune system and their functions. 
This response is what we call inflammation. It may manifest in any organ, either locally (e.g. an 
abscess of the skin), or systemically (e.g. as in sepsis). All organs possess resident immune cells, and 
the kidney is not an exception. Under homeostatic conditions, resident DCs localized mainly in the 
renal interstitium are strongly implicated in the development of interstitial nephritis by secreting 
cytokines and chemokines that recruit neutrophils; macrophages on the other hand, are found mainly 
in the medulla and cortex crucial for keeping tissue homeostasis and repair; and finally a few 
lymphocytes, whose function under normal conditions is still not fully understood [31-34].  
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Table 3: Main components of the innate immune system and their main function 
  System Characteristics Function 
Cells  
Monocytes and  macrophages,  
 
Phagocytosis, antimicrobial peptides; secretion 
of inflammatory cytokines (IL-1β, IL-6) 
NK-cells, dendritic cells (DCs)  
 
NK-cells: cellular toxicity 
DCs: part of the adaptive immune system, but 
play a key role in innate immunity as APC. 
Strong producers of IFN-γ, IL-12 
Granulocytes (neutrophils, 
eosinophiles, basophiles)  
 
Phagocytose and kill bacteria, produce 
antimicrobial peptides 
Mast cells 
 
Release TNF-α, IL-6, IFN-γ in response to 
PAMPs 
Epithelial cells 
 Production of  mediators local innate immunity 
Humoral 
(proteins) 
Complement system (C3b, C5a, C7, 
C9), IFN (alpha, beta, gamma), 
cytokines (IL, TGF, TNF), pentraxins 
(CRP), collectins  
Complement: opsonization, kill pathogens, 
lymphocyte activation. 
IFNs and cytokines: activation of immune cells, 
response magnification.  
Pentraxins: acute phase reaction.  
Antimicrobial 
peptides 
α- and β- defensins, granulysin, 
secretory leukoprotease inhibitor 
Disruption of membrane integrity of pathogens 
and other mechanisms 
Adapted from Janeway C.A. et al. and Turvey S.E. et al. Abb.: IFN: Interferon, IL: Interleukin, NK-cells: natural killer 
cells, APC: antigen presenting cells, DCs: dendritic cells, TNF: tumor necrosis factor, PAMPs: pathogen-associated 
molecular patterns, IFNs: interferons [24, 35]. 
 
 
1.3.1 The role of pattern recognition receptors in PAMP and DAMP recognition 
Recognition of the pathogen/danger signal is essential for an optimal immune response.  Charles 
Janeway first proposed in the late 90’s that innate immunity uses specific tools for danger 
recognition. He suggested that the unspecific innate immune system actually uses specific germ-line 
encoded PRRs, which can detect bacteria, viruses and other invaders in form of  PAMPs [36]. The 
following section describes each part of the recognition system of the innate immunity.  
PAMPs: Pathogen-associated molecular patterns are conserved molecular patterns throughout 
evolution, essential for the survival of microorganisms. Host cells do not express these molecular 
patterns, allowing automatically a self/non-self discrimination by the innate immune system [37]. 
PAMPs are the pathogens’ signature, allowing the innate immune system to differentiate which kind 
of pathogen (bacterial, fungal or parasite) is present at the site of infection. Through this, the innate 
immunity may recognize a wide range of microorganisms and danger signals, in a reasonably 
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specific manner using only a limited number of germ-line encoded receptors, as opposed to the 
adaptive immunity, which constantly renews the genome that encodes the receptor [38, 39].  
Damage-associated molecular patterns or DAMPs: Immunology was dominated by the self/non-
self theory since the 1950’s. In 1994, Polly Matzinger proposed a novel theory, “the danger theory”, 
which explained how the immune system is more concerned about “danger” or “no danger”, rather 
than self/non-self [40]. This theory introduced the term DAMP “Danger-associated molecular 
patterns”, which covers what we understand as a danger or alarm signal produced by the organism 
itself. They can be constitutively expressed or induced; located in the intracellular space (ICS) or 
secreted to the extracellular space (ECS), or part of the ECM. When cells undergo programmed cell 
death, for example, such as apoptosis, cell detritus is scavenged by the remaining living cells 
annexed to it. This is a process that constantly takes place in the gut mucosa and does not lead to the 
activation of the immune response. Necrosis, on the other hand, is also a form of programmed cell 
death, but instead, leads to the release of intracellular material to the ECM. The surrounding cells 
recognize the residuals of the diseased cell and translate them into danger signals, thus inducing an 
immune response. Nucleotides (ATP, UTP) and other hydrophobic molecules such as oxidized LDL, 
β-defensin, protein A, and fibronectin, which are found normally in the ICS, alarm and activate the 
immune system when released to the ECS [40, 41].  Situations like cell stress, necrosis, and allograft 
implantation, promote DAMP release and induce sterile inflammation. Among the most studied 
DAMPs are proteins such as high mobility group box 1 (HMGB-1) or S100 localized to the 
cytoplasm, heat shock proteins (HSP) in endosomes, hyaluronic acid products from the ECM, 
mitochondrial products as mtDNA, mitochondrial reactive oxygen species (ROS), and many others 
[42-44]. Figure 4 shows a schematic representation of different PAMPs and DAMPs together with 
their receptors and expression within the cell. 
PRRs: Almost every cell of the innate immune system uses PRRs for the recognition of pathogens. 
Several types of these receptors have been described over the past few years. They are localized in 
different cell compartments, some being membrane bound, others in the cytosol, and others in the 
ECS. Toll like receptors (TLRs) are a good example of PRRs. Their discovery in the late 1990’s 
reassured Janeway’s theory and changed science’s perception of an “unspecific” innate immune 
system. Till then, innate immunity was known for its antigen-presenting function and phagocytosis 
system managed by the adaptive immunity. To date, many TLRs have been discovered and classified 
depending on the activating ligand; these may be self or non-self, soluble or membrane bound. In 
humans, 13 different types of TLRs (2–10) have been described. These transmembrane proteins can 
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recognize DAMPs and PAMPs, which may consist of proteins, carbohydrates, nucleotide acids, or 
other structures. TLR-4, for example, binds PAMPs such as bacterial LPS or DAMPs such as 
HMGB1 or HSPs. Ligand-receptor complex triggers a downstream signaling cascade, including the 
activation of MyD88, which then activates and recruits a series of proteins that further can activate 
the transcription factor NF-kB [45, 46]. NF-kB, a well-known transcription factor in the innate 
immune system, promotes the transcription of multiple cytokines such as interleukins, interferons 
(IFNs), tumor necrosis factor (TNF), MCP-1 and many others, depending on the triggering stimulus 
and the type of cell [47]. On the other hand, extracellular, soluble PRRs like pentraxins (a family of 
multimeric PRRs) have a completely different mechanism. C-reactive protein (CRP) and serum 
amyloid protein are both short pentraxins released from the liver as acute phase proteins and are 
widely used as clinical parameters for infection diagnostics. They act as receptors, effectors, and 
modulators almost simultaneously. PTX3, part of the long pentraxin family, is released from 
endothelial and inflammatory cells upon inflammation [48]. Table 4 describes different PRRs, 
together with their ligands, expression and function [49, 50]. This thesis focuses on the cytosolic 
NOD-like receptors (NLRs). Their discovery and especially the formation of the NLRP3 
inflammasome have been of great interest to the scientific community and will be discussed in the 
next chapter. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
21 
 
Table 4: Pattern recognition receptors  
PRR Family Sites of expression Examples 
Ligands 
(PAMP/DAMP) Functions of PRR 
Toll-like 
receptors 
(TLR) 
Multiple cells TLR 2-10 LPS, LTA, HMGB1  
Activate innate immune cells 
and initiate adaptive immune 
response 
C-type 
lectin (CLR) 
Plasma, 
macrophages, 
DCs, NK cells 
Dectin-1 
Macrophage 
mannose 
receptor 
 
Bacterial 
mannose, fungal β 
glucan 
Opsonization of bacteria and 
virus, activation of 
complement. Inhibits killing 
host cells expressing HLA and 
self-peptides 
Scavenger 
receptors Macrophages 
Scavenger 
receptors 
Bacterial cell 
walls Phagocytosis of bacteria 
Pentraxins Plasma  
CRP 
Serum 
amyloid P 
Phosphatidyl-
choline, bacterial 
cell walls 
Opsonization of bacteria, 
activation of complement 
Integrins Macrophages, DCs, NK-cells 
CD11b,c; 
CD18 LPS 
Signals cells, activates 
phagocytosis 
NOD-like 
receptors 
(NLRs) 
Innate cells AIM2, NLRP3 Crystals, A-toxin 
Cytosolic proteins involved in 
innate sensing (self/non-self) 
RIG-I-like 
receptors  
(RLRs) 
Myeloid cells, 
epithelial cells,  
RIG-I, 
MDA 5 Viral RNA  
IFN-1 production, activation of 
innate immunity and infection 
control  
 Adapted from [1-3]. Abb.: LPS: lipopolysaccharide, LTA: lipoteichoic acid, HMGB 1: high-mobility group box 1, HLA: 
human leukocyte antigen, DCs: dendritic cells, NK-cells: natural killer cells, CRP:c-reactive protein, CD: cluster of 
differentiation, AIM2: absent in melanoma 2, MDA 5:  melanoma differentiation-association, RNA: ribonucleic acid, 
IFN-1: interferon-1.  
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Figure 4: PAMPs and DAMPs with receptors. Pattern recognition receptors and ligands (PAMPs or DAMPs). 
Depicted are: Extracellular PRRs CRP and PTX3; Toll-like receptors: TLR-2,-3 and -4 with respective ligands LTA 
and the DAMP HMGB1, dsRNA and LPS; C-type lectins: dectin-1 and mannose receptor with respective ligands: 
fungal β glucan and mannose; Nod-like receptors: NLRP3 with crystals as respective ligands; RIG-I like receptors: 
RIG I with respective ligand viral dsRNA. Schematic representation of TLR-4 signaling pathway (left) with activation 
of TIRAP and TRAF and further gene transcription. Abb.: PAMPs: Pathogen-associated molecular patterns, DAMPs: 
Danger-associated molecular patterns, CRP: C-reactive protein, PTX3: pentraxin 3; TLR: Toll like receptor; LTA: 
lipoteichoic acid, LPS:lipopolysaccharide, HMGB1: High-mobility group box 1; dsRNA: double strand ribonucleic 
acid; NLRP3: NOD-like receptor protein 3. 
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1.3.2 NOD-like receptors and the inflammasome  
Nucleotide-binding oligomerization domain (NOD)-like receptors are evolutionarily conserved 
receptors, present in plants and animals (zebra fish) as R genes [51]. The NLR family consists of 22 
proteins in humans and 33 in mice. Their main functions are regulation of cell death, inflammation 
and innate immune responses, and are mainly expressed in innate immune cells, e.g. DCs, 
macrophages and neutrophils, as well as in tissue epithelia of the gut, heart, liver, and kidney.  
These protein receptors are built of a tripartite structure composed of a central invariable nucleotide 
binding domain with ATPase activity called NOD domain, NBD, or NACHT domain; a C-terminal 
domain with leucine rich repeats (LRRs), probably responsible for the ligand recognition and 
regulation; and a variable N-terminal domain, the effector domain, which is defined by respective 
binding structures such as CARD (caspase activation and recruitment domain), PYD (pyrin domain), 
AD (acidic transactivator domain), and BIR (Baculovirus inhibitory N-terminal domains). The 
CARD and PYD domain belong to the death fold superfamily. These are structure motifs commonly 
found in apoptosis- or inflammation-related processes. 
NLRs are classified in four subfamilies according to the structure binding the N-terminal domain: 
NLRA (NLR binding AD domain), NLRB (NLR binding BIR), NLRC (NLR bind CARD), NLRP 
(NLR binding PYD domain) and NLRX (this has an unknown binding domain and only one class 
has been found in mitochondria) [52]. Figure 5 shows different NLR families with its respective 
structures.  
Upon activation with PAMPs or DAMPs, NLRs will trigger a signaling cascade, which will induce 
the production of antimicrobial and proinflammatory mediators such as TNF-α, IL-6 and IL-1β. But 
not all NLRs use the same signaling pathway. Three end-targets of NLR signaling have been studied 
to the date, these include the activation of (1) NF-kB, of (2) MAPKs and (3) Casp-1.   
NOD-1 and NOD-2 (two well-studied NLRs belonging to the NLRC subfamily) are known for 
activating MAPKs as well as NF-kB. NLRP-3 and two other NLRs including NLRP1and NLRC4 
(also known as IPAF) activate Casp-1 and sometimes caspase-5 in humans (caspase-11 in mice). 
Caspases are known for their important role in cell death induction and proinflammatory function. 
These three NLRs including the non-NLR family protein AIM2 (absent in melanoma 2) build multi-
protein complexes called inflammasomes which serve as Casp-1 activating platforms and are 
essential for the secretion of IL-1β and IL-18, and the induction of pyroptosis, an alternative way of 
cell death [53-55]. 
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Figure 5: The NLR family and subfamily. Schematic representation of the NLR family members and subfamilies with 
examples of human NLRs. Abb.: NLR: Nod-like receptor; NBD: Nucleotide-binding domain; LRR: Leucine-rich 
repeats; CARD: Caspase-activation and recruitment domain; PYD: pyrin domain; AD: acidic transactivator domain; 
BIR: Baculovirus inhibitory N-terminal domains. Adapted from [53, 56] 
 
 
1.3.3 The NLRP3 inflammasome: structure, activation and function 
The NLRP3 inflammasome or cryopyrin, described for the first time in 2002 by Jürgen Tschopp, is 
the most studied inflammasome to date [56, 57]. This multi-protein complex serves as a platform for 
Casp-1 activation and maturation of IL-1β and IL-18. Both cytokines are part of the IL-1 family, 
which includes a variety of other cytokines (IL-1α, IL-1β, IL-33, IL-18, among others) that play a 
central role in the inflammatory response. IL-1β is a p o ten t pyrogenic and inflammatory cytokine 
mainly produced by blood monocytes, tissue macrophages and DCs. Low concentrations of IL-1β 
can cause fever and hypotension, whereby additional proinflammatory cytokines, such as IL-6, are 
released. Due to its powerful response upon stimuli, nature has developed several mechanisms to 
regulate its excessive production [58]. 
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Expression: The NLRP3 inflammasome is mainly expressed in spleen myeloid immune cells 
(neutrophils, macrophages, monocytes, DCs), although it is also present in epithelial cells of the 
esophagus, oropharynx and urothelial layer of the bladder [59]. Other compartments as bone marrow, 
blood and liver have shown a predominant expression of NLRP3 in myeloid cells compared to 
lymphoid cells. Lymph nodes and thymus only poorly express NLRP3 [60]. In most cells, NLRP3 is 
inducible, showing low expression under homeostatic conditions. Monocytes, for example, express 
high concentrations of the NLRP3 inflammasome, which is not highly inducible upon stimulation. 
On the other hand, expression of NLRP3 has been shown to be highly inducible in macrophages, 
DCs and BMDCs particularly under an inflammatory setting [60, 61].  
Structure: The NLRP3 inflammasome has three main components: (1) a sensor protein NLRP3, 
which recruits upon activation (2) the adaptor protein ASC (adaptor protein apoptosis speck protein 
with caspase recruitment), also known as PYCARD or CARD5, containing two death-fold domains 
named PYD and CARD that further bind the “effector” domain of the complex, and (3) the protease 
Casp-1. Casp-1 auto-activates after binding ASC through the CARD-CARD domains, which leads to 
pro-IL-1β and pro-IL-18 cleavage [62]. 
Function:  Inflammasomes are key protagonists of the inflammatory response, not only due to the 
secretion of the cytokines IL-1β and IL-18, but also for the instruction of a novel form of cell death: 
Pyroptosis. This name stands for "the falling of fire", which was given due to the high burst of pro-
inflammatory signals that result from cells undergoing this type of cell death. Pyroptosis involves 
membrane disintegration and release of intracellular components into the ECS in a Casp-1-mediated 
manner, thus representing another type of programmed cell death [63]. 
Activation: The activation of the NLRP3 inflammasome is mediated by several kinds of molecules, 
which include PAMPs, e.g. LPS, fungal zymosan, nigericin, and DAMPs such as monosodium urate 
crystals (MSU), calcium oxalate crystals [64, 65], uromodulin [66], and ATP as shown in Table 5 
below. Many of the mechanisms leading to inflammasome activation are still not fully understood. In 
vitro experiments have shown that the activation of NLRP3 inflammasome requires two steps: first, a 
priming step, in which NLRP3 and pro-IL-1β are transcribed by induction of the nuclear factor NF-
kB. As pointed above, not all cells express high levels of NLRP3 under resting conditions, which 
makes this step important for acquiring the needed concentrations of NLRP3.  ASC and Casp-1 are 
constitutively expressed in most cells, and no priming is needed. Ligands like LPS, lead to the 
activation of the transcription factor NF-kB through TLR-4-signaling, CpGs and even IL-1β-
mediated IL-1 receptor activation and MyD88 mediated NF-kB activation are some of the classical 
priming steps known for NLRP3. The second step will lead to the actual activation of the complex 
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with oligomerization and ensemble of the three inflammasome components. Several mechanisms 
have been proposed to date: (1) formation of pore channels in the cell membrane, either by bacterial 
toxins from the ECS or by increasing extracellular ATP concentration activating P2X7 channels, 
which allow potassium (K+) efflux, thus lowering the intracellular K+ concentration and activating 
the complex [67]; (2) elevation of intracellular ROS concentrations, related either to the K+ efflux or 
mitochondrial suffering from oxidative stress [68] and (3) phagocytosis of particulate components 
such as MSU or calcium oxalate crystals, which induce rupture of the lysosomes and thus release 
cathepsins, consequently activating the inflammasome complex [65]. All these activators suggest an 
additional function of the NLRP3 inflammasome in sensing cellular homeostasis [69]. Now, how 
these mechanisms interact with the NLRP3 inflammasome or whether these activation steps (priming 
and activation) are also required in vivo, is still unknown. The mechanisms regulating the assembly 
and activation of the NLRP3 inflammasome involve conformational changes of the NLR receptor 
domain, which is “locked” by the LRR-domain,  HSP-90 and SGT-1 under resting conditions [56]. 
Other regulatory proteins including A20, are also involved in the negative regulation of NLRP3 [70]. 
Figure 6 presents a schematic version of the NLRP3 inflammasome and the postulated priming and 
activating mechanisms.  
 
Table 5: Ligands involved in inflammasome induction and activation 
Groups Examples 
PAMPs 
 
Bacteria 
 
Viruses 
Toxins 
LPS, peptidoglycan  
Muramyl dipeptide (MDP) [71]  
Bacterial RNA [72] 
Neisseria gonorrhoea, Escherichia coli, Listeria monocytogenes 
[73], Staphylococcus aureus [74]  
Adenovirus, Influenza virus [75], Encephalomyocarditis virus  
Α-Toxin (S. aureus), Gramicidin (Bacillus brevis), listeriolysin 
O Nigericin (Streptomyces hygoscopius)  
DAMPs ATP, malarian hemozoin [76], 
Calciumpyrophosphate dihydrate, calcium phosphate [77], 
calcium oxalate, monosodium uratcrystals (MSU) [78], 
cholesterol crystals [79], cystein crystals [80], 
silica, asbestos, aluminum [81, 82], 
Uromodulin [66], glycoprotein 
ASC speck complexes,  
myoglobin, reactive oxygen species (ROS) 
Adapted from [57, 62]  
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Figure 6: Mechanisms of activation and induction of the NLRP-3 inflammasome. Schematic representation of 
NLRP3 inflammasome priming and activation. Priming: PAMP or DAMP recognition through TLRs or IL-1R activate 
NF-kB induced transcription of NLRP3, pro-IL-1β and pro-IL-18. Constitutional expression of ASC and pro-Casp-1. 
Activation: K+ efflux through pore-forming toxins, membrane integrity loss or associated to P2X7 receptor activation; 
cytosolic or mitochondrial ROS production as a result from oxidative stress;  crystal induced inflammasome activation 
throughgh endocytosis and lysosomal rupture with cathepsine B release. The exact ligand-receptor interation is still 
unknown. Activated NLRP3 inflammasome cleaves IL-1β and IL-18 and secretes it out of the cell or activates 
pyroptosis.  
 
1.3.4 Role of the NLRP3 inflammasome in disease 
The NLRP3 inflammasome is pivotal for the inflammatory response. Several human pathologies can 
be directly associated to the activation of the NLRP3 inflammasome. Mutations in the Nlrp-3 gene 
that provoke its persistent activation lead to the auto-inflammatory disease Muckle-Wells syndrome 
and other CAP associated syndromes (Cryopyrin-associated auto-inflammatory syndromes) [83, 84]. 
Microbial agents such as bacteria, fungi, viruses and parasites are also known to trigger NLRP3 
inflammasome activation in vivo. The well-known Influenza A virus has been shown to mediate 
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innate immunity in vivo through NLRP3 activation. This NLRP3-mediated response could result 
from exposure to specific viral RNA species which was mediated through lysosomal maturation and 
ROS [75]. Furthermore, viral M2 ion channels lead to potassium efflux and ROS production thus 
activating the assembling of the protein complex [85]. Also, Salmonella typhii, a bacterium known 
for causing typhoid or enteric fever, which manifests with a sudden onset of fever and diarrhea, 
activates the NLRP3 inflammasome. Its activation in innate immune cells leads to pyroptosis-
mediated cell death, eliminating the bacteria. The importance of this mechanism was observed in 
Casp-1-deficient mice, who severely suffered following infection with this bacterium [86].  
Among other potent ligands that activate inflammasomes are particulate compounds, such as 
exogenous crystals like asbestos and silica, which are endocytosed by pulmonary macrophages, 
activating the NLRP3 inflammasome and leading to pulmonary disease [87, 88]. Endogenous 
crystals such as MSU crystal deposits in gout, also activate the NLRP3 inflammasome by 
endocytosis, inducing an acute inflammatory response in the joints [89, 90]. Several studies have 
confirmed an association between high levels of IL-1β in joints of gout patients and crystal-related 
inflammation [65, 91, 92].  
The biomolecular mechanisms of the metabolic syndrome, a disease marked by abdominal obesity, 
high triglyceride levels, high blood pressure, and type II diabetes mellitus, is also related to 
activation of the NLRP3 inflammasome [93]. Obesity, for example, has been demonstrated to have 
an important inflammatory component because large amounts of adipose tissue stimulate NLRP3 in 
adipocyte-infiltrating macrophages, leading to chronic inflammation [94, 95]. In addition, insulin 
resistance and later apoptosis of pancreatic β-cells observed in patients with type II diabetes is linked 
to the activation of NLRP3. Studies have shown that IL-1β can inhibit insulin signaling and 
aggravate pancreatic β-cell dysfunction, thus contributing to the mechanisms leading to type II 
diabetes mellitus [96, 97]. Cholesterol crystals, responsible for atherosclerosis, also activate NLRP3 
inflammasomes in macrophages leading to the inflammatory response that is the base of plaque 
formation in arterial walls and progression of disease [98]. 
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1.4 Mesenchymal healing and fibrosis  
The wound healing process concludes with mesenchymal healing. Mesenchymal tissue or connective 
tissue can be considered as an organ system itself. It is found in all tissues of living organisms (lung, 
bones and skin), showing different properties in their composition and topology, but keeping the 
same basic functions and components. Various cells (fibroblasts, adipocytes, and endothelial cells), 
fibrous proteins (collagens, elastin, fibronectin) and proteoglycans (small leucine-rich proteoglycans 
–SLRPs-) are the principal components of this organ system. The functions of the ECM involve 
mainly the physical scaffolding of organs, giving tissues strength, elasticity and protection. 
Additionally, ECM provides biochemical and biomechanical cues for the morphogenesis of tissues 
together with its differentiation and extracellular homeostasis [99, 100]. All of this is mediated by 
several growth factors secreted from surrounding resident cells, which contribute to the dynamic 
modulation, migration and differentiation of cells [101]. Chronic diseases are characterized by 
persistent injury of tissues, whereby, mesenchymal healing becomes overshooting, a pathologic 
process, resulting in the exaggerated ECM deposition and tissue fibrosis. The following section 
thoroughly describes the main components of mesenchymal tissue and the pathophysiology of 
fibrosis.  
Fibroblasts: Since Virchow’s work on the ECM in the 19th century, it is known that fibroblasts are 
the main producers of ECM in all tissues [102]. They are the lead protagonists of mesenchymal 
healing, tissue remodeling and fibrosis, and are present in almost every organ of the body. But not all 
fibroblasts share the same functions. Phenotypical differences within organs or even within one 
organ itself have been regularly found. In the kidney, one of the fibroblast subpopulations has been 
shown to produce erythropoietin (EPO), a cytokine hormone that regulates red blood cell 
homeostasis [103, 104]. Fibroblasts produce fibrous proteins (mostly collagens) in a dynamic 
manner, maintaining constant tissue and ECM homeostasis and adapting it to the organs’ needs. 
Some organs are under continuous tensional state (prostate, saliva gland), and maintaining tissue 
homeostasis, especially in these tissues, is key for preventing aberrant fibrosis and tumorigenesis 
[105]. Additionally, fibroblasts secrete several modulatory cytokines such as transforming growth 
factor β1  or (TGF-β1), connective tissue growth factor (CTGF), both powerful profibrotic 
cytokines, vascular endothelial growth factor (VEGF a key  factor in neo-vascularization and 
lymphangiogenetic processes), matrix metallo proteinases (MMPs) that help rearranging the tissues 
through degrading ECM components, and tissue inhibiting MMPs or TIMPs, which inhibit MMPs 
[106-108].   
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Characterizing fibroblasts has been and still is a very difficult task. No specific markers have been 
found that would exclusively target fibroblasts. In the kidney, for example, markers such as 
vimentin, desmin, fibroblast specific protein 1 (FSP-1) and alpha smooth muscle actin (α-SMA, 
which labels activated fibroblasts or myofibroblasts), are used as markers for mesenchymal cells as 
are fibroblasts [109]. The origin of these cells has been an intensive subject of discussion. Under 
normal conditions, parenchymal tissues (liver and kidney) show only a few resident fibroblasts in the 
interstitial space, which are localized between the tissue epithelia. Upon stimulation, e.g. in tissue 
injury with concomitant elevated levels of TGF-β, larger quantities of fibroblasts are needed in order 
to cover the defect. This leads to the differentiation of several endothelial and epithelial cells 
converting them into fibroblasts. This process is called endothelial to mesenchymal transition 
(EndMT) and epithelial to mesenchymal transition (EMT) respectively. Recent studies have shown 
that cells undergoing EMT get arrested in the G2/M phase promoting a phenotype change of the cell 
[110-112]. This process is characterized by the loss of epithelial markers such as E-cadherin or ZO- 
1 and the increase of mesenchymal markers such as α-SMA. Other fibroblasts progenitor cells 
include pericytes, fibrocytes (considered here as circulating precursors of fibroblasts) and bone 
marrow-derived mesenchymal stem cells. Figure 7 shows a schematic representation of the possible 
origins of myofibroblasts in the kidney. 
     
Figure 7: Origin of myofibroblasts (activated fibroblasts) in renal interstitium. Schematic representation of the 
different myofibroblast origins in the renal interstitium. 1: Recruitment and activation of bone marrow fibroblasts.               
2: Activation of renal interstitial fibroblasts. 3: Tubular cells undergo phenotype change, a process called epithelial 
to mesenchymal transition  or EMT. 4: Pericyte differentiation and activation. 5: Endothelial cell undergo 
endothelial to mesenchymal transition  or EndMT. 
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Fibrosis: Fibrosis is defined as aberrant scarring of tissues during the wound healing process. Under 
normal conditions, fibroblast proliferation and activation for wound healing purposes are strictly 
regulated. Many different stimulating agents such as TGF-β and other growth factors including 
inflammatory cytokines IL-6, fibroblast growth factors (FGFs), and IL-13, are key in aberrant 
scarring processes [113, 114]. ECM’s degradation products can also activate macrophages, which in 
turn secrete more growth factors (GFs), TGF-β, MMPs and other cytokines that will further recruit 
resident fibroblasts, and promote their migration and proliferation. Collagen I, collagen III, 
fibronectin, and hyaluronic acid are the main ECM components produced by fibroblasts and 
represent the hallmark feature of mesenchymal healing [115]. Continuous mechanical stress, tissue 
injury and interstitial inflammation further enhance migration of bone marrow fibrocytes, together 
with the promotion of EMT and EndMT, thus recruiting and activating more fibroblasts. Activated 
fibroblasts or myofibroblasts are defined as highly contractile cells with a high capacity of ECM 
production and expression of α-SMA [116]. In several pathologic fibrotic processes like in 
pulmonary fibrosis, liver cirrhosis and renal fibrosis, the presence of high numbers of myofibroblasts 
has been demonstrated [109, 117]. The rigid collagen deposition and the increasing stiffness of tissue 
lead to basement membrane disruption, loss of epithelial polarity, as well as cell-cell adhesion, and 
finally leading to cell death (apoptosis). Compared to an acute injury, where tissue homeostasis 
restores with no or few fibrotic lesions, chronic injuries such as in diabetic nephropathy, liver 
cirrhosis or idiopathic pulmonary fibrosis show persistent tissue remodeling, increasing infiltration of 
myofibroblasts and ECM production, and vascular remodeling that finally result in the aberrant stage 
of fibrosis. The altered mechanical stability, reduced elasticity and loss of epithelial functional cells 
(replaced by an acelullar scar), deteriorate the organ functionality.  
Tubulointerstitial fibrosis is the hallmark of CKD. In contrast to AKI, where the tubular cell 
regeneration process is left with no fibrotic lesions, chronic injury leads to an irreversible fibrosis 
and stiffening of the renal tissue. Data has shown that the degree of fibrosis correlates with the 
impaired excretory function, suggesting fibrosis as an important therapeutic target [22]. The loss of 
tubular epithelial cells, the rarefication of the peritubular microvasculature and the accumulation of 
ECM are histopathological features, which contribute to the irreversible progression and worsening 
of CKD [118, 119]. Unfortunately, no effective anti-fibrotic therapies have been yet developed for 
clinical use [120].  Figure 8 shows a schematic representation of the development of renal interstitial 
fibrosis upon chronic kidney injury.  
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Figure 8: Renal interstitial fibrosis. Schematic representation of the tubular interstitial space and development of 
fibrosis. Chronic injury leads to tubular cell damage, which releases DAMPs and activates the immune system, releasing 
further profibrotic cytokines. DAMPs and profibrotic cytokines activate resident fibroblasts into myofibroblasts. 
Damaged tubular cells and disrupted basement membrane induce EMT. Fibroblast accumulation and activation enhances 
ECM deposition and fibrosis. Abb: α-SMA: alpha smooth muscle actin, EMT: epithelial to mesenchymal transition, 
TGF-β: transformig growth factor beta, MMP-9: matrix metalloproteinase 9.    
 
1.4.1 Biomolecular basis of mesenchymal healing and fibrosis: TGF-β signaling 
Previously, I have described how fibroblasts and matrix deposition can lead to tissue fibrosis. But 
what are the molecular mechanisms behind this process? Upon injury, TGF-β and other cytokines are 
released from innate immune cells including monocytes, macrophages, DCs, and epithelial cells 
within the wounded tissue. ECM-producing fibroblasts activate and respond immediately to re-
establish tissue stability. It is known that TGF-β is the most potent profibrotic cytokine released 
during wound healing, as found in hypertrophic scars of the skin, which showed very high 
concentrations of the cytokine [121, 122]. Other cytokines as CTGF, CCN2, ED-A fibronectin also 
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contribute to this process, compared to IFN γ and prostaglandin E2 (PGE2), which normally have a 
proinflammatory response, but interestingly also an anti-fibrotic function [123, 124].  
TGF-β belongs to a family of proteins contributing to diverse functions in the organism including 
embryonic development, wound healing, tissue homeostasis, chemotaxis and cell cycle control. The 
TGF-β superfamily is responsible for regulation, differentiation and apoptosis of epithelial and 
hematopoietic cells. The following cytokines belong to the TGF-β superfamily: bone marrow 
stimulating proteins (BMPs), known for their influence on cartilage and bone induction; GFs, anti-
müller hormones (AMH) and TGF-β itself (including TGF-β1, TGF-β2 and TGF-β3, being type 1 
the most representative). This family is known to inhibit the proliferation of most cells (e.g. 
inflammatory cells), inducing apoptosis in epithelial cells, and interestingly stimulating the 
proliferation of mesenchymal cells [125]. These effects of TGF-β have been evaluated several times. 
An experiment with mice lacking TGF-β1 showed impaired last-stage wound repair and decreased 
epithelialization and collagen deposition compared to wild type mice. Deficiency of TGF-β in mice 
was lethal due to the wasting syndrome, a generalized inflammatory response associated with tissue 
necrosis, organ failure and death [126].  
TGF-β in its inactive form is found constitutively expressed in the ECS. This latent precursor is 
bound by a disulfide bridge to a protein called latent TGF-β binding protein (LTBP). In this way, 
TGF-β is incapable of binding to its receptor, thus preventing its uncontrolled activation [127]. 
Cytokines like MMP-9 [128], TSP-1 (thrombospondin-1) [129], integrin α-β and other mediators 
like ROS and low pH of the ECS, can activate TGF-β through proteolytic cleavage of the TGF-β-
LTBP complex. Active TGF-β binds to the transmembrane receptor TGF-β receptor II (TβRII), a 
serine/threonine kinase that recruits the transmembrane receptor TGF-β receptor I (TβRI), which 
subsequently leads to R-SMADs (receptor regulated SMADs) phosphorylation, specifically SMAD2 
and SMAD3 [130-132]. SMADs are homologous proteins of both Drosophila MAD proteins 
(mothers against decapentaplegic homolog) and the Caenorhabditis protein SMA (small body size) 
[133]. They are a group of globulated proteins with different functions involving the regulation of the 
TGF-β signaling pathway and gene transcription. SMAD1, SMAD2, SMAD3 and SMAD5 are the 
main regulators of TGF-β signaling, while SMAD4 is considered a common-mediator SMAD. 
SMAD6 and SMAD7 have been shown to have an inhibitory role on the SMAD2/3 complex. 
Phosphorylation of SMAD2 and 3 builds a complex with co-SMAD (SMAD4), subsequently binding 
with other co-transcriptional factors to regulate gene expression. SMAD1, SMAD5, and SMAD9 are 
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stimulated by BMP-7, an antifibrotic cytokine [134].  Other signaling pathways also participate in 
TGF-β signaling, e.g. the RAS/MER/ERK signaling pathway has been shown to influence SMADs 
in epithelial cells by inhibiting SMAD3, thus diminishing the response to TGF-β1 [135]. Figure 9 
shows a simplified schematic of TGF-β signaling. In spite of the intensive studies regarding TGF-β, 
contradictory results still emerge among scholars, e.g. one study showed TβRII null mice had more 
renal interstitial fibrosis and collagen deposition, compared to wild type mice after UUO. The 
contradictory results of TGF-β rely mostly on its dose dependent activity [136].  
 
 Figure 9: TGF-β1 signaling pathway. Schematic representation of the TGF-β signaling pathway: Latent TGF-β is 
constitutively expressed in ECM. After activation, TGF-β is released, binding TGF-R2 who undergoes oligomerization 
and recruits TGF-R1. The activated receptor phosphorylates Smad2/3 complex, which then binds Smad4. Smad 4 
together with other cofactors induces gene transcription of several profibrotic (αSMA, collagen I & -III, fibronectin)  and 
anti-fibrotic genes including Smad7, which inhibits Smad2/3 phosphorylation. TGF-R1 and TGF-R2 complex activation 
additionally induces RAS/MEK/ERK signaling. Abb.: TGF-β: transforming growth factor β, αSMA: alpha smooth 
muscle actin.  
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1.5 The NLRP3 inflammasome in kidney diseases 
 
Most kidney diseases leading to ESRD are glomerular, non-microbial pathologies and result in renal 
interstitial inflammation, which is the hallmark feature of kidney diseases. PRRs have been 
demonstrated to contribute significantly to this process.  However, evidence about the role of the 
NLRP3 inflammasome during kidney diseases is limited. Under normal conditions, the human brain, 
spleen and testis express more NLRP3 than the kidney. Contrary to humans, expression of NLRP3 in 
mice is significantly higher in the spleen and kidney compared to other organs [137]. In healthy 
kidneys, the inflammasome components NLRP3 and ASC are highly expressed in resident 
macrophages, DCs and tubular cells, compared to the glomerular cells [138]. Other studies have 
suggested inflammasome components NLRP3, ASC and Casp-1 are also expressed in mouse 
podocytes [139, 140]. Patients with IgA-nephropathy showed increased NLRP3 expression in 
glomerular cells compared to healthy kidneys, but still significantly less compared to tubular 
epithelial cells in humans [141]. Nevertheless, the expression of NLRP3 in renal interstitial 
fibroblasts has not been determined. Studies involving resident fibroblasts from the heart and 
gingival fibroblast evidenced the expression of  NLRP3 [142, 143]. However, not all these cells have 
proved to have a functional NLRP3 inflammasome with concomitant production of the cytokines IL-
1β and IL-18, as seen in tubular epithelial cells, which express NLRP3 but not the active forms of 
these cytokines [138]. The next paragraphs describe important findings on the role of the NLRP3 
inflammasome in acute and chronic kidney diseases. 
1.5.1 Inflammasome in AKI and CKD pathology 
Several DAMPs are known to activate the NLRP3 inflammasome. AKI generally presents with acute 
tubular necrosis releasing DAMPs that worsen the renal injury. Several mouse models of AKI 
including ischemia reperfusion injury (IRI) with post-ischemic tubular necrosis [144, 145] and toxic 
(cisplatin-induced) tubular injury [146, 147] have shown increased levels of IL-1β and IL-18 in 
kidneys of mice post-AKI. In humans, biopsies of critically ill patients with AKI showed also 
increased levels of IL-18 [148]. Crystal-induced AKI was also proven to be mediated through the 
NLRP3 inflammasome. Herein, Nlrp-3-, Asc-, Casp-1- and IL-1β-deficient mice were significantly 
protected from calcium oxalate-induced AKI, compared to the wild type mice. But the study 
suggested that these results were mainly due to the diminished inflammatory response, i.e. reduced 
DCs and macrophages infiltration into the renal interstitium, and not due to renal parenchymal cells 
that underwent necrosis upon crystal exposure, without IL-1β production [64]. Moreover, the NLRP3 
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inflammasome plays a central role in the development of uric acid-induced nephropathy, gout and 
hyperuricemia-induced progression of diabetic nephropathy [149, 150]. But the interaction between 
crystals and the receptor itself remain uncertain. It is clear that reduction of the intracellular K+ 
concentration is highly associated with crystal-mediated inflammasome activation [143, 188]. MSU 
crystals trigger the release of Na+ following phagocytosis, resulting in osmolarity changes within the 
cell, thus inducing water influx and dilution of the intracellular K+ concentration [189].   
The importance of the NLRP-3 inflammasome has been also shown in CKD animal models. A 
streptozotocin (STZ)-induced diabetic nephropathy model demonstrated the contribution of NLRP3 
in non-myeloid cells of the kidney (such as intra-glomerular endothelial cells and podocytes), with 
the aggravation of diabetic nephropathy in mice [151]. Other studies using a UUO model showed 
significant protection from renal injury in purinergic receptor-7 (P2x7)-deficient mice compared to 
wild type mice [151]. In general, the protection observed in CKD models involving reduced 
inflammasome activity was associated with a reduced inflammatory component in CKD. A direct 
relationship between the NLRP3 inflammasome and the development of aberrant fibrosis in CKD is 
still not well defined. 
1.5.2 Inflammasome-independent NLRP3 signaling in kidney disease  
Muruve et al. suggested that the NLRP3 inflammasome as well as the cytokines IL-1β and IL-18 
contribute to renal injury and progression of CKD in the UUO mouse model [152]. In this study, 
Nlrp-3-deficient mice were significantly protected from renal injury upon UUO and this protection 
correlated with a diminished Casp-1 activation and reduced maturation of IL-1β and IL-18 [152]. 
The next study performed by the same group showed primary tubular epithelial cells (pTECs) 
following stimulation with TGF-β1 were unable to release IL-1β in vitro despite the increased 
expression of NLRP3 [138]. Also, EMT was associated with this process. These results suggested an 
inflammasome-independent role in TECs during renal fibrogenesis [138]. One possible explanation 
for this might be an interaction between TGF-β1 downstream signaling and the inflammasome 
component NLRP3 in TECs. Additionally, SMAD2 phosphorylation was diminished in Nlrp-3-
deficient TECs stimulated with TGF-β1, suggesting that NLRP3 enhances TGF-β1 signaling, in an 
inflammasome-independent manner [138].  
Furthermore, a study involving Nlrp-3-, Asc-, Il-1R-deficient and IL-18-deficient mice with an lpr/lpr 
background (a mild phenotype of spontaneous lupus-like autoimmunity) showed contradictory 
results [153]. Lack of Il-1R and Il-18 did not affect the phenotype, whereas mice lacking NLRP3 and 
ASC showed a massive lymphoproliferation and severe lupus nephritis, which was absent in lpr/lpr 
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controls. The increased DC and macrophage activation, as well as elevated expression of 
proinflammatory mediators and expansion of T- and B-cell subsets in Nlrp-3- and Asc-deficient mice 
suggested an immunosuppressive effect of NLRP3 and ASC [153]. This highlights a possible role for 
NLRP3 and ASC in TGF-β1 signaling. Further experiments corroborated these results showing a 
significant suppression of TGF-β1 target genes and SMAD2 phosphorylation in both mutant mouse 
strains, suggesting an important role of NLRP3 and ASC in SMAD2 phosphorylation and thus TGF-
β1 signaling. 
 
 
1.6 Mouse models of CKD 
 
Several mouse models have been established for studying CKD. Generally, in vivo models are 
advantageous as they allow an accurate approach as they mimic the different disease mechanisms 
and pathophysiology, enable the focused study of genetic implications and give the investigator 
liberty for experimental planning and design. However, in vivo models in rodents and other species 
do not reflect with precision the human disease and its consequences, mostly due to the marked 
genetic differences between species. In this study, we focused on a CKD model, which would 
specifically replicate the tubulointerstitial fibrosis and which would closely mimic the human disease 
complications. The preferred models for our target were the UUO and the oxalate-induced 
nephropathy model. Table 6 summarizes the most frequently used mouse CKD models based on the 
underlying pathology [154]. 
 
Table 6: Mouse models of CKD, classified by pathology 
Pathology Model Mechanism 
Glomerulonephritis  Lupus nephritis  Immune complex GN Anti-GBM-nephritis Autoimmune-mediated GN 
 
Glomerulosclerosis  
Aging Spontaneous podocyte loss 
PAN/adriamycin nephropathies Toxic podocyte loss 
5/6 nephrectomy  Surgical nephron reduction 
 Unilateral ureteral obstruction (UUO) Obstructive nephropathy 
Interstitial fibrosis Oxalate nephropathy Crystal and direct tubular toxin 
 AAN (aristocholic acid nephropathy) Toxic nephron loss  
 Cyclosporin A nephropathy Vasoconstriction and  ischemia 
Adapted from Yang, H.C., et al.[154] Abb.: GS: glomerulosclerosis, GN: glomerulonephritis, GBM: glomerular 
basement membrane; PAN: puromycin aminonucleoside; UUO: unilateral ureteral obstruction. 
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Unilateral Ureteral Obstruction model: Obstructive nephropathy is a common cause of acute or 
chronic kidney diseases. It leads to urine stasis and elevation of the pressure in the urinary tract. 
Causes of urinary tract obstruction may be congenital or acquired due to intrinsic or extrinsic factors. 
One common cause of urinary tract obstruction in children is the vesicoureteral reflux, mostly found 
in infants due to misplacement of the ureter in the bladder. Patients with unilateral vesicoureteral 
reflux manifest repeated urinary tract infections but no functional impairment. On the contrary, 
bilateral vesicoureteral reflux may lead to ESRD if not treated [155]. Acquired defects are very 
common in adults, mostly as a result of kidney stones, infections and trauma, tumors of the urinary 
tract and side-tissues or retroperitoneal fibrosis. 
The increased hydrostatic pressure upon the collecting duct system and subsequent elevated tubular 
pressure leads to tubular dilation and dysfunction. When the elevated hydrostatic pressure reaches 
the glomerular space, GFR declines until ceasing completely. Additionally, tubular malfunction leads 
to natriuresis and polyuria. Increased PGE2, ANP and particularly angiotensin II aggravate this 
scenario by inducing more profibrotic cytokines. Meanwhile, the renal interstitium becomes 
edematous and infiltrated with mononuclear inflammatory cells, which upon progression activate 
interstitial fibroblasts, increasing ECM production resulting in tubulointerstitial fibrosis and atrophy 
of the papilla, medulla and cortex [3, 156]. Azotemia and other consequences of CKD do not 
develop upon unilateral obstruction; these patients may present with hypertension, usually a 
consequence of RAAS over-activation by the obstructed kidney.  
Urinary tract obstruction induced by ligating one of the mouse ureters (Figure 10) results in 
tubulointerstitial inflammation and fibrosis. The rapid disease development, simple and economic 
surgical requirements make it an optimal model for studying renal interstitial fibrosis, which explains 
why it is so widely used in the scientific community [157]. Unfortunately, this model does not mirror 
human CKD because it does not show alterations of kidney function parameters in blood and urine 
with the systemic consequences of the disease.  
Chronic oxalate nephropathy model:  Oxalate is a metabolic end product in humans. Normally, 40 
to 50 mg of oxalate are excreted in the urine every day. Elevated levels of urine oxalate lead to 
super-saturation and production of intrarenal crystals and kidney stones [158]. Three main causes of 
oxalate-induced kidney injury in humans are known: (1) primary hyperoxaluria (type 1 and type 2), a 
rare autosomal recessive disease that presents already in childhood with recurrent formation of 
calcium oxalate stones and when not discovered can quickly lead to ESRD; (2) dietary 
hyperoxaluria, which represents the most frequent form of hyperoxaluria in humans; and (3) enteric 
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hyperoxaluria, as a result of the fatty acid malabsorption due to e.g. bariatric surgery, and Chron's 
disease involving small intestines or pancreatic insufficiency. Under normal conditions, insoluble 
calcium oxalate is excreted with the stool. Decreased absorption of fatty acids from the intestinal 
lumen sequesters calcium.  This stops binding of oxalate to calcium and therefore, increases its 
solubility and intestinal absorption [159]. Furthermore, acute oxalosis due to ethylene glycol 
poisoning can induce AKI as a consequence of the widespread intrarenal crystal deposition [160]. 
Unlike many other crystal nephropathies which involve localized crystallization in the renal pelvis 
(kidney stone formation) or in the collecting duct system and renal medulla like MSU crystals, 
calcium oxalate (in mice) and cysteine (in humans) crystallization can be found diffusely in the renal 
interstitium and inside the tubular lumen, affecting the whole kidney parenchyma [161].  Urine, with 
its high osmolarity and pH variations, boosts crystallization of the filtered oxalate. Different 
mechanisms for the tubular cell injury have been proposed: (1) the activation of the immune system 
upon crystals inducing the infiltration of inflammatory cells and production of proinflammatory 
cytokines and chemokines and the concomitant obstruction of the tubules pose as an indirect 
mechanism for tubular cell injury. (2) Crystals are cytotoxic and induce upon direct contact oxidative 
stress and tubular cell death, which will, in turn, activate the immune system and enhance renal 
inflammation. The continuous renal inflammation and tubular damage lead to tubular atrophy and 
activation of resident fibroblasts, promoting ECM production and renal interstitial fibrosis [161, 
162].  
Two models of hyperoxaluria have been developed in mice: an acute and a chronic model. In the 
acute model, hyperoxaluria is induced by intraperitoneal injection of 100 mg/kg sodium-oxalate and 
3% sodium-oxalate in drinking water, leading to a marked kidney injury within 24 hours [64, 163].  
In order to imitate hyperoxaluria-induced CKD in humans, mice were fed a high oxalate diet 
prepared by adding high-soluble sodium-oxalate to a virtually calcium-free diet for up to 14 days. 
Blood and urine were analyzed throughout the experiment and kidneys harvested after sacrifice.  
Indeed, a recent study by Knauf et al. observed that a high oxalate and calcium-free diet in C57BL/6 
mice resulted in elevated serum and urine oxalate concentrations, increased intrarenal crystal 
deposition and severe damage of the tubular cell architecture, leading to renal inflammation and 
interstitial fibrosis, and thus mimicking CKD [164].  
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Figure 10: Implemented mouse models of CKD. Schematic anatomical representation of the applied mouse models of 
CKD. Left: Unilateral ureteral obstruction displays ligation of the ureter with urine stasis in distal, proximal ureter and 
renal pelvis. Right:  High soluble oxalate diet results in diffused crystal deposition in the kidney parenchyma.  
 
 
 
1.7 Hypothesis 
Based on the published literature, we hypothesized that the inflammasome component NLRP3 drives 
renal fibrogenesis in CKD by augmenting TGF-β receptor signaling and not only via Casp-1-
mediated IL-1β release.  
 
Accordingly, the objectives of this study were: 
1. Assessment of the NLRP3 inflammasome-dependent and -independent signaling during 
UUO.  
2. Assessment of the NLRP3 inflammasome-dependent and -independent signaling during 
hyperoxaluria-induced nephrocalcinosis and CKD. 
3. Assessment of the NLRP3 inflammasome-dependent and -independent signaling in murine 
fibroblasts and the influence on their proliferation and their capacity to produce ECM.  
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2. Materials and Methods 
2.1 Materials 
Table 7: Instruments and Devices 
Instrument Designation Manufacturer 
Balance Analytic balance BP 110 S Sartorius, Göttingen, DE 
 Mettler PJ 3000 Mettler-Toledo, Greifensee, CH 
Centrifuges Centrifuge 5415 C Eppendorf, Hamburg, DE 
 Centrifuge 5418 C Eppendorf, Hamburg, DE 
 Haraeus, Minifuge T VWR Internation, Darmstadt, DE  
 Haraeus, Sepatech Biofugue A Heraeus Sepatech, Osterode, DE 
 Universal 16 Hettich, Bäch,CH 
Microscopes Light microscope Leitz DM Il Leica Microsystems, Solms, DE 
 Libra 120 Carl-Zeiss AG, Oberkochen, DE 
 CCD-Camera Tröndle, Moorenweis, DE 
 Light microscope Zeiss AxioPlan 2  Carl-Zeiss AG, Oberkochen, DE 
 Axiocam HR Carl-Zeiss AG, Oberkochen, DE 
Microscope imaging Cell P software Olympus, Hamburg, DE 
Fluorescence microscope Leica DC 300 F Leica Microsystems,Cambridge, UK 
 Olympus BX50 Olympus Microscopy, Hamburg, DE 
Cell Culture   
Cell incubator Heracell Type B5060 EC-CO2 Heraeus Sepatech, Osterode, DE 
Cell counting chamber Neubauer cell counting chamber Roth, Karlsruhe, DE 
Workbench Sterile card hood class II, type A/B3 
The Baker Company, Stanford, ME, 
USA 
UV-light  Bachofer , Reutlingen, DE 
ELISA   
ELISA reader Tecan, GENios Plus Tecan, Crailsheim, DE 
ELISA plate washer Microplate washer ELx50 Biotek, Bad Friedrichshall, DE 
Real-Time PCR   
Nano drop Spectrophotometer PEQLAB Biotech., Erlangen, DE 
Light Cycler 480 Real-time PCR system Roche, Basel, CH 
Light Cycler 480 Multiwell-plate 96 Roche, Basel, CH 
Western Blot   
Gel electrophoresis 
chamber Gel electrophoresis chamber PeqLab Biotech., Erlangen, DE 
X-ray developer X-ray developer machine AGFA, Köln, DE 
Blotting System Semi-dry blotting system BioRad, München, DE 
SDS-gel electrophoresis 
chamber 
Mini VE, vertical 
electrophoresis system 
Amersham Bioscience, Glattbrugg, 
CH 
Voltage source SDS-
electrophoresis Power  PAC 3000 BioRad, München, DE 
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Instrument Designation Manufacturer 
Other Devices   
Tissue homogenizer Ultra Turrax T 25 IKA GmbH, Staufen, DE 
Microtome Microtome HM 340 E Microm, Heidelberg, DE 
Cryomicrotome Cryostat RM 2155 Leica Microsystems, Bensheim, DE 
 Cryostat CM 3000 Leica Microsystems, Bensheim, DE 
pH meter  pH meter WTW WTW GmbH, Weilheim, DE 
Thermomixer  Thermomixer 5436 Eppendorf AG, Hamburg, DE 
 Thermocycler UNO II Biometra, Göttingen, DE 
Vortex mixer Vortex Genie 2tm Bender &Hobein, Zürich, CH 
Workbench Sterile workbench Microflow, biological safety cabinet class II Nunc GmbH, Wiesbaden, DE 
Rotary mixer Heavy duty rotator Bachofer Laboratoriumsgeräte, Reutlingen, DE 
Roller mixer Stuart roller mixer SRT6d Bibby Scientific, Stone, UK 
Water bath Water bath HI 1210 Leica Microsystems, Bensheim, DE 
Pipette Aids   
Manual dispenser Multipipette Plus Eppendorf AG, Hamburg, DE 
Manual pipette aid Research Plus 30 – 300 µl Eppendorf AG, Hamburg, DE 
 Pipetman 2, 10, 20, 100, 200, 1000 µl Gilson, Middleton, WI, US 
 Pipetus classic Hirschmann Laborgeräte, Eberstadt, DE 
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Table 8: Disposable instruments  
 
 
 
 
Instrument Designation Manufacturer 
Eppendorf  tubes 1.5, 2, 15, 50 ml TPP Trasadingen, CH 
Falcon tubes 15, 50 ml BD, Heidelberg, DE 
   
Serological pipettes 5, 10, 25 ml BD Heidelberg, DE 
Pipettes Pipettes Pipetman Gilson, Middleton, WI,USA 
Pipette tips 1-1000 µl type Gilson Peske, Aindling-Arnhofen, DE 
 Pipette tips ep T.I.P.S Eppendorf AG, Hamburg, DE 
Embedding cassettes Embedding cassettes “Biopsy” ISOLAB, Wertheim, DE 
X-ray films BioMax XAR Film Kodak Sigma Aldrich, Deisenhofen 
Syringes Diskardit II 1 ml, 2 ml, 5 ml BD, Fraga, ES 
Tweezers Sterile tweezers Angiokard Medizintechnick GmbH & Co. KG, Freiburg, DE 
Pre-separation filters MACS pre-separation filter 100 µm 
Miltenyi Biotec, Bergisch 
Gladbach, DE 
 Cell strainer 70 µm BD Falcon, Franklin Lakes, US 
Filter systems Vacuum filtration system 150 ml, 500 ml TPP; Trasadingen, CH 
Filter paper Whatman paper Sigma Aldrich, Deisenhofen, DE 
Cell culture plates 6-, 12-, 96-well plate TPP, Trasadigen, CH 
ELISA 96-well plate NUNC Immuno-plate F96, Maxisorp Thermo Scientific, Waltham, US 
Cell scraper Cell scraper 24 cm  TPP, Trasadigen, CH 
Western blot membrane Immobilon P transfer membrane 0,45 µm pore size  
Miltenyi Biotec, Bergisch 
Gladbach, DE 
Needles Needles BD, Drogheda, IE 
Microscope slides Super frost r Plus Menzel-Gläser, Braunschweig, DE 
Tissue culture dishes Ø100 mm, Ø150 mm TPP,Trasandigen, CH 
Ultra-cut  Leica Microsysteme, Wetzlar, DE 
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Table 9: Chemicals, kits, reagents and solutions  
 
 
 
 
Product Designation Manufacturer 
Cell Culture   
Antibiotics Penicillin-streptomycin PAA Laboratories, Pasching, AT 
Fetal bovine serum 
(FBS) Fetal bovine serum Biochrom KG, Berlin, DE 
Cell detachment  Trypsin/EDTA (1x) PAA Laboratories GmbH, Cölbe, DE 
Cell buffer & media Dulbecco's phosphate buffered saline 1x (PBS)  PAA Laboratories GmbH, Cölbe, DE 
 Dulbecco's modified eagle medium (DMEM) Biochrom KG, Berlin, DE 
Cell freezing Dimethyl sulfoxide (DMSO) Merck, Darmstadt, DE 
MTT Assay   
Cell proliferation assay Cell titer 96 A Queous  Promega GmbH, Mannheim, DE 
Real-Time PCR   
RNA isolation kit Ambion Pure Link RNA Mini Kit 
Life technologies, GmbH, Darmstadt, 
DE 
Reverse transcription Acrylamide Ambion, Darmstadt, DE 
 Hexanucleotide Roche, Mannheim, DE 
 dNTPs  (25 mM) GE Healthcare, München, DE 
 RNAsin Promega, Mannheim, DE 
 DTT  (0,1 M) Invitrogen, Karlsruhe, DE 
 Strand buffer (5x) Invitrogen, Karlsruhe, DE 
 Superscript II Invitrogen, Karlsruhe, DE 
 RNase free spray Gene Choice, Frederick, US 
 SYBR Green dye Applied Biosystems, Norwalk, US 
 Taq DNA Polymerase New England Biolabs, Ipswich, US 
 PE buffer (10x) Finnzymes, Espoo, FIN 
 dNTPs (1,25mM) Metabion, Martinsried, DE 
 MgCl2 (25 mM) Fermentas, St.LeonRot, DE 
ELISA   
ELISA kit  OptEIA mouse IL-1β kit Bd; Franklin Lakes, US 
ELISA coating Poly-L-Lysine Cultrex, Trevigen, Gaithersburg, US 
ELISA signal detection OptEIA BD, Fraga, ES 
Abb: dNTPs: nucleosid triphosphate, RNAsin: ribonuclease inhibitor, DTT: dithiothreitol, RNase: ribonuclease, MgCl: 
magnesium chloride, DMEM: Dulbecco's modified eagle medium, DMSO: Dimethyl sulfoxide, PBS: Dubelcco’s 
phosphate buffered saline, EDTA: Ethylenediaminetetraacetic acid, ELISA: enzyme-linked immunosorbent assay  
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Western blot   
RIPA buffer Radio immunoprecipitation assay buffer Sigma-Aldrich, St.Louis, USA 
Protease inhibitor Complete protease inhibitor tablets Roche, Mannheim, DE 
Tris Trisaminomethane Rot, Karlsruhe, DE 
Blocking solution Skin milk powder  Merck, Darmstadt, DE 
SDS Sodium dodecyl sulfate BioRad, München, DE 
Tween 20 Polysorbate 20 Sigma-Aldrich, Steinheim, DE 
APS 10% ammonium persulfate BioRad, München, DE 
Acrylamide 30% acrylamide Carl Roth GmbH, Karlsruhe, DE 
Protein assay Bio-Rad protein assay BioRAd, München, DE 
Blocking solution  Roche, Mannheim, DE 
Bromophenol blue  Merck, Darmstadt, DE 
TEMED Tetramethylethylenediamine BioRad, München, DE 
   
Marker (proteins) Lane marker non-reducing sample buffer (5x) 
Thermo Scientific, Rockford, 
US 
Miscellaneous   
Acetone  Merck, Darmstadt, DE 
Lysis buffer Ammonium chloride Merck, Darmstadt, DE 
EDTA Ethylenediaminetetraacetic  Calbiochem, San Diego, US 
Eosin  Sigma, Deisenhofen, DE 
Ethanol  Merck, Darmstadt, DE 
Formalin  Merck, Darmstadt, DE 
Hydroxyethyl cellulose  Sigma-Aldrich, Steinheim, DE 
Hydrogen chloride  Merck, Darmstadt, DE 
Isopropanol  Merck, Darmstadt, DE 
Calcium chloride  Merck, Darmstadt, DE 
Calcium dihydrogen 
phosphate  Merck, Darmstadt, DE 
Calcium hydroxide  Merck, Darmstadt, DE 
β-mercaptoethanol  Roth, Karlsruhe, DE 
Sodium acetate  Merck, Darmstadt, DE 
Sodium chloride  Merck, Darmstadt, DE 
Sodium citrate  Merck, Darmstadt, DE 
Triton X Tetramethylbutylphenyl-polyethylene glycol Fluka, Chemie AG, Buchs, CH 
Tissue fixation Solution of  formaldehyde 18% Thermo Fisher Scientific, Waltham, US 
Tissue mobilization RNA later Qiagen GmbH, Hilden, DE 
Abb: EDTA: Ethylenediaminetetraacetic acid, RNA: ribonucleic acid 
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Table 10: Buffers 
 
 
Experiment Buffer Composition 
ELISA   
 Sodium bicarbonate (0,05 M) 2.1g  NaHCO   
2.645g Na2CO3  
in 500 ml H2O 
   
 PBS (10x) 80.0 g NaCl               
  11.6 g Na2HPO4      
  2.0 g KH2PO4     
  2.0 g KCl     
in 1 L H2O (ph:7.0) 
   
 Tris NaCl (10x) Tris: 60.57 g 
NaCl: 81.8 g 
all in 1 L H2O (pH:7.0) 
   
 Sulfuric acid H2SO4 
Western blot   
 TBS 50 mM tris 
  150 mM NaCl (pH 7.6) 
   
 TBS-T 0.1% Tween-20 in TBS 
 Running buffer 3 g tris 
  14.4 g glycine 
  0.5 g SDS 
  In 1000 ml dd H20 (pH 8.3) 
 Transfer buffer 1.5 g tris 
  7.2 g glycine 
  in 500 ml dd H2O  
 Separating buffer 18.2 g tris (1.5 mM) 
  0.4 g SDS 
  In 1000 ml dd H2O (pH: 8.8) 
 Collecting buffer 6.05 g tris (0.5 mM) 
  0.4 g SDS  in 100 ml dd H2O 
(pH 6.8) 
   
Abb: Tris (hydroxyethyl) aminomethane and sodium chloride , TBS: Tris-buffered saline , TBS-T: Tris-buffered saline 
plus Tween-20 ,SDS: Sodium dodecyl sulfate ,ddH2O: distilled water, PBS: Phosphate buffered saline.    
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Table 11: PCR Primer sequences  
 
Gene Forward Reverse 
18 S 5´-GCAATTATTCCCCATGAACG-3´ 5´-AGGGCCTCACTAAACCATCC-3´ 
Acta 2  5´-ACTGGGACGACATGGAAAAG-3´ 5´-GTTCAGTGGTGCCTCTGTCA-3´ 
Asc 5´-GAGCAGCTGCAAACGACTAA-3´ 5´-GCTGGTCCACAAAGTGTCCT-3´ 
Casp1 5´-TCAGCTCCATCAGCTGAAAC-3´ 5´-TGGAAATGTGCCATCTTCTTT-3´ 
Ccl2  5´-CCTGCTGTTCACAGTTGCC-3´ 5´-ATTGGGATCATCTTGCTGGT-3´ 
Col 1a1 5´-ACATGTTCAGCTTTGTGGACC-3´ 5´-TAGGCCATTGTGTATGCAGC-3´ 
Col 4a1 5´-GTCTGGCTTCTGCTGCTCTT-3´ CACATTTTCCACAGCCAGAG-3´ 
Ctgf 5´-AGCTGACCTGGAGGAAAACA-3´ 5´-CCGCAGAACTTAGCCCTGTA-3´ 
Cxcl 2  5´-CGGTCAAAAAGTTTGCCTTG-3´ 5´-TCCAGGTCAGTTAGCCTTGC-3´ 
E-cadh 5´-GAGGTCTACACCTTCCCGGT-3´ 5´-CCACTTTGAATCGGGAGTCT-3´ 
Fib1 5´-GGAGTGGCACTGTCAACCTC-3´      5´-ACTGGATGGGGTGGGAAT-3´ 
Fsp1 5´-CAGCACTTCCTCTCTCTTGG-3´ 5´-TTTGTGGAAGGTGGACACAA-3´ 
α -Gst 5´-CAATGGCCGGGAAGCCCGTG-3´ 5´-CTTCAAACTCCACCCCTGCTGC-3´ 
 Il-1β 5´-TTCCTTGTGCAAGTGTCTGAAG-3´ 5´-CACTGTCAAAAGGTGGCATTT-3´ 
Il-18 5´-CCAAATCAGTTCCTCTTGGC-3´ 5´-GGCCAAAGTTGTCTGATTCC-3´ 
Il-1r 5´-TGAGGAGGCAGTTTTCGTTT-3´ 5´-GAGCCCCAGTAGCAGTTCA-3´ 
Il-6 5´-TGATGCACTTGCAGAAAACA-3´ 5´-ACCAGAGGAAATTTTCAATAGGC-3´ 
Kim-1 5´-TGGTTGCCTTCCGTGTCTCT-3´ 5´-TCAGCTCGGGAATGCACAA-3´ 
Lfabp 5´-AGGCAATAGGTCTGCCCGAGGAC-3´ 5´-CCAGTTCGCACTCCTCCCCCA-3´ 
Mmp9 5´-TTGACAGCGACAAGAAGTGG-3´ 5´-GCCATTCACGTCGTCCTTAT-3´ 
Nlrp-3   5´-AGAAGAGACCACGGCAGAAG-3´ 5´-CCTTGGACCAGGTTCAGTGT-3´ 
Pdgf  5´-ATGCAACGGCTCGTTTTAGTC-3´ 5´-CGGAGTCGCAAAAGTGTCC-3´ 
Smad 2  5´-ATGTCGTCCATCTTGCCATTC-3´ 5´-AACCGTCCTGTTTTCTTTAGCTT-3´ 
Smad 3  5´-AGGGGCTCCCTCACGTTATC-3´ 5´-CATGGCCCGTAATTCATGGTG-3´ 
Smad 4  5´-ACACCAACAAGTAACGATGCC-3´ 5´-GCAAAGGTTTCACTTTCCCCA-3´ 
Tgfβ1 5´-GGAGAGCCCTGGATACCAAC-3´ 5´-CAACCCAGGTCCTTCCTAAA-3´ 
Tgfr1 5´-GCTCCTCATCGTGTTGGTG-3´ 5´-CAGTGACTGAGACAAAGCAAAGA-3´ 
Tgfr2 5´-AGTCGGATGTGGAAATGGAA-3´ 5´-ACAGCTGTGGAAGCTTGACC-3´ 
Vegf 5´-GTACCTCCACCATGCCAAGT-3´ 5´-TCGCTGGTAGACATCCATGA-3´ 
Vimentin 5´-AGAGAGAGGAAGCCGAAAGC-3´ 5´-TCCACTTTCCGTTCAAGGTC-3´ 
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Table 12: Antibodies for immunofluorescence, immunohistology and western blotting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method Name Manufacturer 
Immunohistology CD3+  Serotec, Oxford, UK 
 Collagen 1   Cell Signaling, Danvers, MA,  USA 
 F4/80 Serotec, Oxford, UK 
 α-SMA Cell Signaling, Danvers, MA,  USA 
 Anti-mouse IgG Caltag Laboratories, Burlingame, CA, USA 
Immunofluorescence Anti-mouse α-SMA Dako GmbH, Hamburg, DE 
   
Western blot HRP-linked anti-rabbit 
secondary antibody 
Cell Signaling, Danvers, MA,  USA 
 HRP-linked anti-mouse 
secondary antibody 
Cell Signaling, Danvers, MA,  USA 
 β-actin antibody Cell Signaling, Danvers, MA,  A 
 NLRP3 antibody Cell Signaling, Danvers, MA,  USA 
 Smad 2/3 antibody Cell Signaling, Danvers, MA,  USA 
 Phospho-smad2 (Ser 465/467)  Cell Signaling, Danvers, MA,  USA 
Abb.: CD: Cluster of differentiation, α-SMA: alpha smooth muscle actin, HRP: horseradish peroxidase, IgG: 
immunoglobulin G, NLRP-3: Nod-like receptor protein 3, SMAD: small body size mothers against decapentaplegic 
homolog , Ser: serine.  
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Table 13: Stimulants and cytokines
 
 
Table 14: Animal experiments 
Method Name Manufacturer 
Mouse Strains 
 
C57BL/6 N Charles River Laboratories 
International Inc., Sulzfeld, DE 
 Asc -/- (BL/6 background) J. Tschopp (University of 
Lausanne, Lausanne, 
Switzerland). 
 Nlrp-3-/- (BL/6 background) J. Tschopp (University of 
Lausanne, Lausanne, 
Switzerland). 
Mouse handling and 
preservation 
Macrolon Type II cages with 
filter cover 
Bioscape, Emmendingen, D 
 Standard chow Sniff, Soest, Germany 
 
 
 
 
 
 
 
Method Name Manufacturer 
Cell Culture   
 ATP (5 mM) Invitrogen, Eugene, USA 
 LPS (10 ng/ml) Invivogen, Toulouse, FR 
 mTGF-β1  Cell Signaling, Danvers, MA 
Animal models   
 Pan-caspase inhibitor “Z-VAD” Invivogen, Eugene, USA 
 IL-1 receptor antagonist “Anakinra”  Swedish Orphan Biovitrum, Stockholm, S 
Abb.: C57BL/6: C57 black 6 N, BL/6: black 6 N, Asc -/-: Apoptosis-associated speck-like protein containing a CARD 
knock out mice, Nlrp3-/-: nod-like receptor protein 3 knock out mice.    
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2.2 Methods 
 
2.2.1 Cell culture 
Basic principles and theory of cell culture: Cell culture is a method where cells from different 
tissues and origins are grown in an artificial environment. Strains may be classified according to their 
origin and lifespan. Primary cells are isolated directly from tissue and show a limited lifespan. This 
thesis used isolated primary mouse embryonic fibroblasts (pMEFs) from mouse embryos. 
Continuous cell lines are cell clones genetically transformed, which have a much longer lifespan than 
the primary cells. For this thesis, a cell line called NIH-3t3 was used. Each new batch underwent 
Mycoplasma contamination screening using a PCR-kit (Pan Vera, Stratagene; also see Coté, 2000).  
 
General terms and conditions: A sterile environment was assured for the manipulation of cells. 
The cell culture hood was treated 10 to 15 min with UV light and cleaned with 70% Ethanol. To 
keep a sterile environment, laminar air-flow was used during cell handling. All other instruments 
were disinfected with 70% Ethanol solution prior to use. All cells were grown under standard 
conditions (in an incubator set at 37°C supplied with 5% CO2/air). 
 
Culture and passage of cells: Frozen primary cells or cell lines were cultured in 10 to 15 ml of pre-
warmed (37ºC) Dulbecco’s modified Eagle’s medium (DMEM), with 1% Penicillin/Streptomycin 
(PS) and 10% Fetal bovine serum (FBS). The medium was changed after 48 hrs. Cells were split by 
over 80% confluence. Detachment followed using warm trypsin/EDTA and incubation for 5 min at 
37°C. After complete detachment, the warm medium was poured in order to annul the effect of the 
enzyme, and placed into Falcon tubes. Cells were spun at 1000 rpm, the old medium was replaced 
with fresh DMEM containing 10% FBS and 1% PS and then cultured in two new plates.  
Cell count and vitality: Vitality of the cells was regularly checked with the light microscope. After 
detaching cells with Trypsin/EDTA and centrifugation at 75 rpm for 5 min, cells were diluted in 1ml 
DMEM and gently mixed. 10µl were taken and diluted in a falcon, which contained 1ml DMEM, 
giving the proportion 1 in 10. This proportion changed, depending on the pellet and the dilution 
needed (1:5 to 1:100).  Neubauer’s chamber was used for cell counting (Figure 11). 
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Figure 11: Neubauer cell chamber. Neubauers cell chamber is a widely used method for cell counting. Concentrations 
between 250.000 cells/ml and 2.5 million cells/ml are usually necessary for obtaining an accurate estimation of the 
original concentration. Cells are counted in the blue (*) marked squares. Concentration is calculated using the following 
equation:                   Equal concentrations were plated in 6-, 8-, 12- or 96-well plates 
respectively. 
 
Cryopreservation and defrosting of the cells: Healthy cells, at earlier passages were frozen for 
their future use. They were detached from the culture plates with Trypsin/EDTA and spun down for 
3 min at 1000 rpm. The pellet was maintained on ice and carefully re-suspended in cold medium (90 
% culture medium and 10 % DMSO) by mixing up with the pipette. 1.5 ml aliquots were quickly 
dispensed into freezing vials and stored at 4°C. Later slowly frozen at –20°C for 1 hr. and then at                
-80°C. For cell thawing, vials were placed in a water bath at 37°C. For culturing, cells were 
dispensed in 5 ml of warmed DMEM and spun down at 1000 rpm for 5 to 7 min. The cell pellet was 
re-suspended in fresh medium and transferred to 100 mm² culture plates. 
 
2.2.1.1. Stimulation of NIH-3t3 cells and primary mouse embryonic fibroblasts  
NIH-3t3 cells and pMEFs were plated in 6-, 8- or 12-well plates with a maximum concentration of 
0.3x106 (NIH-3t3) and 0.5x106 (pMEFs) cells per well. After 24 hrs, cells were stimulated with 
different cytokines or other non-protein stimulators according to the experimental design. NIH-3t3 
cells were stimulated with mouse TGF-β1 at different concentrations (10, 50 and 100 ng/ml) and for 
various time points (0, 6, 12, 24 and 48 hrs) in order to optimize the results of following experiments. 
Other experiments required co-stimulation with LPS (100 ng/ml) and/or ATP (5 mM). PMEFs from 
WT and Nlrp-3-deficient mice were also stimulated with mouse TGF-β1 (optimized concentration: 
10 ng/ml), LPS (100 ng/ml) and/or ATP (5 mM) according to the experimental design.  
 
            
𝑛°𝑐𝑒𝑙𝑙𝑠/𝑠𝑞𝑢𝑎𝑟𝑒
4
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑥 1𝑚𝑙 𝑥 104 
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2.2.1.2 Isolation of primary mouse embryonic fibroblasts  
12.5 to 13 days pregnant C57 black 6 (C57BL/6 N) female mice from WT and Nlrp-3-deficient mice 
were sacrificed for the posterior isolation of pMEFs. Approximately 8 to 10 mouse embryos were 
extracted from each mouse. Directly after extraction, embryos were placed in PBS and dissected with 
sterilized scissors, scalpel and dissecting forceps. The inner-organs were extracted. The skeleton was 
minced and soaked in warmed DMEM. Minced pieces were then placed in 20 ml falcon tubes with 
trypsin and kept at 37º C for 15 min. Under the sterile laminar flow hood, trypsinized tissue was 
soaked and filtered through a 100 µm cell filter in DMEM, placed into 50 ml Falcons, and spun for 5 
min at 1000 rpm. The supernatant was removed, pellet re-suspended in 10 to 50 ml fresh DMEM 
with 10% FCS and 1% PS, and plated on 100 mm² culture dishes. After 48 to 72 hrs cells viability 
was checked under a light microscope and debris was removed. Fresh DMEM was changed every 48 
hrs. After achieving 80% confluence (2 to 5 days after), cells were split as previously described.  
 
2.2.2 Cell viability assay 
Basic principles and theory: Cell viability assay or MTT assay is a method used to quantify 
proliferation and viability of cells in response to an external stimulus. It is based on the chemical 
reaction of its yellow compound MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) tetrazolium, which is reduced in presence of NADH or NADPH to formazan (Figure 12). 
This reaction is produced by dehydrogenase enzymes, which generate reducing equivalents. The 
equivalents NADH and NADPH can only be produced by metabolic activity and thus living cells. 
The purple/blue intracellular formazan can be solubilized and measured with spectrophotometric 
devices by the changes in the light absorbance of the wells. The absorbance increases proportionally 
to the produced formazan, which mirrors the proliferation status of the cells.  
Procedure: Cells, NIH-3T3 fibroblasts and pMEFs, were plated in a 96-well cell proliferation plates 
at a concentration of approx.10000 cells/well. After 24 hrs, the medium was changed to plain 
DMEM with 1% PS, and without FCS in order to avoid its influence on the cell growth rate and 
enhance synchronization of their proliferation. Mouse TGF-β1 and LPS were added to the wells as 
determined in the experimental design. Pure DMEM was used as a negative control. After 24 to 48 
hrs, 15 µl of MTT dye were added to the samples (in the dark) and left for 4 to 6 hrs wrapped in an 
aluminum cover to avoid light. 75 µl of detergent solution were then added to stop the reaction. After 
24 hrs in the dark, data were analyzed with the ELISA Reader with an absorbance filter of 490 nm 
wavelength.  
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Figure 12: MTT chemical reaction. The yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
tetrazolium is reduced by living cells by NADH which transfers the electrons to the MTT turning into Formazan, which 
has a stable blue color. Adapted from [165].  
 
2.2.3 Biomolecular methods: Gene expression and quantification 
Generalities: For the detection and quantification of genes (DNA, RNA) a PCR (Polymerase Chain 
Reaction) or RT-qPCR (Real Time quantitative Polymerase Chain Reaction) is needed. These 
require different steps. For the RNA expression analyses following steps are required: 
1. RNA isolation 
2. RNA quantification and purity check 
3. cDNA preparation 
4. RT-qPCR 
 
2.2.3.1. RNA isolation 
RNA was isolated from tissues (kidneys from C57BL/6 mice from WT, Nlrp-3-deficient and Asc-
deficient mice) and cells (NIH-3t3 cell line and pMEFs) with the RNA isolation kit Ambion Pure as 
instructed by the kit’s protocol. Kidneys were placed in 600 μl lysis buffer (containing 1% β-
mercaptoethanol) and homogenized for approx. 60-80 seconds in total and then spun at 6000 rpm for 
5 min.  For RNA isolation from cells, 500 μl lysis buffer (containing 1% β-mercaptoethanol) were 
used. Cells were spun at 6000 rpm for 5 min. Hereinafter same protocol was used for both tissue and 
cells. Meanwhile, an equal amount of volume was prepared in another tube with 70% ethanol. 
Supernatant from homogenized tissue was gently mixed and transferred into the 70% ethanol 
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column. Centrifugation at 11000 rpm followed for 15-30 sec. Remaining ethanol was removed and 
350 μl of wash buffer I were added to the columns. Samples were spun at 11000 rpm for 15-30 sec 
two times in a row. 500 μl wash buffer II were then added into the columns and spun at 11000 rpm 
for 15-30 sec three times in a row. Samples were then spun at 11000 rpm for 1 min and columns 
were placed into new elution tubes. Here, 35 μl of RNase free water were added to the samples and 
incubated for 1min at room temperature (RT). Samples were spun at 11000 rpm at last for 1 min and 
placed on ice.  
2.2.3.2. RNA quantification and purity check 
Using the NanoDrop spectrophotometer, isolation purity and quantity were checked. 2 μl were taken 
from each sample and loaded on the measuring surface. Absorbance was measured at the desired 
wavelength, determining RNA concentration in each sample. From the determined concentration, we 
calculated the necessary amount (in µl) needed for the extraction of 1µg RNA per sample. 
Furthermore, absorbance ratio 260/280 nm was used for RNA purity-check. Values around 2.0 (+/- 
0.2 ) were rated as pure [166]. 
2.2.3.3. cDNA preparation 
Reverse transcription is the process used for producing complementary DNA from extracted RNA. 
For this, the enzyme reverse transcriptase (Superscript) is needed. Samples were separated into two 
groups, with and without Superscript, the latter used as a control. For each sample we placed 1 μg of 
sample RNA together with RNase free water, and a “Premix”, containing 9 µl of buffer 1 , 2 µl 1 M 
dithiothreitol (DTT), 0.9 µl 25 mM of nucleoside triphosphates (dNTPs), 1 µl ribonuclease inhibitors 
(RNAsin), 0.5 µl acrylamide, and 0.5 µl hexamer in a new Eppendorf vial. The amount of RNase 
free water was given complementarily to the amount of sample RNA, in order to achieve 16.5 μl per 
sample. Finally, Superscript was added to the samples together with the 6.9 μl of premix and were 
spun at 42°C for 90 min. Synthesized cDNA was either directly used, or kept at -80°C.     
 
2.2.3.4. Real Time-PCR 
Basic principles and theory of the Polymerase chain reaction: PCR is a method used to localize, 
analyze and compare the gene expression at DNA or RNA level of different genotypes based on the 
cell’s natural method for duplication of its genetic material. A DNA-fragment (or template) from 
cells or tissue; a heat-stable DNA polymerase (Taq-Polymerase), primers (forward and reverse), 
nucleotides or dNTPs, specific buffers and MgCl² are the necessary components to reproduce this 
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reaction. It undergoes 3 steps: (1) denaturation, where double strand DNA separates after heating at 
95°C; (2) annealing, where the respective primers bind to the DNA strands and (3) extension, where 
heat-stable DNA polymerases (Taq-polymerase from the bacteria Thermus aquaticus), which works 
at a temperature of about 70-72° C, will attach the correspondent nucleotides of the DNA strand and 
reflect the genetic material. This process will repeat till completing approx. 30 to 45 cycles, 
amplifying the DNA with a factor 220 to 240 [167].  
The gene amplification rate undergoes three phases: (1) An exponential phase, where for each cycle 
an exact duplication of the product takes place; (2) a linear phase, where the reaction slows down due 
to the consumption  its components (dNTPs) and (3) a plateau phase, where the reaction is 
completely stopped and no other products are formed. This is the phase where the amplified DNA is 
detected in agarose gel. 
Real-Time quantification PCR: Unlike PCR, qPCR or RT-qPCR has the advantage of not only 
detecting the desired gene-template but also quantifying the concentration of the targeted DNA in a 
sample. The other advantage of the qPCR relies on the time-point of DNA detection. A PCR will 
show the detected DNA at the end of the reaction. The q-PCR in change uses fluorescent substances 
which bind the target DNA strands while amplifying them, resulting in an increased emission of 
fluorescence. This fluorescence is directly proportional to the expression of the target DNA. Higher 
expressed genes will be easier for the Taq-polymerase to detect, leading to an earlier appearance of 
fluorescence. The so-called Ct or Cp value (Cycle threshold) represents the achievement of a defined 
threshold (threshold of how many cycles were achieved until that point) and reflects a significant 
change in fluorescence emission compared to the background fluorescence. The number of cycles 
needed to reach this specific threshold level is inversely correlated to the amount of nucleic acid that 
was in the original sample; i.e. the lower the Cp value, the more target DNA is present in the sample. 
This value is always found in the exponential phase of amplification [168].  
Procedure: Light Cycler 480 Real-time PCR Systems (Roche, Basel, CH) was used for RT-PCR. 
The prepared cDNA samples were diluted in a 1:10 ratio with RNase free water. 2 µl were taken 
from this dilution and placed in microwells of a 96 multiwell plate, together with 10 μl of SYBR-
Green mastermix, 0.6 μl of forward and reverse primers of the desired genes respectively, 0.16 μl of 
TaqMan polymerase and 6.64 μl of distilled water. Plates were sealed with a plastic film and placed 
in the Light Cycler 480. Cp values were given after 95 min running program (Figure 13).  
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2.2.4 Immunological Methods 
2.2.4.1. Immunofluorescence cell staining  
Immunofluorescence staining was used to evidence different target proteins in cells after stimulation 
with mouse TGF-β1. PMEFs were plated in a 4 well chamber slide at a concentration of 5000 cells 
per well in DMEM together with 10% FCS and 1% PS. After 24 hrs, medium was changed to plane 
DMEM which included mouse TGF-β1. For cell fixation and permeabilization, medium was 
removed and 500 µl of acetone were added per well and then kept at -20° C for 10 min. Wells were 
then blocked with 5% BSA for 3 hrs at 25° C. Incubation with primary antibody (1/100 in PBS plus 
5% BSA) followed for 2 hrs at 25° C. A rabbit anti-mouse (1/10000) antibody was used as secondary 
antibody [169]. Fluorescence was assessed using a fluorescence microscope (Leica DC 300 F, 
Cambridge, UK) and then quantified using analysis software Image J.  
2.2.4.2. Enzyme-linked immunosorbent assay: 
Basic principles and theory: The enzyme-linked immunosorbent assay or ELISA is a technique 
used for the detection of proteins, antigens, and other biomolecules from serum, plasma, cell culture 
supernatants and other substances. Many techniques can be found to perform this experiment. In this 
particular case, we used the so-called “sandwich” ELISA, in which 2 antibodies are used for the 
detection of our target protein. In it, the first antibody (capture antibody) will fix the target protein to 
the plate and later a second antibody (detection antibody) linked to an enzyme (in this case 
horseradish peroxidase or HRP) will attach on the surface of the first antibody. A substrate (here: 
Streptavidin-horseradish peroxidase conjugate or SAv-HRP) will react with the HRP enzyme 
producing luminescence. The amount of color produced is quantified by measuring the absorbance 
with a spectrophotometer. Figure 14 shows a schematic representation of the ELISA “sandwich”.  
Figure 13: Cp value in RT-PCR. Schematic 
representation of the amplification curve in RT-PCR: 
After the initiation phase, luminescence rises until 
arriving the threshold (Ct or Cp value), reflecting a 
significant change in fluorescence. The number of 
cycles needed for the threshold is inversely correlated 
to the amount of nucleic acid in the sample.  
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Procedure: We used OptEIA`s set for mouse IL-1β ELISA for the detection of IL-1β in 
supernatants from NIH-3t3 and pMEFs after 24 hrs of stimulation with LPS (100 ng/ml) and ATP (5 
mM). ELISA`s 96 well plate was coated with 100 μl of capture antibody, diluted in coating buffer, 
sealed and incubated overnight at 4° C. Wells were then aspirated and washed 3 times with 300 μl 
wash buffer per well using ELISA’s microplate washer. In order to remove any residual buffer, the 
plate was inverted and blotted on absorbent paper. 200 μl of assay diluents were added per well and 
incubated it at RT for 1 hr. Aspiration and washing step were repeated three times. Standards (used 
for determining concentration gradient) and sample dilutions were placed on ice. 100 μl of each 
standard, sample, and control were pipetted and incubated at RT for 2 hrs.  Aspiration and washing 
steps were repeated five times. 100 μl of detection antibody were then added and diluted in assay 
diluent to each well, then incubated for 1 hr at RT. Aspiration and washing step were again repeated 
five times. New 100 μl of enzyme reagent were diluted in assay diluent and added to each well. After 
30 min of incubation at RT, aspiration and washing followed, now seven times. 100 μl of substrate 
solution were added to each well and incubated for 30 min (unsealed) at RT in the dark. In order to 
stop the reaction, other 50 μl of stop solution were added to each well. Results were quantified with 
the ELISA Reader at an absorbance of 450 nm within 30 min after stopping the reaction [170].  
Analysis: Standards defined different concentrations, which were used to build a linear function. 
This function was then used to calculate the concentration values in the samples. Blanks were 
subtracted from the standards. 
 
  
Figure 14: ELISA sandwich. A capture 
antibody coats the plate to further bind the  
target protein. A detection antibody linked 
to HRP binds specifically to the targeted 
protein, which after addition of 
Streptavadin-HRP reacts with the enzyme, 
producing luminescence. Abb.: HRP: 
horseradish peroxidase.  
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2.2.4.3. Western Blot 
Basic Principles of western blotting: Western blot is a technique researchers use to evidence the 
presence and amount of a desired protein in cells, tissue, serum or other substances. Four basic steps 
are essential in this process:  
1. Isolation of proteins from cells or tissue 
2. Protein estimation using Bradford’s Assay 
3. Separation of proteins with gel electrophoresis (SDS – PAGE) 
4. “Blotting”: Transfer of proteins to a solid support (PVDF membrane)  
5. Detection of the targeted protein with antibodies and developing 
Protein isolation: The technique used for extraction of proteins from cells and tissue followed basic 
principles with minor differences:  
From Tissue: Kidneys from sacrificed mice were carefully extracted. After thawing, or directly after 
sacrifice, tissues were placed in 1.5 ml Eppendorf tubes containing 520 µl of lysis buffer (composed 
of  500 µl RIPA Buffer and 20 µl protease inhibitor in a 25 to 1 ratio. The protease inhibitor stock 
tablet was previously prepared and diluted in 2 ml water. For identifying phosphorylated proteins, a 
phosphatase inhibitor was added to the mixture in a 4 to 1 ratio.  This inhibitor was used to prevent 
the lysis of the phosphate-bindings. Samples were kept on ice during this step to avoid protein 
denaturation and were later homogenized using blade homogenizer for 30 sec.   
From Cells: Media was extracted from previously stimulated cells and then washed with PBS. Wells 
were then placed on ice and lysis buffer was added in the same amount and proportions as described 
above. Cells were detached with a 24 cm cell scraper and gently mixed with a pipette. The 
supernatant was placed into 1.5 ml Eppendorf tubes and later homogenized as described above. 
Following homogenization, samples from both tissue and cells were kept at 4° C for 2 hrs on a rotor. 
Afterwards, they were spun at 12000 rpm for 20 min at 4° C. The remaining supernatants, which 
contained the protein fraction, were collected and placed in 1.5 ml Eppendorf tubes.  
Protein estimation - Bradford’s assay - and Sample preparation: The amount of protein collected 
from the samples always depends on quality and amount of the extracted tissue or cells. The 
determination and equalization of protein concentration in samples are essential for the posterior 
comparison between them. Bradford’s assay was used for analysis of protein concentration. It uses 
Coomassie Brilliant Blue G-250 dye, which binds to proteins and by doing so turns into its stable 
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blue form. The concentration can be measured with a spectrophotometer at 595 nm absorbance filter 
[171].  
Samples and standards were placed in a 96 well plate.  Bovine serum albumin (BSA) was used for as 
a control. BSA was diluted with water at different concentrations, forming a linear function, which 
served as a reference for the samples. We took 1 µl of each sample and diluted it in 9 µl of water. At 
the end, Coomassie Brilliant Blue was given to the standards, samples and blanks. After 10 min 
incubation at RT, absorbance was measured with Elisa reader and a 590 nm absorbance filter. Using 
the function derived from standards, protein concentration was determined. For the gel 
electrophoresis, equal amounts of protein were needed from the samples (60 to 100 µg protein per 
column). The amount of solution needed per sample; in order to get 60 µg protein for each column, 
was calculated using the following equation:  
 
This applies in our experiment as followed: 
 
 
With V = volume of sample needed. The needed volume of water to dilute the samples will then 
result from:  
 
Finally, 25 µl of 4X loading buffer (100 mM Tris-HCl, 4% SDS, 20% glycerol and 0.2% 
bromophenol blue) were added to each sample. SDS (sodium dodecyl sulfate) was used to line up 
proteins and impart a negative charge. This allows proteins to separate only by size. Samples were 
then boiled at 95°C for 5 min in order to denature the higher order structure and ensuring that the 
negative charge of amino acids is not neutralized. 
Gel Electrophoresis (SDS–PAGE) and semi-dry transfer 
Gel Electrophoresis: This method is used to separate molecules (DNA, RNA or proteins) by size. 
Here, molecules travel through a polyacrylamide gel from the cathode to the anode. Here, acrylamide 
is used to determine the pore size. The smaller the protein, the more acrylamide was needed.  
SDS-gel preparation: Two types of gel were prepared: one stacking gel used to place the samples 
and order them in a line (less amount of acrylamide), and a separating gel (with a higher amount of 
acrylamide) used for the actual separation of the molecules. Table 10 above lists the ingredients of 
both gels. The gel was placed after solidification in the electrophoresis chamber, together with the 
100 µ𝑙 − 𝑉µ𝑙 = 𝑉𝑜𝑙𝑢𝑚𝑒 (µ𝑙)𝑜𝑓 𝑊𝑎𝑡𝑒𝑟 𝑛𝑒𝑐𝑒𝑠𝑠𝑎𝑟𝑦 𝑓𝑜𝑟 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
𝑁1 𝑥 𝑉1 = 𝑁2 𝑥 𝑉2 
𝑆𝑎𝑚𝑝𝑙𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 �
𝑚𝑔
𝑚𝑙
� 𝑥 𝑽 µ𝑙 = 𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 �
𝑚𝑔
𝑚𝑙
� 𝑥 100 µ𝑙 
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running buffer, which was added until stacking gel was covered. 10 to 20 µl of each sample were 
loaded in the stacking gel. The previously added bromophenol blue allowed tracking of the proteins 
during the electrophoresis. Lane non-reducing protein marker was placed in the first well and served 
as a reference to protein size. Samples ran for 30 min at a lower voltage (100 V) in the stacking gel 
and higher voltage (140 V) in the separating gel during 60 min. 
“Blotting”-transfer to the PDVF membrane-: Blotting refers to the transfer of molecules from a 
membrane to a solid support. In this case, a semidry transfer was used as pictured below (Figure 15): 
              
 
  
Whatman paper was used as “sponge” after being soaked in transfer buffer. Polyvinylidene 
difluoride membrane (PDVF-membrane) was soaked in methanol for its activation and then placed 
in transfer buffer. Each step required removal of excess liquid, giving it its “semi-dry” character.  
The “transfer-sandwich” was placed in a semi-dry transfer unit, which ran for 120 min at 25 V. After 
transfer, the gel was discarded and the membrane was washed with TBS-T (preparation see table 10).   
Detection of targeted protein and developing: In order to avoid a non-specific binding of the 
antibodies to the membrane, blocking for 60 min at RT with 5% milk in Tris-buffered saline (20mM 
Tris-HCl, 150 mM NaCl and 0,1% Tween 20) was performed. Incubation of the primary antibody 
followed overnight at 4° C on a roller-mixer. Next day, after washing several times with TBS-T, the 
membrane was incubated with the respective secondary antibodies in 5% milk Tris-buffered saline. 
Washing with TBS-T was repeated in order to prepare the PDVF membrane for developing. Signals 
were visualized by an enhanced chemiluminescence system (ECL) using an x-ray developer. β-actin 
was used as a control in all experiments [172].  
Figure 15: “Blotting” or semidry 
transfer. The separated proteins are 
transferred to a PDVF membrane. 
Transfer buffer is carefully removed 
from Whatman paper. On top follows 
the PDVF membrane and 
subsequently the gel with the 
separated proteins. After a new piece 
of transfer buffer-soaked Whatman 
paper, the semidry transfer unit is 
closed. The “transfer-sandwich” ran 
for 120 min at 25 V. Abb: PDVF: 
polyvinylidene difluoride.  
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2.2.5 Animal experiments 
2.2.5.1. General terms and conditions  
Mouse handling and preservation: C57BL/6 N WT mice were purchased from Charles River 
Laboratories, Sulzfeld, DE. Nlrp-3- and Asc-deficient mice (with BL/6 background) were obtained 
from J. Tschopp (University of Lausanne, Lausanne, Switzerland).  Mice were housed in filter-top 
cages with unlimited access to food and water. Cages, nest lets, food and water were sterilized before 
use. A maximum of five mice were kept in cages with a 12 hr light-dark cycle. The mouse housing 
status corresponded with the “specific pathogen-free” guidelines. Mouse handling was performed in 
sterile banks (except for sacrifice). All experimental procedures were approved by the local 
government authorities. 
General guidelines for surgery: For every surgical procedure, general terms and conditions 
described by the guidelines and suggestions of local government authorities were to be followed. The 
special permit by the Regierung von Oberbayern was a prerequisite for performing any surgical 
procedure.   
Organ extraction and preservation: Kidneys were extracted from mice after sacrifice by cervical 
dislocation, then placed in PBS and cut with a scalpel in three parts for subsequent analysis. The first 
third was left in liquid nitrogen for cryopreservation. The second third was placed in histological 
cassettes with 1.8% formalin and after 24 hrs embedded in paraffin blocks for histopathological 
analysis. The third part was preserved at -20° C for RNA analysis.  
 
2.2.5.2. Animal Models:  
Chronic oxalate nephropathy: The description and purposes of this model are discussed in the 
previous chapter. For this model, we used male 8-12 week old gender-matched C57BL/6 N WT      
(n = 4), Nlrp-3- (n = 4), Asc-deficient (n = 4), vehicle- (n = 4) and anakinra-treated (n =4) mice, who 
received a high soluble oxalate diet which was prepared by adding 50 μmol/g sodium oxalate to a 
calcium-free standard diet. Oxalate- and calcium-free control diet was given for three days before 
switching to high soluble oxalate diet. The anakinra-treated mice group received intraperitoneal 
injections of anakinra in a dose of 5 mg/kg/ day for 14 days. Urine and plasma samples were 
collected at different time points prior to sacrifice. After 14 days mice receiving an oxalate-rich diet 
were sacrificed. Kidneys were extracted for analysis. All animal experiments were performed in 
accordance with the European protection law of animal welfare and with approval by the local 
government authorities Regierung von Oberbayern (reference number: 55.2-1-54-2532-189-2015). 
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Unilateral ureteral obstruction: 8 to 12 week old C57BL/6N WT (n = 7), Nlrp-3- (n = 6), Asc-
deficient (n = 6) and zVAD-treated (n = 6) mice were housed under the previously described 
conditions. The general guidelines for surgery were stringently followed for the UUO surgery 
(including pre- and post-surgery procedures). Mouse body temperature was adjusted by placing the 
mouse on a HEKA breeding device. The breeder’s temperature was settled at 37° C, the heating 
plates at 42° C. Narcosis and analgesia were performed as described by the general guidelines for 
mouse surgery. Mice were immediately placed in the breeder after anesthesia, kept for 10 min and 
then strapped to the plate. Shaving of the area of the incision with the razor blade followed after 
disinfection of the fur with ethanol. After cutting the skin with a scalpel, a cutaneous layer was 
separated from muscles and peritoneum with forceps. The peritoneal cavity was opened to find the 
bladder. After carefully positioning the bladder outside the body with the large forceps, a mucous 
layer around the bladder was removed. Ureters were to be found caudal to the bladder. A 5-0 
(Ethibond) non-absorbable suture was used to ligate the left ureter with 2 double knots. The bladder 
was then repositioned in the peritoneal cavity. Muscles were then sutured with 5-0 (Vicryl) suture 
followed by the skin with (Ethibond-double knots). All events during and after surgery were 
carefully documented. Distress and pain score were registered regularly. After 10 days, mice were 
sacrificed by cervical dislocation and both kidneys (ligated and not) were harvested for analysis. All 
animal experiments were performed in accordance with the European protection law of animal 
welfare and with approval by the local government authorities Regierung von Oberbayern. 
 
2.2.5.3 Urinary creatinine, plasma creatinine and plasma BUN  
Urinary creatinine and plasma creatinine levels were measured using Jaffe´s enzymatic reaction with 
the Creatinine FS kit. Urine samples were diluted 10 times with distilled water, whereas plasma 
samples were used undiluted. Different dilutions of the standard were prepared using the stock 
provided with the kit. Working mono-reagent was prepared by mixing 4 parts of reagent 1 (R1) and 1 
part of reagent 2 (R2) provided within the kit. Then, 10μl of each of the diluted samples and 
standards were added to a 96 well plate with a flat bottom. The mono-reagent (200µl) was added to 
each well and the reaction mixture was incubated for one minute before measuring the absorbance at 
492 nm immediately after and 1 (A1) and 2 (A2) min of addition using ELISA reader. The change in 
absorbance (Δ A) was calculated as: 
Δ A = [(A2 – A1) sample or standard] – [(A2 – A1) blank] 
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Creatinine was calculated as:   
Creatinine (mg/dl) = ΔA sample /ΔA standard * Concentration of standard (mg/dl) 
Plasma BUN levels were measured using a Urea FS kit. Different dilutions of the standard were 
prepared using the stock provided with the kit. Working mono-reagent was prepared by mixing 4 
parts of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 2 μl of each of the 
sample and standards were added to a 96 well plate. The mono-reagent (200 µl) was added to each 
well and the reaction mixture was incubated for one minute before measuring the absorbance at 360 
nm immediately after and 1 (A1) and 2 (A2) min of addition using ELISA plate reader.  
The change in absorbance (Δ A) was calculated as:  
Δ A = [(A1 – A2) sample or standard] – [(A1 – A2) blank] 
And BUN content of samples was calculated as [173]:   
BUN (mg/dl) = ΔA sample /ΔA standard * Concentration of standard (mg/dl)*0.467 
 
 
2.2.6 Histologicalpathological staining and evaluation 
Kidney tissues were preserved as described above. After paraffin embedment, 2 µm thick sections 
were cut with the cryomicrotome Cryostat RM 2155 and placed with ammonium persulfate on 
microscope slides. After drying for 12 hrs at 37°C, xylene and ethanol were added for de-
paraffinization and rehydration of the samples and then washed with PBS.  
Periodic Acid-Schiff: Re-hydrated sections were incubated in periodic acid (2% in distilled water) 
and washed with distilled water. Then, sections were incubated with Schiff solution for 20 min at 
RT. After washing with tap water, samples were stained with hematoxylin for 2 min. Sections were 
then washed with tap water and 90% ethanol before drying with closure coverslips.  
Immunostaining: For immunostaining, rehydrated sections were incubated in H2O2 and methanol 
(20 ml of 30% H202 in 180 ml of methanol) for 20 min in the dark and then washed with PBS. 
Sections were dipped in antigen unmasking solution (3 ml of antigen unmasking solution together 
with 300 ml of distilled water) and cooked in the microwave for a total of 10 min, with continuous 
water check over time. They were then cooled at RT for 20 min and washed with PBS. Sections were 
then incubated with Avidin (Vector for blocking endogenous biotin) followed by an incubation with 
biotin. Slides were then washed with PBS prior to incubation with primary antibodies. The primarily 
used antibodies are listed in Table 12. Negative controls were performed for each staining by 
incubating with a respective isotype antibody instead of primary antibody. Incubation with primary 
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antibody was performed either for 1 hr at RT or overnight at 40° C in a wet chamber. They were then 
washed with PBS. Slides were incubated with biotinylated secondary antibodies (1:300, dilution in 
PBS) for 30 min and then washed with PBS. Substrate solution (ABC solution, Vector) was added 
and sections were incubated for 30 min at RT in a wet chamber. After washing with PBS and Tris, 
sections were stained for DAB by counterstaining with methyl green (Fluka). Posteriorly they were 
washed with alcohol (96%) to remove excess stain and xylene. Sections were dried and mounted 
with Vecta Mount (Vector). 
Pizzolato’s staining: Calcium-oxalate deposition in kidney sections was visualized with Pizzolato’s 
staining. Kidney sections were placed in paraffin, then deparaffinized and rehydrated with distilled 
water. Silver nitrate hydrogen peroxide solution was poured onto slides and subsequently placed 
under a 60 Watt light bulb for 30 min. After careful washing with distilled water, slides were 
counter-stained for 5 min. Repeated washing with distilled water followed. Finally, 95% alcohol, 
100% alcohol and xylene were used for dehydration.   
 
2.2.6.1 Histopathological evaluation and scoring 
PAS: Histopathological evaluation of mouse kidneys was assessed by using a tubular injury score. 
This semi-quantitative scoring evaluated the percentage of tubular dilation, cast formation, flattening 
of the tubular cells and denudation of the renal tubules with or without loss of brush border (loss of 
tubular cells from basal membrane), having for each point a minimum (0 pts) and maximum (5 pts) 
as described in table 15. Kidney sections were evaluated using a light microscope Leica DII. 
Quantification is expressed as mean ± SEM [174].  
Table 15: Tubular injury score for evaluation of kidney injury 
Adapted from [173] 
Score Estimated damage Estimated Percentage 
0 None 0% 
1 Very mild <10% 
2 Mild 11% - 40% 
3 Significant 41% - 60% 
4 Severe 61% - 79% 
5 Very severe >80% 
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Alfa-SMA and collagen I: Interstitial fibrosis was assessed by quantification of α-SMA and 
collagen I positivity per kidney section. Kidney sections were evaluated using light microscope Leitz 
I and photographed. Image J software was used for quantification analysis of positive areas from 
kidney sections. Data are presented as mean ± SEM %/area [175]. 
Crystal deposition:  Calcium-oxalate crystal deposition was assessed using Pizzolato’s staining. 
Kidney sections were evaluated using light microscope Leitz I and photographed. Quantification 
analysis of calcium-oxalate positivity was assessed using Image J software. Data are presented as 
mean ± SEM %/area.   
CD3 +: CD3 antibody was used for assessment of the expression of the T-cell receptor complex 
(TCR). Kidney sections were analyzed using light microscope Leitz I and photographed. CD3 
positivity was counted in each kidney section and then a mean was calculated for each kidney. 
Results are presented as mean ± SEM.   
F4/80 +: Immunostaining using F4/80 antibody assessed macrophage infiltration per kidney section. 
Slides were evaluated with a light microscope Leitz I and subsequently photographed. F4/80 
positivity was assessed using Image J software. Results are presented as mean ± SEM %/area.   
 
2.2.7 Statistical analysis 
All the results are shown in column bar graphs and represent the means of each group with their 
correspondent standard errors of the mean (SEM). For determining statistical differences between 
groups unpaired student’s T-test and one-way ANOVA were used. P-values are shown as follows: 
*p<0.05; **p<0.01; ***p<0.001.   
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3. Results 
3.1 In vivo studies 
 
3.1.1 Unilateral ureteral obstruction model  
CKD is associated with abnormalities of kidney function and structure [4] and its progression 
correlates with the amount of interstitial inflammation and fibrosis [176]. The UUO animal model is 
often used for studying renal inflammation and interstitial fibrosis. To address the potential role of 
NLRP3 and ASC in the development of renal interstitial fibrosis in vivo, UUO surgery was 
performed in age and gender-matched C57BL/6 WT, Nlrp-3- and Asc-deficient mice and sacrificed 
after 10 days.  
3.1.1.1 NLRP3 inflammasome axis is up-regulated in C57BL/6 mice upon UUO.  
Muruve et al. previously suggested that the NLRP3 inflammasome is activated in mice after UUO 
surgery [152]. We corroborated these observations by measuring mRNA expression levels of the 
NLRP3 inflammasome related genes Nlrp-3, Asc and Casp-1, and the proinflammatory cytokines 
pro-IL-1β and pro-IL-18 in kidneys of WT mice after UUO compared to control mice. mRNA 
expression levels of Nlrp-3, Asc and Casp-1 were significantly higher in WT mice after UUO 
compared to control mice (Figure 16). Similarly, expression levels of the pro-inflammatory cytokines 
pro-IL-1β and pro-IL-18 showed a significant increase in WT mice after UUO compared to control 
mice. These findings suggest that the Nlrp-3-IL-1β-axis was up-regulated in mice after UUO 
surgery.                                        
                      
Figure 16: UUO involves up-regulation of NLRP-3 inflammasome associated genes. WT C57BL/6 mice (n = 7) 
underwent UUO surgery and were sacrificed at day 10. Graphs show mRNA expression levels of inflammasome related 
genes Nlrp-3, Asc, Casp-1 and cytokines pro-Il-1β and pro-Il-18 in WT kidneys compared to control kidneys (n = 7), 
without UUO. Significant up-regulation of these genes is observed in mice that underwent UUO. Gene expression is 
shown as x-fold increase of the target gene over the 18s mRNA expression. These results represent the mean ± SEM of 
one out of two independent experiments. Abb.: Ctrl: control, WT: wild type, *p<0.05, **p<0.01.  
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3.1.1.2 Nlrp-3- or Asc-deficiency protects mice from tubular injury upon UUO 
In the next series of experiments renal pathological changes were assessed in C57BL/6 WT, Nlrp-3- 
and Asc-deficient mice after UUO and compared to control mice without UUO. Renal injury was 
evaluated on PAS stained kidneys that showed a marked tubular cell flattening, atrophy and 
denudation in WT mouse kidneys after 10 days UUO (Figure 17 A and B). These pathological 
features were ameliorated in Nlrp-3- and Asc-deficient mice, which showed significant protection 
when assessed by tubular injury scoring (Figure 17 A and B). These findings were corroborated by 
estimating mRNA expression levels of the kidney injury markers Kim-1, L-FABP and π-GST, which 
were significantly less expressed in both Nlrp-3- and Asc-deficient mice compared to WT mice 
(Figure 17 C). Taken together, we confirm that lack of Nlrp-3 and Asc in mice diminishes renal 
injury upon UUO. 
3.1.1.3 Nlrp-3- or Asc-deficiency protects mice from renal inflammation upon UUO 
Inflammation is the response of the immune system to an injurious trigger. The NLRP3 
inflammasome is well-known for its crucial role in inflammatory processes.  Therefore, we evaluated 
the inflammatory component in WT, Nlrp-3- and Asc-deficient kidneys upon UUO and compared it 
to control mice, without UUO. Immunostaining for the macrophage/monocyte marker F4/80 
revealed an increased infiltration of these cells into the tubulointerstitial space of WT kidneys after 
UUO compared to controls. This expression was significantly reduced, although not abolished, in 
Nlrp-3-deficient mice compared to the WT group (Figure 18 C and D). However, this observation 
could not be replicated in Asc-deficient mice (Figure 18 C and D). An increased infiltration of CD3+ 
T-lymphocytes in WT mice upon UUO was observed compared to control mice as indicated by CD3 
immunostaining (Figure 18 A and B). Whereas less CD3+ T-lymphocytes were found in Nlrp-3- and 
Asc-deficient mice as quantified in figure 18 B. Additionally, mRNA levels of the inflammatory 
markers CCL2 and CXCL2 were significantly increased in kidneys of WT mice compared to control 
mice. In Nlrp-3- and Asc-deficient mice the expression of CCL2 and CXCL2 was less but not 
significant compared to the WT group (Figure 18 E). Taken together, both inflammasome 
components NLRP-3 and ASC drive renal inflammation upon UUO.   
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Figure 17: Nlrp-3- or Asc-deficiency protect mice from tubular injury upon UUO. C57BL/6 mice from WT          
(n = 7), Nlrp-3-/- (n = 6) and Asc-/- (n = 6) underwent UUO surgery, were sacrificed at day 10 and compared to control 
mice (n = 7) without UUO. (A) PAS staining of kidney sections from control, WT, Nlrp-3-/- and Asc-/- mouse kidneys 
after 10 days UUO. Arrows show dilated proximal tubules with tubular cell flattening. (B) Quantification of tubular 
injury after pathologic scoring showed significant less injury in Nlrp-3-/- and Asc-/- mouse kidneys. (C) MRNA 
expression levels of kidney injury markers L-FABP, Kim-1 and π-GST in controls, WT, Nlrp-3-/- and Asc-/- mouse 
kidneys. Significant less expression of these markers is observed in Nlrp-3-/- mouse kidneys compared to the WT. 
Gene expression is shown as x-fold increase of the target gene over the 18s mRNA expression. These results represent 
the mean ± SEM of one out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, NLRP3-/-: 
Nlrp-3-deficient mice, ASC-/-: Asc-deficient mice *p<0.05, **p<0.01. 
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Figure 18: Renal inflammation is reduced in Nlrp-3- and Asc-deficient mice undergoing UUO. C57BL/6 mice 
from WT (n = 7), Nlrp-3-/- (n = 6) and Asc-/- (n = 6) underwent UUO surgery, were sacrificed at day 10 and compared 
to control mice (n = 7) without UUO. (A) Immunostaining of kidney sections for Th-cell marker CD3 and (B) 
quantification analysis reveal a significantly increased expression in the WT group and a trend to less expression in the 
Nlrp-3-/- and Asc-/- group.     (C) Immunostaining of kidney sections for macrophage marker F4/80 and (D) 
quantification analysis of F4/80 positivity reveal a significant reduction of these in Nlrp-3-/- compared to WT mouse 
kidneys. This could not be shown for Asc-/- mice. (E) MRNA expression levels of inflammation markers CXCL2 and 
CCL2 in Ctrl, WT, Nlrp-3-/- and Asc-/- mouse kidneys after 10 days UUO show a trend to less expression of the 
markers in Nlrp-3-/- and Asc-/- compared to the WT. Gene expression is shown as x-fold increase of the target gene 
over the 18s mRNA expression. These results represent the mean ± SEM of one out of two independent experiments. 
Abb.: Ctrl: control mice, WT: wild type mice, Nlrp-3-/-: Nlrp-3 deficient mice, Asc-/-: Asc deficient mice *p<0.05,
**p<0.01. 
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3.1.1.4 Nlrp-3- or Asc-deficiency protects mice from interstitial fibrosis upon UUO  
The UUO model is characterized by a prominent tubulointerstitial fibrosis produced in a short period 
of time. In order to address the role of NLRP3 and ASC in tubulointerstitial fibrosis in vivo, 
immunostaining of the myofibroblasts marker α-SMA and ECM matrix protein collagen I was 
assessed in kidney sections of control, WT, Nlrp-3- and Asc-deficient mice after UUO. 
Quantification of immunostaining for α-SMA and quantification analyses showed a significant 
increase in the expression of α-SMA in the WT group after UUO compared to the controls. Nlrp-3-/- 
and Asc-/- mouse kidneys revealed significantly less interstitial deposition of α-SMA when 
compared to the WT group (Figure 19 A and B). These findings correlated with the increased 
collagen I deposition in WT mice after UUO, which was also significantly reduced in Nlrp-3-/- and 
Asc-deficient mice (Figure 19 C), as quantified in figure 19 D. Thus, we conclude that NLRP3 and 
ASC augment renal fibrogenesis upon UUO. 
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Figure 19: Nlrp-3- or Asc- deficiency protects mice from tubulointerstitial fibrosis after UUO. C57BL/6 mice 
from WT (n = 7), Nlrp-3-/- (n = 6) and Asc-/- (n = 6) underwent UUO surgery, were sacrificed at day 10 and 
compared to control mice (n = 7) without UUO. (A) Immunohistochemestry of myofibroblast marker α-SMA and (B) 
quantification analysis of the α-SMA positive areas in kidney sections after UUO (results in mean % area ± SEM). (C) 
Immunohistochemestry of fibrosis marker collagen I and (D) quantification of collagen I positive areas in kidney 
sections after UUO (results in mean % area ± SEM). Significant less expression of both fibrosis markers in Nlrp-3- 
and Asc-deficient mice is shown compared to WT kidneys after UUO surgery. These results represent the mean ± 
SEM of one out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, Nlrp-3-/-: Nlrp-3-
deficient mice, Asc-/-: Asc deficient mice, *p<0.05, **p<0.01. 
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3.1.1.5 Caspase inhibition only partially improves renal injury and inflammation upon UUO 
We have previously demonstrated that Nlrp-3- or Asc-deficiency protects mice from renal injury, 
inflammation and tubulointerstitial fibrosis upon UUO. Whether this effect relies on the NLRP3-
Casp-1-dependent reduced IL-1β secretion was not assured. A recent study suggested a Casp-1-
independent role of NLRP3 in tubular epithelial cells [138]. To address the role of Casp-1 in renal 
injury, inflammation and interstitial fibrosis, in particular on inflammasome-activation and cleavage 
of IL-1β, 2 mg/kg/day of the pan-caspase inhibitor zVAD were given by intraperitoneal injection to 
C57BL/6 mice, starting with treatment from day -1 prior to UUO surgery until sacrifice on day 10. 
PAS stainings of control, WT and zVAD-treated mice revealed increased tubular injury in WT and 
zVAD treated mice compared to the controls after UUO (Figure 20 A). Pathological scoring showed 
significantly less injury in zVAD-treated mice compared to the WT group (Figure 20 C). Although 
this difference was considerably less than previously observed in Nlrp-3- and Asc-deficient mice 
when compared to the WT group as demonstrated in figure 17 A and B. mRNA expression analysis 
of the kidney injury markers Kim-1, L-FABP and π-GST revealed a significantly higher expression of 
these markers in both WT and zVAD-treated mice compared to the controls, with no significant 
difference between WT and zVAD-treated kidneys (Figure 20 B).  
Furthermore, immunohistochemical analysis of the monocyte/macrophage marker F4/80 in kidney 
sections from WT, zVAD-treated mice and controls, demonstrated a significantly reduced infiltration 
of macrophages in zVAD-treated mice compared to the WT group (Figure 21 A and C). This was not 
the case for CD3+ T-lymphocytes, which did not show any significant difference between WT and 
zVAD-treated mice (Figure 21 B and D). Finally, expression profiling of the inflammation markers 
pro-IL-1β, pro-IL-18, Cxcl2 and Ccl2 did not show any significant difference between WT and 
zVAD-treated mice after 10 days UUO (Figure 21 E). These findings suggest that the Casp-1-
dependent IL-1β cleavage is involved in renal injury and tubulointerstitial inflammation upon UUO. 
Nevertheless, these results did not show a profound protection as observed in Nlrp-3- and Asc-
deficient mice, suggesting a role of NLRP3 and ASC beyond Casp-1-mediated IL-1β cleavage in 
renal injury and inflammation upon UUO. 
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Figure 20: Caspase inhibition only partially protects mice after UUO. C57BL/6 mice from WT (n = 7) and zVAD-
treated (n = 7) mice underwent UUO surgery and were sacrificed at day 10. Kidney sections of mice without UUO (n = 7) 
were used as control. (A) PAS-staining from WT, zVAD-treated and control kidneys after 10 days UUO. Arrows point at 
dilated and injured tubules. (B) MRNA expression of Kim-1, L-FABP and π-GST was quantified with RT-PCR and 
compared to control mice. Here, no significant differences are observed between WT and the zVAD-treated group. Gene 
expression is shown as x-fold increase of the target gene over the 18s mRNA expression. (C) Tubular injury score analysis 
of mouse kidneys upon 10 days UUO compared to controls (in Mean ± SEM). Significant differences are observed 
between the zVAD-treated and WT group. These results represent one out of two independent experiments. Abb.: Ctrl: 
control mice, WT: wild type mice, zVAD: treatment with pan Caspase inhibitor zVAD. *p<0.05, **p<0.01. 
  
74 
 
     
          
        
 
Figure 21: Caspase inhibition reduces renal inflammation after UUO. C57BL/6 mice from WT (n = 7) and 
zVAD-treated (n = 7) mice underwent UUO surgery and were sacrificed at day 10. Kidney sections of mice without 
UUO (n = 7) were used as control. (A) Immunohistochemestry of macrophage/monocyte marker F4/80 in WT, 
zVAD-treated and control kidneys. (B) Immunohistochemestry of T-lymphocyte marker CD3+ in WT, zVAD-treated 
and control kidneys. (C) Quantification of F4/80 positivity in kidney sections (results in mean % area ± SEM). 
Significantly less positivity of F4/80 in zVAD-treated mice compared to WT. (D) Quantification analysis of CD3 
positivity in kidney sections (results in mean % area ± SEM). Here, no significant differences are observed between 
groups after UUO. (E) MRNA expression of proinflammatory cytokines pro-IL-1β, pro-IL-18, and inflammation 
markers Cxcl2 and Ccl2 in kidneys of WT and zVAD-treated mice after 10 days UUO show no significant difference 
between groups. Gene expression is shown as x-fold increase of the target gene over the 18s mRNA expression. These 
results represent the mean ± SEM of one out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type 
mice, zVAD: treatment with pan-caspase inhibitor zVAD. ns: not significant. *p<0.05,**p<0.01. 
. 
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3.2.1.4 Caspase inhibition ameliorates, but does not protect mice from tubulointerstitial 
fibrosis after UUO 
Next, we evaluated whether Casp-1-inhibition and therefore, the inability of the NLRP3 
inflammasome to release active IL-1β resulted in the reduction of renal interstitial fibrosis upon 
UUO. To address this, immunohistochemistry of the myofibroblasts marker α-SMA and the ECM 
protein collagen I was evaluated in kidney sections of WT and zVAD-treated mice after 10 days 
UUO (Figure 22 A-C). Quantification of α-SMA positivity revealed a significantly reduced 
expression of α-SMA in zVAD-treated mice compared to the WT group (Figure 22 C left). However, 
the collagen I stainings showed no significant difference between the WT and zVAD-treated mice 
(Figures 22 C right). Although Casp-1 inhibition with zVAD showed some level of reduction in 
immunohistochemical α-SMA expression, this was not as pronounced as in Nlrp-3- and Asc-deficient 
mice, as shown in figure 19. Western blot analysis of α-SMA protein expression revealed 
significantly less expression of α-SMA in the kidneys of Nlrp-3-deficient mice compared to the WT 
and the zVAD-treated group (Figure 22 D and F). Finally, mRNA expression profiling of the fibrotic 
markers α-SMA, collagen I, vimentin, CTGF and VEGF in kidneys of zVAD-treated and WT mice 
revealed no significant difference between these two groups (Figure 22 E). Taken together, our 
results suggest that Casp-1 inhibition ameliorates renal interstitial fibrosis upon UUO, but to a less 
extent compared to the protective effect observed in Nlrp-3-deficient mice. These observations 
suggest an additional inflammasome-independent role for NLRP3 in the development of renal 
interstitial fibrosis upon UUO.  
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Figure 22: Caspase 1 inhibition ameliorates, but does not protect mice from tubulointerstitial fibrosis after 
UUO. C57BL/6 mice from WT (n = 7) and zVAD-treated (n = 7) mice underwent UUO surgery and were sacrificed at 
day 10. Kidney sections of mice without UUO (n = 7) were used as control.                                                                                         
(A) Immunohistochemistry of myofibroblast marker α-SMA and (B) collagen I. (C) Quantification analyses of the α-
SMA and collagen I positive areas in kidney sections after UUO (results in mean area % ± SEM). No significant 
difference is observed between the WT and zVAD-treated group. (D) Western blot analysis of α-SMA expression in 
WT, zVAD-treated, Nlrp-3-/- and Asc-/- mouse kidneys. (F) Quantification analysis reveals significant less expression 
of the protein in the Nlrp-3-/- and Asc-/- group. (E) MRNA expression levels of profibrotic markers α-SMA, col1a1, 
vimentin, CTGF and VEGF reveals no significant difference between WT and zVAD-treated groups. Gene expression 
is shown as x-fold increase of the target gene over the 18s mRNA expression. These results represent one out of two 
independent experiments. Abb.: C: contra lateral, U: UUO, Ctrl: control mice, WT: wild type mice, zVAD: treatment 
with pan-caspase inhibitor zVAD. *p<0.05, **p<0.01. 
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3.1.1.6 NLRP3, but not Casp-1, modulates TGF-β1 signaling  
The above-described results suggest an inflammasome-independent role for NLRP3 in renal 
interstitial fibrosis. It is known that the leading mechanism for the development of renal interstitial 
fibrosis involves TGF-β1 signaling and that the expression of several fibrotic markers is enhanced 
upon secretion of TGF-β1 [120]. One possible explanation for the protection from renal interstitial 
fibrosis in Nlrp-3-deficient mice could be an interaction between NLRP-3 and TGF-β1 signaling. To 
address this, we evaluated the expression of different genes involved in TGF-β1 signaling in kidneys 
of WT, Nlrp-3-deficient and zVAD-treated mice. The mRNA expression levels of Tgf-β1, TgfβRI 
and R-SMADs (Smad 2 and Smad 3) were significantly higher in WT and zVAD-treated mice after 
UUO compared to the controls. No difference, however, was noted between WT and zVAD-treated 
mice. The lack of Nlrp-3 resulted in a decrease in mRNA expression of these genes compared to the 
WT and zVAD-treated group, although no significance was observed (Figure 23 A).  
We then hypothesized that the inflammasome component NLRP-3 might have a direct relation with 
TGF-β1 signaling. This has been suggested in other studies from our group [153]. Western blot 
analysis of SMAD 2/3 and phosphorylated SMAD 2 in WT, zVAD-treated and Nlrp-3-deficient 
mouse kidneys were performed. WT, zVAD-treated and Nlrp-3-deficient mouse kidneys revealed no 
difference in protein expression of SMAD 2/3 after UUO surgery. Nevertheless, protein expression 
of phosphorylated SMAD 2 was significantly reduced in Nlrp-3-deficient mice compared to the WT 
and zVAD-treated groups (Figures 23 B-D). These results suggest that NLRP-3, and not the NLRP-3 
inflammasome activation, regulates SMAD 2 phosphorylation in mice after 10 days UUO, and  
therefore reducing tubulointerstitial fibrosis. 
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Figure 23: NLRP3 but not caspase-1 modulates TGF-β1 signaling. C57BL/6 mice from WT (n = 7) and zVAD-
treated (n = 7) mice underwent UUO surgery and were sacrificed at day 10. Kidney sections of mice without UUO (n = 
7) were used as control. (A) MRNA expression levels of Tgf-β1, TgfβRI, Smad2, Smad 3 and Smad 4 in kidneys in WT, 
zVAD-treated mice and Nlrp-3-/- mice after 10 days UUO. Gene expression is shown as x-fold increase of the target 
gene over the 18s mRNA expression. (C) Western blot analysis of Smad 2/3 protein and phosphorylated Smad 2 in WT, 
zVAD-treated and Nlrp-3-deficient mice after 10 days UUO compared with contra lateral kidneys respectively. (D) 
Quantification of Smad 2/3 protein expression relative to β-actin expression in western blot. (E) Quantification of 
phosphorylated Smad 2 protein expression relative to β-actin expression in western blot. These results represent the mean 
± SEM of one out of two independent experiments.  Abb.: C: contra lateral, U: UUO, Ctrl: control mice, WT: wild type 
mice, zVAD: treatment with pan caspase inhibitor zVAD. *p<0.05, **p<0.01. 
WT 
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3.1.2 Chronic oxalate nephropathy model 
The UUO animal model does not mimic human chronic kidney disease, as it only assesses the renal 
pathological features and none of the functional abnormalities. Therefore, we designed an alternative 
experiment using the hyperoxaluria and nephrocalcinosis-induced CKD animal model. This model 
uses a high-soluble oxalate diet in mice to induce renal disease. It mirrors human CKD more closely, 
as it leads to structural as well as functional alterations of advanced kidney disease. Recent studies 
from our group demonstrated that this model is appropriate for studying CKD in C57BL/6 mice, 
causing also the uremic and cardiovascular complications that are observed in CKD patients [163]. 
The next set of experiments was performed to evaluate the role of the inflammasome components 
NLRP3 and ASC in the chronic oxalate diet-induced CKD murine model.  
3.1.2.1 High oxalate diet-induced CKD promotes expression of inflammasome components  
In order to assess inflammasome activation upon a high oxalate diet-induced CKD, we first analyzed 
mRNA expression levels of the inflammasome components Nlrp-3, Asc, Casp-1 and pro-IL-1β in 
kidneys of WT mice after 14 days of a high oxalate diet in comparison to control mice, which 
received a normal diet. As shown in figure 24 A the mRNA expression levels of the inflammasome 
components were significantly up-regulated in hyperoxaluric mice compared to control mice, 
suggesting an important role of the NLRP3 inflammasome in hyperoxaluria and nephrocalcinosis-
induced CKD. 
      
 Figure 24: NLRP3-inflammasome axis is up-regulated in high-oxalate induced CKD. C57BL/6 WT mice (n = 4) 
were fed with a high-soluble oxalate diet for 14 days. Controls without oxalate diet (n = 4) were used as reference. (A) 
The mRNA expression levels of inflammasome components Nlrp-3, Asc, Casp-1 and pro-IL-1β are significantly increased 
in WT mice after 14 days of oxalate diet compared to control mice (without an oxalate diet). Gene expression is shown as 
x-fold increase of the target gene over the 18s mRNA expression. These results represent the mean ± SEM of one out of 
two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, Nlrp-3-/-: Nlrp-3 deficient mice, Asc-/-: Asc 
deficient mice *p<0.05, **p<0.01. 
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3.1.2.2 Nlrp-3- and Asc-deficient hyperoxaluric mice do not develop oxalate nephropathy 
Recently published data had suggested that NLRP3 plays an important role in the development of 
hyperoxaluria induced CKD [177]. Nevertheless, mice lacking Nlrp-3 were unable to develop 
nephrocalcinosis upon a 14-day oxalate-rich diet [177]. Our previous mRNA expression data showed 
that the NLRP3 inflammasome axis is up-regulated in WT mice after a 14-day high-soluble oxalate 
diet. To verify the role of NLRP3 and ASC in hyperoxaluria-induced CKD, age and gender-matched 
C57BL/6 WT, Nlrp-3- and Asc-deficient mice were fed a high-soluble oxalate diet for 14 days or 
received a control diet, without oxalate.  
Initial assessment of the kidney function parameters plasma BUN and plasma creatinine on day 0 
and day 14 (prior to sacrifice), revealed significantly higher levels in WT mice on day 14 compared 
to controls, whereas Nlrp-3- and Asc-deficient mice showed no elevation of these parameters. This 
finding was consistent with the previously published data on Nlrp-3-deficient mice [177] and further 
corroborated it for Asc-deficient mice (Figure 25 A). In order to exclude a possible protection of 
these mice due to altered intestinal oxalate absorption, oxalate concentration levels were measured in 
plasma and urine of WT, Nlrp-3- and Asc-deficient mice on day 0 and day 14. Quantification 
analysis of plasma oxalate levels showed no significant difference on day 14 between all groups with 
a high oxalate diet. Urinary oxalate excretion, on the other hand, was significantly higher in Nlrp-3-
deficient mice compared to WT mice. Asc-deficient mice showed a similar trend as the Nlrp-3-
deficient group, although no significant difference was achieved (p=0,057) (Figure 25 A). These 
findings suggest that there is no alteration in the intestinal oxalate intake of the mutant mouse strains.  
Subsequently, intrarenal crystal deposition was assessed using Pizzolato staining. Here, kidney 
sections of oxalate-fed WT mice revealed a marked intrarenal crystal deposition compared to the 
control group. Whereas Nlrp-3- and Asc-deficient mice did not display any crystal deposition (Figure 
25 B and C).  
Renal injury and inflammation: The level of tubular injury in mice after 14 days of a high oxalate 
diet was assessed using tubular injury scoring in PAS-stainings from kidney sections. WT mice 
presented a marked tubular injury with a significant damage of the tubular architecture compared to 
the control group (Figure 26 A and B). In contrast, Nlrp-3- and Asc-deficient mice were completely 
protected from renal injury (Figure 26 B). mRNA expression of the kidney injury marker Kim-1 
significantly increased in WT mice compared to the control group, an expression which was absent 
in both mutant mouse strains (Figure 26 C). Additionally, immunostainings of the 
macrophage/monocyte marker F4/80 and the T-lymphocyte marker CD3 showed a significant 
A 
B 
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infiltration of these cells in hyperoxaluric WT mice compared to the controls (Figure 26 D-F). No 
infiltration of immune cells was observed in Nlrp-3-/- and Asc-/- mouse kidneys.   
 
 
Figure 25: A high-soluble oxalate-rich diet does not induce hyperoxaluria-related CKD in mice lacking Nlrp-3 or 
Asc despite high levels of plasma and urine oxalate. C57BL/6 mice of WT (n = 4), Nlrp-3-/- (n = 4) and Asc-/- (n = 4) 
were fed with high soluble oxalate diet for 14 days. Controls without oxalate diet (n = 4) were used as reference. (A) BUN 
(left) and Creatinine (right) in mg/ml were measured in the plasma of mice at day 0 previous to oxalate intake and day 14 
(results in mean ± SEM). (B) Oxalate concentration in µmol/l was measured in plasma (left) and urine (right) of mice at 
day 0 previous to oxalate intake and day 14 (results in mean ± SEM). (C) Crystal deposition shown with Pizzolato staining 
of kidney sections from mice after 14 days of high oxalate diet was compared to controls. (D) Quantification of crystal 
deposition in Pizzolato staining after 14 days oxalate diet (results in % area ± SEM). No crystal deposition is observed in 
Nlrp-3- and Asc-deficient mouse kidneys. These results represent one out of two independent experiments. Abb.: Ctrl: 
control mice, WT: wild type mice, Nlrp-3-/-: Nlrp-3 deficient mice, Asc-/-: Asc deficient mice *p<0.05, **p<0.01. 
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Figure 26:  Nlrp-3- and Asc-deficient mice do not develop hyperoxaluria-related CKD, and hence no renal 
injury and inflammation.  C57BL/6 mice of WT (n = 4), Nlrp-3-/- (n = 4) and Asc-/- (n = 4) were fed with a high-
soluble oxalate diet for 14 days. Controls without oxalate diet (n = 4) were used as reference. (A) PAS-stainings from 
kidney sections of Ctrl, WT, Nlrp-3-/- and Asc-/- mice.  (B) Quantification analysis using tubular injury scoring show 
a complete protection in Nlrp-3- and Asc-deficient mice compared to WT mice. (C) MRNA expression levels of 
kidney injury marker Kim-1 was quantified with RT-PCR. Gene expression is shown as x-fold increase of the target 
gene over the 18s mRNA expression. (D) Immunohistochemistry of monocyte/macrophage marker F/480 and (E) T-
lymphocyte marker CD3 of kidney sections from ctrl, WT, Nlrp-3-/- and Asc-/-. (F) Quantification analysis of F4/80 
and CD3 positive areas respectively (results in mean area % ± SEM). These results represent the mean ± SEM of one 
out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, Nlrp-3-/-: Nlrp-3 deficient mice, 
Asc-/-: Asc deficient mice.  *p<0.05; **p<0.01  
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Interstitial fibrosis: Renal interstitial fibrosis was assessed using immunohistochemistry of α-SMA 
and collagen I in kidney sections of mice after 14 days of a high oxalate diet. Here, a marked 
deposition of these proteins was observed in the renal interstitium of WT mice compared to the 
controls.  Whereas Nlrp-3- and Asc-deficient mice were completely protected from deposition of 
both matrix proteins (Figures 27 A-C). Accordingly, expression profiling of the fibrosis markers 
fibronectin, col1a1 and col4a1 showed a significantly higher expression in oxalate-fed WT mice 
compared to controls, Nlrp-3-/- and Asc-/- mouse kidneys. mRNA expression of the epithelial 
marker e-cadherine was highly expressed in Nlrp-3-deficient mice compared to the WT mice, which 
correlated with the reduced tubular damage and preserved epithelial architecture (Figure 27 D).  
These findings showed that hyperoxaluric mice lacking Nlrp-3 or Asc do not display intrarenal 
calcium oxalate crystal deposition after a high-soluble oxalate diet, and consequently do not develop 
nephrocalcinosis-related CKD. This phenomenon was observed despite elevated plasma and urine 
oxalate levels in both mutant mouse strains, thus excluding an alteration in intestinal oxalate 
absorption.    
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Figure 27: Mice lacking Nlrp-3 or Asc do not develop hyperoxaluria-related CKD and thus, no renal 
tubulointerstitial fibrosis. C57BL/6 mice of WT (n = 4), Nlrp-3-/- (n = 4) and Asc-/- (n = 4) were fed with a high 
soluble oxalate diet for 14 days. Controls without oxalate diet (n = 4) were used as reference. (A) Immunohistochemical 
analysis of myofibroblasts marker α-SMA and (B) collagen I from kidney sections and (C) quantification analysis of α-
SMA  and collagen I positivity shows increased deposition of both proteins in WT mouse kidneys compared to controls, 
Nlrp-3-/- and Asc-/- mice. Results are shown in mean of % area ± SEM. (D) MRNA expression levels of fibronectin, α-
SMA, col1a1, col4a1, epithelial marker e-cadherine were quantified with RT-PCR. Gene expression is shown as x-fold 
increase of the target gene over the 18s mRNA expression. These results represent the mean ± SEM of one out of two 
independent experiments.Abb.: Ctrl: control mice.*p<0.05, **p<0.01;***p<0.001. 
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3.1.2.3 Inhibition of IL-1 receptor with anakinra does not improve renal function in mice with 
hyperoxaluria-induced CKD  
The assessment of the NLRP3 inflammasome using the hyperoxaluria and nephrocalcinosis-induced 
CKD mouse model in Nlrp-3- and Asc-deficient mice was limited due to the lack of intrarenal 
calcium oxalate crystal deposition in both mutant mouse strains. Therefore, a new experiment was 
designed. C57BL/6 mice were fed a high-soluble oxalate diet while receiving a treatment with the 
IL-1 receptor antagonist anakinra or a vehicle. This recombinant IL-1r antagonist inhibits the effects 
of cytokines from the IL-1 family and is extensively used therapeutically for the treatment of 
autoimmune diseases such as rheumatoid arthritis. In order to evaluate the role of the NLRP3 
inflammasome-dependent Il-1β activation in nephrocalcinosis-mediated CKD, C57BL/6 
hyperoxaluric mice were either treated with the recombinant Il-1 receptor antagonist anakinra or a 
vehicle.  
Initial assessment of kidney function parameters in plasma of vehicle and anakinra-treated mice 
showed significantly higher plasma BUN levels in anakinra-treated mice after 14 days of a high 
oxalate diet compared to the vehicle group. On the other hand, plasma creatinine levels in the 
anakinra-treated mice were slightly reduced compared to the vehicle group after 14 days of high 
oxalate diet (Figure 28 A). To rule out an altered intestinal oxalate intake due to anakinra treatment, 
plasma and urine oxalate concentrations were measured on day 0 and day 14.  Plasma oxalate levels 
showed no significant differences between the vehicle- and anakinra-treated mice (Figure 28 B). On 
the other hand, urinary excretion of oxalate was significantly diminished in anakinra-treated mice 
compared to the vehicle group (Figure 28 B).  
Subsequently, crystal deposition was assessed using Pizzolato staining in kidney sections of 
hyperoxaluric mice and compared to controls. Quantification analysis revealed a marked deposition 
of calcium oxalate crystals in kidneys of both vehicle- and anakinra-treated mice with no significant 
difference between the groups (Figure 28 C).  
These results show that in contrast to the mutant mouse strains, IL-1 receptor inhibition does not 
influence intrarenal calcium oxalate crystal deposition. More importantly, these findings suggest that 
inhibition of IL-1 receptor does not protect mice from renal function impairment in nephrocalcinosis-
induced CKD.   
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Figure 28: Il-1 receptor inhibition does not protect mice from hyperoxaluria-induced CKD. C57BL/6 mice received 
a vehicle (n = 4) or anakinra (n = 4) treatment and were fed a high soluble oxalate diet for 14 days. Mice without oxalate 
diet were used as controls (n = 4). (A) BUN (left) and plasma creatinine (right) in mg/ml were measured in plasma of 
mice at day 0 previous to oxalate intake and day 14 (results in mean ± SEM). (B) Oxalate concentration in µmol/l was 
measured in plasma (left) and urine (right) of mice at day 0 previous to oxalate intake and day 14 (results in mean ± 
SEM). (C) Quantification analysis of crystal deposition in kidney sections after 14 high-soluble oxalate diet. (D) 
Pizzolato staining of kidney sections from mice after 14 days of high oxalate diet was compared to controls. These results 
represent the mean ± SEM of one out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, 
BUN: blood urea nitrogen *p<0.05, **p<0.01;***p<0.001 
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3.1.2.4 IL-1 receptor inhibition does not protect mice from kidney injury in hyperoxaluria-
induced CKD 
Renal pathological features were assessed in the vehicle- and anakinra-treated mice after 14 days of a 
high-soluble oxalate diet compared to a control diet. PAS staining of kidney sections revealed 
increased renal injury in both vehicle- and anakinra-treated mice compared to controls (Figure 29 A 
and B). Pathological scoring revealed no significant differences between the vehicle- and the 
anakinra-treated groups (Figure 29 B). The mRNA expression of the kidney injury marker Kim-1 
was significantly increased in both vehicle- and anakinra-treated mice compared to controls but no 
significant difference was evidenced between the hyperoxaluric groups (Figure 29 C). These results 
suggest that Il-1 receptor inhibition does not protect mice from renal injury upon hyperoxaluria and 
nephrocalcinosis-induced CKD. 
        
 
 
 
Figure 29: Anakinra treatment does not protect mice from tubular injury. C57BL/6 mice of WT (n = 4) were 
given a vehicle (n = 4) and anakinra (n = 4) treatment simultaneously to a high-soluble oxalate diet for 14 days. Mice 
without oxalate diet (n = 4) were used as controls. (A) PAS stainings of kidney sections from ctrl, vehicle- and 
anakinra-treated mice. Arrows indicate dilated and injured tubules. (B) Quantification analysis using tubular injury 
scoring of kidney sections after 14 days high-soluble oxalate diet. (C) MRNA expression level of kidney injury marker 
Kim-1 was quantified using RT-PCR. Results are shown as Kim-1 to 18s ratio in fold increase. These results represent 
one out of two independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, *p<0.05, **p<0.01; 
***p<0.001 
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3.1.2.5 IL-1 receptor inhibition reduces macrophage and Th-lymphocytes infiltration in 
hyperoxaluria-induced CKD, but does not protect mice from renal interstitial fibrosis. 
Our previous results suggested that IL-1r inhibition does not protect mice from a high oxalate diet-
induced CKD.  
In order to evaluate the effects of anakinra in renal inflammation, we performed 
immunohistochemical analysis of the macrophage/monocyte marker F4/80 and the Th-cell receptor 
marker CD3 of kidney sections. These showed less F4/80+ macrophages in anakinra-treated mice 
compared to the vehicle-treated mice (Figure 30 A and B). In addition, Th-cell infiltration was 
reduced in anakinra-treated mice compared to vehicle-treated mice. These findings indicate that 
anakinra treatment reduces renal inflammation in mice upon a high oxalate diet-induced CKD.   
Furthermore, renal interstitial fibrosis was assessed using immunohistochemical analysis of 
myofibroblasts marker α-SMA and the ECM protein collagen I. Interestingly, both anakinra- and 
vehicle-treated mice showed a high deposition of α-SMA and collagen I in the renal interstitium 
(Figure 31 A-D). Quantification analysis revealed significantly less deposition of α-SMA in 
anakinra-treated mice compared to the vehicle-treated mice. Collagen deposition, on the other hand, 
was increased in anakinra-treated mice compared to the vehicle-treated group (Figure 31 C and D). 
Additionally, mRNA expression profiling of the profibrotic markers α-SMA, col1a1, col4a1, 
fibronectin, FSP, vimentin and the epithelial marker e-cadherin, did not show any significant 
difference in their expression levels when comparing anakinra-treated vs. vehicle-treated 
hyperoxaluric mice. Overall, both groups showed increased expression of these markers compared to 
controls. Taken together, these results indicate that IL-1 receptor blockade with anakinra reduced 
renal interstitial inflammation in mice with a high oxalate diet-induced CKD, but this did not prevent 
mice from developing a progressive renal interstitial fibrosis. The findings point to an IL-1 signaling-
independent mechanism in the pathogenesis of hyperoxaluria- and nephrocalcinosis-induced CKD. 
  
To further understand the mechanisms leading to this effect, TGF-β signaling was evaluated in 
hyperoxaluric mice after a 14-day high-soluble oxalate diet. The mRNA expression levels of TGF-
β1, TGF-R1, TGF-R2, CTGF and PDGF were assessed in anakinra- and vehicle-treated mice and 
revealed a significant increase in both hyperoxaluric mice compared to control mice, without any 
significant differences between the hyperoxaluric groups (Figure 31 F). In summary, we conclude 
that IL-1β-mediated IL-1receptor signaling is not essential for the development of renal interstitial 
fibrosis in hyperoxaluria-induced CKD. 
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Figure 30: IL-1 receptor inhibition protects mice from renal inflammation in hyperoxaluria related CKD. 
C57BL/6 vehicle- (n = 4) and anakinra-treated mice (n = 4) were fed a high-soluble oxalate diet for 14 days. Mice 
without oxalate diet were used as controls (n = 4). (A) Immunohistochemical analysis of the macrophage/monocyte 
marker F4/80 in kidney sections and (B) quantification of F4/80 positivity reveals a significant reduction in macrophage 
deposition in the anakinra-treated group. (C) Immunohistochemical analysis of T-lymphocyte marker CD3 in kidney 
sections and (D) quantification of CD3 positivity (results in % area ± SD) corroborates the previous findings.  These 
results represent the mean ± SEM of one out of two independent experiments. These results represent one out of two 
independent experiments. Abb.: Ctrl: control mice, WT: wild type mice, *p<0.05, **p<0.01; ***p<0.001 
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Figure 31: Il-1 receptor inhibition does not protect mice from tubulointerstitial fibrosis in hyperoxaluria-related 
CKD. C57BL/6 mice of vehicle- (n = 4) and anakinra-treated mice (n = 4) were fed a high soluble oxalate diet for 14 
days. Mice without oxalate diet were used as controls (n = 4). (A) Immunohistochemical analysis of myofibroblasts 
marker α-SMA in kidney sections and (B) quantification of α-SMA positivity showed increased deposition in vehicle- 
and anakinra-treated mice. (C) Immunohistochemical analysis of ECM protein collagen I in kidney sections and (D) 
quantification of collagen I deposition show a significantly increased deposition in the anakinra-treated group. Results are 
shown in mean of % area ± SEM.  (E) mRNA expression levels of profibrotic markers α-SMA, Col1a1, Col4a1, 
Fibronectin, FSP, Vimentin and epithelial marker e-cadherine were quantified with RT-PCR. (F) MRNA expression 
levels of TGF-β-signaling markers TGF-β1, TGF-R1, TGF-R2, CTGF and PDGF were quantified with RT-PCR. Gene 
expression is shown as x-fold increase of the target gene over the 18s mRNA expression. These results represent the 
mean ± SEM of one out of two independent experiments. Abb.: Ctrl: control mice*p<0.05, **p<0.01;***p<0.001 
 
 
  
91 
 
3.2 In vitro studies 
 
The NLRP3 inflammasome was primarily known for its role in inflammation. Hence, current studies 
have mainly focused on characterizing its function in inflammatory cells such as DC’s and 
macrophages. Our previous in vivo described results suggest that the NLRP3 inflammasome is also 
essential for the development and progression of renal fibrogenesis.  
Given these observations and since fibroblasts are the main cells responsible for fibrosis, we 
performed several in vitro experiments using fibroblast (the main matrix-producing cells in fibrotic 
diseases) and evaluated the role of the NLRP3 inflammasome in the function of these cells.  
 
3.2.1 NIH-3t3 fibroblast express NLRP3 and its expression augments upon stimulation with 
LPS and TGF-β1 
We first tested whether fibroblasts express the inflammasome component NLRP3. For this, NIH-3t3 
cells were pre-treated with NLRP3 inflammasome-inducer LPS and the potent profibrotic cytokine 
TGF-β1. 
Western blotting and mRNA analysis of NIH-3t3 cells showed expression of Nlrp-3 at both mRNA 
and protein level, which increased upon stimulation with LPS (Figure 32 A and C). Additional 
stimulation with mouse TGF-β1 showed a further increase in mRNA expression of Nlrp-3 in the 
NIH-3t3 cell line (Figure 32 A and B). These results demonstrated that Nlrp-3 is expressed in LPS-
stimulated NIH-3t3 cells and that this was further enhanced following TGF-β1 stimulation.  
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Figure 32: NIH-3t3 cells express NLRP-3 upon induction. NIH-3t3 cells were stimulated with LPS (100 ng/ml) and 
mTGF-β1 (10 ng/ml) for 2 and 8 hrs respectively.  (A and B) Total mRNA was isolated and Nlrp-3 expression was 
quantified with real time polymerase chain reaction (RT-PCR). Data are expressed as Nlrp-3/18s ratio in fold increase. 
(C) Total protein was isolated from NIH-3t3 cells after stimulation with LPS (100 ng/ml) for 24 hrs. Nlrp-3 expression 
was determined by western blot analysis. β-actin was used as control. (D) Quantification analysis of western blotting 
reveals a significant increase in Nlrp-3 expression after stimulation with LPS. Results are shown as Nlrp-3/β-actin ratio. 
These values represent one out of two independent experiments. Abb.:  med: medium, LPS: lipopolysacharide, TGF-β1: 
transforming growth factor beta 1. *p<0.05 
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3.2.2 LPS and TGF-β increased the expression of profibrotic and inflammasome genes in NIH-
3t3 fibroblasts in a time-dependent manner. 
Production of ECM components is the main function of fibroblasts. In order to assess whether 
NLRP3 is implicated in ECM production, we evaluated its expression and the expression of 
profibrotic markers in NIH-3t3 cells. For this, fibroblasts were stimulated with LPS and mouse TGF-
β1 simultaneously and then harvested at different time points (6, 18 and 24 hrs). mRNA expression 
levels of the profibrotic markers α-SMA, collagen I (Col-1a1), and fibronectin were significantly 
increased after 18 hrs of stimulation (Figure 33 A). This correlated with the expression of Nlrp-3, 
which also showed an expression peak after 18 hrs stimulation. However, no significant difference 
was achieved compared to the controls (Figure 33 B). Whereas Asc and Casp-1 mRNA expression 
did not show the same time-dependent correlation (Figure 33 B). These results imply a positive 
correlation between the expression of profibrotic markers and Nlrp-3 upon stimulation with LPS and 
mouse TGF-β1 in NIH-3t3 cells.  
 
 
 
                     
Figure 33: Profibrotic markers are expressed in a time dependent manner and correlate with the expression of 
inflammasome components in NIH-3t3fcells  NIH-3t3 cells were incubated with DMEM medium (med) and stimulated 
with LPS (100 ng/ml) and mouse TGF-β1 (10 ng/ml) for 6, 18 and 24 hrs (A) Total mRNA was isolated and quantified 
with RT-PCR. Expression of α-SMA, collagen I (Col-1a1) and fibronectin was increased after stimulation in a time 
dependent manner. (B) Total mRNA expression of inflammasome components Nlrp-3, Asc, and casp-1 in NIH-3t3 cells 
was analyzed with RT-PCR after stimulations. Data are expressed as x-fold increase of the target gene over the 18s 
mRNA expression. These values represent one out of two independent experiments. Abb.: med: medium, LPS: 
lipopolysacharide, TGF-β1: transforming growth factor beta 1.*p<0.05. 
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3.2.3 NIH-3t3 cells proliferate independently of Casp-1  
Previous experiments demonstrated that the inflammasome component NLRP3 is present in NIH-3t3 
cells, together with ASC and Casp-1. Additionally, expression of profibrotic markers was 
significantly increased after stimulation with LPS and mouse TGF-β1, suggesting a correlation with 
Nlrp-3 expression. However, whether these effects depend on inflammasome activation and Casp-1-
mediated Il-1β release is not yet clear. To address this question, the proliferation rate of native NIH-
3t3 fibroblasts that were pretreated with pan-caspase inhibitor zVAD was analyzed after stimulation 
with LPS and mouse TGF-β1. ZVAD is a well-known caspase inhibitor with low cell toxicity and 
ideal for studies investigating caspase activity in cells. Both groups were stimulated with LPS and 
mouse TGF-β1 for 24 hrs and analyzed using MTT assay.  
As predicted, NIH-3t3 cells showed a significant increase in their ability to proliferate upon 
treatment with LPS or LPS in combination with mouse TGF-β1, which was independent of Casp-1 
inhibition with zVAD. These results suggest that Casp-1 activation does not play a role in the 
proliferative capacity of NIH-3t3 fibroblasts (Figure 34 A).  
      
 
 
 
                       
 
Figure 34 A: Proliferation of NIH-3t3 cells is caspase 1 independent. NIH-3t3 cells were incubated with DMEM for 
24 hrs. Medium was exchanged and the zVAD pre-treated group received (30 mM) pan-caspase inhibitor zVAD. Both 
groups were stimulated with LPS (100 ng/ml) and/or mouse TGF-β1 (10 ng/ml) for 24 hrs. MTT proliferation assay was 
performed and quantified with ELISA Reader at 490 nm. Results represent light absorbance in fold increase. Significant 
increase in proliferation rate was observed in both groups after stimulation with LPS or TGF-β1. These values represent 
one out of two independent experiments.Abb.: med: medium, LPS: lipopolysacharide, TGF-β1: transforming growth 
factor beta. *p<0.05,**p<0.01.  
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3.2.4 LPS and TGF-β1 stimulation increase Nlrp-3 expression in primary mouse embryonic 
fibroblasts  
To further evaluate the function of NLRP3 in cells, primary MEFs were isolated from C57Bl6 WT 
and Nlrp-3-deficient mice. mRNA expression of Nlrp-3 was quantified in WT pMEFs, which 
showed a significant increase after stimulation with LPS and mouse TGF-β1 alone or in combination 
(Figure 35 A). Consequently, western blot analysis revealed the presence of Nlrp-3 protein in WT 
pMEFs and confirmed the lack of Nlrp-3 protein in Nlrp-3-deficient mice. Quantification analysis of 
western blot studies showed a significant increase of the Nlrp-3 protein expression in WT pMEFs 
when primed with LPS (Figure 35 B and C). These results confirm the presence of Nlrp-3 in pMEFs, 
which is also inducible upon stimulation with LPS and/or mouse TGF-β1.  
 
 
                            
                                                                                  
 
 
                             
Figure 35: Expression of Nlrp-3 in pMEFs. PMEFs were isolated from WT and Nlrp-3-/- C57Bl6 mouse embryos at the 
13th day of gestation, with posterior cultivation in DMEM for 48 hrs. (A) Total mRNA from WT pMEFs was isolated and 
quantified by RT-PCR after stimulation with LPS (100 ng/ml) and mouse TGF-β1 (10 ng/ml) for 2 and 8 hrs respectively.  
Data are shown as Nlrp-3/18s ratio in fold increase. (B) Western blotting was used to show Nlrp-3 protein expression in 
WT and Nlrp-3-/- pMEFs upon stimulation with LPS (100 ng/ml) for 24 hrs. (C) Quantification analysis of the western 
blot shows a significant increase in Nlrp-3 expression of pMEFs after stimulation with LPS. β-actin was used as a control. 
Results are shown as Nlrp-3/β-actin ratio. These values represent one out of two independent experiments. Abb.: med: 
medium, LPS: lipopolysacharide, TGF-β1: transforming growth factor beta 1. β-actin: beta actin. n.d.: not detectable. 
*p<0.05, **p<0.01. 
 
  
96 
 
3.2.5 LPS and TGF-β1 stimulation increased profibrotic gene expression in WT pMEFs and 
not in Nlrp-3-deficient pMEFs  
In order to evaluate the role of NLRP3 in pMEFs, mRNA expression levels of profibrotic markers 
were analyzed in WT and Nlrp-3-deficient pMEFs.  Cells were stimulated with the inflammasome 
inducer LPS (signal 1) and/or activator ATP (signal 2) together with the profibrotic cytokine mouse 
TGF-β1. Expression profiling of the profibrotic markers α-SMA, col1a1, col4a1 and fibronectin 
showed a significant increase in these markers after stimulation with LPS and TGF-β1, or LPS 
together with ATP and TGF-β1 in WT pMEFs. This effect was absent in pMEFs lacking Nlrp-3 
(Figure 36). In fact, Nlrp-3-deficient cells stimulated with LPS and mouse TGF-β1 expressed 
significantly less α-SMA, col1a1, col4a1 and fibronectin compared to the WT group (Figure 36). 
Furthermore, analysis of TGF-β1 dependent markers such as CTGF (Ctgf), MMP-9(Mmp-9) and 
VEGF (Vegf) that are crucial for fibrogenic processes, revealed a significant increase in the mRNA 
expression in WT pMEFs after stimulation with LPS and mouse TGF-β1. Whereas stimulated 
pMEFs from the Nlrp-3-deficient mice did not up-regulate the mRNA expression levels of the 
profibrotic genes (Figure 37 A).   
Further, analysis of genes involved in TGF-β1 signaling such as TGF receptor 1 (TGFβRI), TGF 
receptor 2 (TGFβRII) and R-SMADs (Smad2 and Smad3) showed a trend towards increased mRNA 
expression in WT pMEFs after stimulation with LPS and mouse TGF-β1, unlike Nlrp-3-deficient 
pMEFs, where no such trend was observed. However, these results did not show significant 
differences between the phenotype groups (Figure 37 B). Expression of the inflammation markers 
IL-6 and IL-1 receptor (IL-1r) was analyzed in WT and Nlrp-3-deficient pMEFs after stimulation 
with ATP, LPS and mouse TGF-β1. Both IL-6 and IL-1 receptor expression were significantly 
higher in stimulated WT pMEFs compared to Nlrp-3-deficient pMEFs (Figure 38).  
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Figure 36: LPS and TGF-β1 stimulation increases profibrotic gene expression in WT pMEFs and not in Nlrp-3-
deficient pMEFs. PMEFs from WT and Nlrp-3-/- mice were primed with LPS (100 ng/ml), ATP (5 mM) and mouse TGF-
β1 (10 ng/ml) for 2, 5 and 18 hrs respectively. (A) Total mRNA expression of α-SMA, fibronectin, col1a1 and col4a1 was 
quantified with RT-PCR. Graphs show a significant increase in the expression of these genes after stimulation with LPS 
and TGF-β1 in WT pMEFs, difference which was absent in Nlrp3-/- pMEFs. Results are shown as x-fold increase of the 
target gene over the 18s mRNA expression.  These values represent one out of two independent experiments. Abb.: α-
SMA: α smooth muscle protein, Fib: fibronectin , col1a1: collagen 1a1 and col4a1: collagen 4a1, med: medium, LPS: 
lipopolysacharide,  ATP: adenosinetriphosphate, TGF-β1: transforming growth factor beta 1. *p<0.05, **p<0.01  
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Figure 37: LPS and TGF- β1 stimulation increased TGF-β1-dependent gene expression in WT pMEFs and not in 
Nlrp-3- deficient pMEFs. PMEFs from WT and Nlrp-3-/- mice were primed with LPS (100 ng/ml), ATP (5 mM) and 
mouse TGF-β1 (10 ng/ml) for 2, 5 and 18 hrs respectively. (A) Total mRNA expression was quantified with RT-PCR. 
TGF-β1 dependent genes such as Vegf, Mmp-9, Ctgf; and genes involved in TGF-β1 signaling, (B) TGFβRI and TGFβRII, 
Smad2 and Smad3 expression showed a marked increase in WT pMEFs compared to Nlrp-3 -/- pMEFs. Data are expressed 
x-fold increase of the target gene over the 18s mRNA expression. These values represent one out of two independent 
experiments. Abb.: Vegf: vascular endothelial growth factor, Mmp-9: Matrix metalloproteinase 9, Ctgf: connective tissue 
growth factor, TGFβRI: TGF-β receptor 1, TGFβRII: TGF-β receptor 2.  med: medium, LPS: lipopolysacharide, ATP: 
adenosinetriphosphate, TGF--β1: transforming growth factor beta 1. *p<0.05 , **p<0,01 
Figure 38: LPS and TGF- β1 stimulation increased proinflammatory gene expression in WT pMEFs and not in 
Nlrp-3- deficient pMEFs. PMEFs from WT and Nlrp-3-/- mice were primed with LPS (100 ng/ml), ATP (5 mM) and 
mouse TGF-β1 (10 ng/ml) for 2, 5 and 8 hrs respectively. (A) Total mRNA expression was quantified with RT-PCR. Gene 
expression of proinflammatory cytokine IL-6 and receptor IL-1R and were analyzed in both groups, showing a significant 
increase of these markers in WT pMEFs compared to the Nlrp-3-/- group. Data are expressed as x-fold increase of the 
target gene over the 18s mRNA expression.  These values represent one out of two independent experiments. Abb.: IL-1r 
Interleukin-1 receptor, IL-6: interleukin 6.  med: medium, LPS: lipopolysacharide,  ATP: adenosinetriphosphate, TGF--β1: 
transforming growth factor beta 1. *p<0.05 , **p<0,01 
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Finally, immunofluorescence microscopy was used to determine the expression of α-SMA in WT 
and Nlrp-3-deficient pMEFs after stimulation with mouse TGF-β1 (Figure 39 A). Although both 
groups showed increased expression and conformational changes upon TGF-β1stimulation, 
quantification analysis of α-SMA positivity revealed that WT pMEFs significantly increased the 
expression of α-SMA compared to Nlrp-3-deficient pMEFs (Figure 39 B).  
Taken together, these results suggest that lack of Nlrp-3 diminishes profibrotic and proinflammatory 
marker expression in pMEFs, thus regulating their activation and function as main ECM producers. 
 
 
 
 
 
 
                         
 
 
Figure 39: TGF-β1 stimulation increased α-SMA expression in WT pMEFs and not in Nlrp-3-deficient pMEFs. 
PMEFs from WT and Nlrp-3-/- mice were primed with mouse TGF-β1 (10ng/ml) for 24 hrs (A) Immunofluorescence 
staining of αSMA in WT and Nlrp-3-/- pMEFs after stimulation with mouse TGF-β1. (B) Quantification of α-SMA 
positive areas in cells shows a significant increase in WT pMEFs and not in Nlrp-3-/- pMEFs. Data are shown as mean % 
area in fold increase. These values represent one out of two independent experiments. *p<0.05 ,**p<0.01 
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3.2.6 TGF-β induced proliferation of pMEFs involves NLRP3 and ASC 
Previous results imply that NLRP3 plays an important role in the expression of profibrotic genes in 
pMEFs. Fibrosis development involves not only the expression of ECM proteins but also the 
proliferation of fibroblasts.  
We, therefore, analyzed whether the inflammasome components NLRP3 and ASC are involved in 
the proliferation of pMEFs. To address this, MTT proliferation assays were performed. WT and 
Nlrp-3-deficient pMEFs were stimulated with different doses of mouse TGF-β1 for 48 hrs. Figure 40 
A shows that both groups proliferated significantly upon TGF-β1 stimulation; however Nlrp-3-
deficient pMEFs were unable to achieve such a high proliferation rate as WT pMEFs. The 
significantly reduced proliferative ability in Nlrp-3-deficient pMEFs was observed in all groups, 
independent of the TGF-β1 dose (Figure 40 A). Furthermore, a similar study including WT, Nlrp-3- 
and Asc-deficient pMEFs, revealed similar results showing a significantly higher proliferation rate in 
WT pMEFs compared to the Nlrp-3 and Asc-deficient groups (Figure 40 B). Altogether, these results 
suggest that Nlrp-3 or Asc-deficiency reduces fibroblast proliferation.                                  
 
 
 
 
 
 
Figure 40: TGF-β1-induced pMEF proliferation involves NLRP3 and ASC. (A) WT and Nlrp-3-/- pMEFs were 
cultured and stimulated with TGF-β1 in a dose dependent manner (10 ng/ml, 25 ng/ml, 50 ng/ml) respectively. After 48 
hrs stimulation, MTT-proliferation assay was performed and absorbance was measured with ELISA reader at 490 nm. 
Significant increase in the proliferation rate is observed in stimulated WT and Nlrp-3-/- pMEFs, although Nlrp-3-/- 
pMEFs showed significantly less proliferation when compared to WT cells. (B) MTT-proliferation assay shows 
proliferation of WT, Nlrp-3-/- and Asc-/- pMEFs upon stimulation with mouse TGF-β1 (10 ng/ml and 50ng/ml). 
Significant increase in proliferation is observed in the WT group compared to the Nlrp-3-/- and Asc-/- pMEFs. Data is 
shown in fold increase. These values represent one out of two independent experiments. Abb.: TGF-β1: transforming 
growth factor β1.*p<0.05 , **p<0.01 
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3.2.7 NIH-3t3 fibroblasts and pMEFs do not release IL-1β 
All the previously described experiments indicated that the inflammasome components NLRP3 and 
ASC play an important role in the regulation of fibroblasts proliferation and ECM production. 
Nevertheless, an inflammasome activation and thus Casp-1-dependent IL-1β cleavage cannot be 
excluded. The experiments in figure 20 suggested that NIH-3t3 fibroblasts proliferation did not 
depend on the Casp-1-mediated IL-1β cleavage and thus excluding an inflammasome-dependent 
NLRP3 signaling for the proliferation of these fibroblasts.  Moreover, the secretion of IL-1β by 
fibroblasts has not yet been defined, as several opposing findings have been reported [178-180]. 
Therefore, we designed an experiment to detect IL-1β secretion from NIH-3t3 cells, WT pMEFs and 
Nlrp-3-deficient pMEFs upon inflammasome stimulation. Bone marrow dendritic cells (BMDCs) 
were used as a control. Cells were primed with LPS (signal 1) and ATP (signal 2) for 24 hrs and 
supernatants analyzed for inflammasome-dependent IL-1β release using ELISA detection kit. Results 
did not show any detectable production of IL-1β in NIH-3t3, WT pMEFs or Nlrp-3-deficient pMEFs, 
compared to BMDCs, which produced large amounts of IL-1β upon priming with LPS and ATP. 
This indicates that the lack of IL-1β secretion in pMEFs is due to a Casp-1-independent role of 
NLRP3 in fibroblast proliferation, ECM production and thus in fibrogenesis.    
 
                       
                                         
 
 Figure 41: NIH-3t3 fibroblasts and pMEFs do not secrete IL-1β.  NIH-3t3 cells, WT pMEFs, Nlrp-3-/- and BMDCs 
were primed with LPS (100ng/ml) and ATP (5mM) for 24 hrs.  Supernatant was then analyzed with IL-1β enzyme-linked 
immnosorbent assay (ELISA) and quantified using ELISA Reader with a 490nm absorbance filter. Cytokine production 
was not detectable in NIH-3t3, WT pMEFs or Nlrp-3-/- pMEFs compared to primed BMDCs. Data is presented in pg/ml. 
These values represent one out of two independent experiments. Abb.: Med: medium, ATP: adenosinetriphosphate, LPS: 
lipopolysacharide. BMDCs: Bone marrow dendritic cells *p<0,05 
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4. Discussion 
CKD is the result of progressive nephron loss aggravated by a prolonged inflammatory response, 
which in time enhances an exaggerated mesenchymal healing process, tissue remodeling and 
extensive scaring of the renal interstitium. This overshooting inflammatory response comprises the 
release of DAMPs, cytokines and chemokines that further promote a persistent damage of functional 
tubular epithelial cells, which consequently die. This epithelial leak undergoes a tissue-repair  
process, which predominantly involves the accumulation and proliferation of resident kidney 
fibroblast and the recruitment of bone-marrow fibroblasts or, to a lesser extent, a phenotype change 
of the tubular epithelial cells turning them into fibroblasts (a process called EMT) [181]. Finally, the 
exaggerated fibroblast accumulation and ECM deposition result in a significant renal interstitial 
fibrosis [181-183]. The exact molecular mechanisms and signaling pathways involved in this 
process, especially the role of the innate immunity and PRRs are of particular interest in the 
scientific community today [184, 185]. 
The cytosolic NLRP3 inflammasome is a PRR capable of recognizing a wide variety of ligands 
presented in form of PAMPs and DAMPs. This multiprotein complex acts as a platform for Casp-1 
activation, leading to the proteolytic cleavage and activation of IL-1β and IL-18 [56, 186, 187]. A 
variety of diseases have been associated with this complex including hereditary syndromes (CAPS) 
and other much more common acquired pathologies such as atherosclerosis and diabetes mellitus 
[56, 186, 187]. The kidney has not been an exception to this. Strong evidence advocates an important 
role of the NLRP3 inflammasome in kidney pathologies, including AKI [144, 147] and CKD [137, 
152]. Its contribution to kidney disease has been mainly associated with the extensive activation of 
IL-1β and IL-18, and thus exaggerated inflammatory response. However, recent data suggested a 
novel inflammasome-independent role of NLRP3, i.e. regardless of Casp-1-mediated IL-1β and IL-
18 release [138, 153, 188].  
This study complements the recent findings regarding an inflammasome-independent role of NLRP3 
in renal fibrogenesis by augmenting TGF-β receptor signaling independent of Casp-1-mediated IL-
1β release.  
The main questions in this study were:  
1. What role do NLRP3 and ASC play in renal interstitial fibrosis in vivo? Are these effects 
exclusively related to a reduced Casp-1-mediated IL-1β release? 
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2. What is the role of NLRP3 or ASC in hyperoxaluria and nephrocalcinosis-induced CKD? Does 
their contribution to the pathogenesis of hyperoxaluria-induced CKD rely entirely on the IL-1-
mediated IL-1 receptor activation?  
3. Do fibroblasts as main protagonists of fibrogenic processes express NLRP3? If yes, does that 
influence their function and proliferation in an inflammasome-dependent or independent 
manner? 
 
4.1 NLRP3 and ASC in the UUO model  
The results in this thesis revealed that mice lacking NLRP3 resulted in reduced renal injury, 
inflammation and interstitial fibrosis upon UUO, which was consistent with recently published data 
by Vilaysane et al. [152]. We reported less tubular injury and less infiltration of inflammatory cells 
(monocyte/macrophages), whereas the infiltration of T-lymphocytes was not significantly impaired 
in mice lacking NLRP3. Similar results have been observed by other groups showing that the number 
of CD3+ T-lymphocytes did not significantly change in a model of autoimmune encephalomyelitis in 
Nlrp-3-deficient mice [189]. NLRP3 is also essential for the development of interstitial fibrosis as 
evidenced by reduced collagen I and α-SMA deposition in mice lacking NLRP3. 
The protective effects of NLRP3 deficiency observed in our experiments are consistent with a 
recently published paper by Guo H. et al. [190]. In this study, they demonstrated in a time-dependent 
manner that the expression of the NLRP3 inflammasome components and interleukin release 
increases in WT mice upon UUO, an effect, which was abolished in mice lacking NLRP3 [190]. 
Both Vilaysane et al. [152] and Guo H. et al. [190] proposed the reduced inflammasome-dependent 
cytokine maturation as the leading mechanism protecting Nlrp-3-deficient mice from renal injury, 
inflammation and fibrosis upon UUO. Additionally, NLRP3-mediated cytokine release was 
associated with mitochondrial dysfunction in mice upon UUO [190]. This theory was supported in 
other murine models of renal injury such as albumin-induced renal injury and 5/6 nephrectomy [191-
193]. On the other hand, studies using an aldosterone-induced renal injury model indicated that 
mitochondrial dysfunction involves increased ROS production triggering the activation of the 
NLRP3 inflammasome, thus leading to tubular cell injury [194, 195].  
But the fact that tubular epithelial cells do not secrete IL-1β  in spite of expressing the inflammasome 
components NLRP3, ASC and Casp-1 [138] suggests that other mechanisms, which do not involve a 
cytokine-mediated injury are involved in this process. This is also supported by studies which 
showed that the protective effects observed in Nlrp-3-deficient mice were not only due to less 
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infiltration of inflammatory cells but also due to reduced NLRP3 expression in renal parenchymal 
cells [152]. 
In this thesis, we propose a novel mechanism that involves an inflammasome-independent function 
of NLRP3 in the development of renal injury upon UUO. To prove this, mice were treated with the 
pan-caspase inhibitor zVAD, thus inhibiting the proteolytic activation of IL-1β and IL-18. ZVAD-
treated mice also showed significant protection compared to non-treated mice regarding tissue injury 
and interstitial inflammation. However, the protective effect in mice lacking NLRP3 went beyond 
the effects observed in zVAD-treated mice. Also, renal interstitial fibrosis was partially ameliorated 
in zVAD-treated mice, but collagen I deposition did not differ between the WT and zVAD-treated 
group. Our results highly suggest that further interleukin-independent mechanisms contribute to the 
development of CKD. 
But the link between IL-1-independent NLRP3 signaling is still not well understood. Some studies 
regarding inflammasome-independent mechanisms have suggested that the NLRP3 regulates TGF-β 
receptor signaling [138, 153]. Consequently, we tested this hypothesis in mice upon UUO. Our data 
revealed that phosphorylation of the TGF receptor signaling components SMAD 2/3 was 
significantly reduced in Nlrp-3-deficient mice compared to zVAD-treated mice upon UUO, 
indicating that NLRP3 augments SMAD 2/3 phosphorylation, a mechanism that does not involve 
Casp-1-mediated IL-1 release.   
It is worth mentioning that while our studies were ongoing another group proposed a mechanism 
involving both mitochondrial dysfunction and regulation of TGF-β signaling by the NLRP3 in an 
inflammasome-independent manner [180], whereby the inflammasome component NLRP3 (most 
likely through its NACHT domain) promoted R-SMAD signaling during fibroblast activation in 
cardiac fibroblasts. Interestingly, NLRP3 was found to be localized to the mitochondria without 
evidencing any translocation in the process of myofibroblast activation. Additionally, mitochondrial 
ROS production strongly correlated with NLRP3 expression. It is not clear whether ROS-mediated 
mitochondrial dysfunction is regulated by NLRP3 activation, or whether NLRP3-mediated 
mitochondrial ROS production regulates SMAD2 phosphorylation in TGF-β signaling. 
Furthermore and contrary to our data, a recent in vitro study using HPTCs (human proximal tubular 
cells) showed that prolonged stimulation with TGF-β1 resulted in an initial increase of NLRP3 
expression on day 3 followed by a subsequent decrease 7 days after stimulation with TGF-β1 [141]. 
The stimulation of HPTCs with TGF-β1 also resulted in a phenotypical change associated with a loss 
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of the epithelial markers ZO-1 and E-cadherin as well as increased expression of the mesenchymal 
markers α-SMA and SMAD2/3 nuclear translocation. Kidney biopsies from patients with severe 
IgA-nephropathy revealed an increased expression of NLRP3 in the tubular epithelium compared to 
normal kidneys, whereby the α-SMA positive areas did not co-localize with NLRP3 in the renal 
interstitial area, thus rejecting the presence of NLRP3 in myofibroblasts [141]. Nevertheless, these 
findings might be related only to cells undergoing phenotypical changes such as fibroblasts that 
originated from TECs (accounting only for approximately 5% of the renal myofibroblasts that 
contribute to renal interstitial fibrosis) [181]. Furthermore, the role of the NLRP3 may vary 
according to the cell type as proven in studies involving NLRP3-mediated hepatocyte pyroptosis 
[196] and NLRP3-mediated fibroblast activation, as shown in this thesis. Contrary to many other 
findings an increased NLRP3 expression was associated with a better clinical outcome in patients 
with IgA nephropathy [141]. 
However, our hypothesis has been supported by several other studies. Our group found that Nlrp-3- 
and Asc-deficient lupus mice had a marked lymphoproliferative syndrome and worsening of the 
clinical outcome as well as lupus nephritis, an effect that resulted from the regulation of TGF-β 
signaling by the inflammasome component NLRP-3, which was not mediated by interleukin release 
[153].   
Interestingly, similar effects were also observed Asc-deficient mice, which also presented less tubular 
injury and interstitial fibrosis upon UUO despite the increase in F4/80+ macrophage numbers in Asc-
deficient mouse kidneys. On the other hand, the precise role of ASC in regulating renal interstitial 
fibrosis remains unclear. Komanda T. et al. indicated a significant protection from renal injury, 
interstitial inflammation and fibrosis in Asc-deficient mice upon UUO [197]. Moreover, this group 
remarked the importance of ASC in renal collecting duct cells, as the expression of ASC was 
significantly up-regulated upon UUO [197]. The protective effects in Asc-deficient mice were most 
probably a result of IL-1β releasing collecting duct cells, as shown in in vitro experiments, whereby 
LPS and ATP were used to prime and activate the inflammasome leading to IL-1β secretion in 
collecting duct cells [197].    
Together, we conclude that the inflammasome component NLRP3 modulates renal interstitial 
inflammation and fibrosis in obstructive nephropathy via regulation of TGF-β receptor signaling, an 
effect that goes beyond inflammasome activation by involving a novel inflammasome-independent 
NLRP3 signaling pathway.  
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4.2 The NLRP3 inflammasome and the Chronic Oxalate Model 
As previously mentioned in the introduction, the UUO mouse model has several limitations in 
mimicking human CKD. Therefore, we used an alternative CKD mouse model: the chronic oxalate-
induced CKD mouse model. This model has been established in our laboratory as described 
thoroughly in chapter 1.6 [163].  
Previous studies from our laboratory described a role for the NLRP3 inflammasome in a model of 
acute calcium oxalate crystal-induced kidney injury [64], whereby calcium oxalate crystals trigger an 
inflammatory response associated with the activation of signaling pathways including the NLRP3 
inflammasome. Additionally, these crystals induce tubular cell death leading to release of DAMPs, 
alarmins, proteases as well as other proinflammatory mediators, which are sensed by resident 
immune cells and parenchymal cells, augmenting the inflammatory response [198]. Mononuclear 
phagocytes and resident DCs can ingest calcium oxalate crystals that consequently lead to lysosomal 
leakage and activation of the NLRP3 inflammasome. Tubular epithelial cells on the other hand also 
express NLRP3 but are unable to produce IL-1β [138, 188, 199]. In this regard, mice lacking Nlrp-3, 
Asc- or Casp-1 were protected from calcium oxalate-induced AKI. This was also the case following 
IL-1 blockade with anakinra, which resulted in reduced renal damage upon injury, indicating that 
oxalate nephropathy-induced AKI mostly relies on the intrarenal inflammatory response from 
resident mononuclear cells and DCs [64].  
In a model of chronic oxalate-induced nephropathy, Knauf F. et al. found that Nlrp-3-deficient mice 
were also protected as indicated by a normal renal pathology compared to WT mice [164]. This renal 
protective effect was due to the lack of intrarenal calcium oxalate crystal deposition in Nlrp-3-
deficient mice. However, the role of ASC, Casp-1 and IL-1β were not assessed in this study. 
Therefore, we performed experiments using Asc- as well as Nlrp-3-deficient mice in a murine model 
of hyperoxaluria-induced CKD. As predicted, Nlrp-3- and Asc-deficient mice did not show any 
differences in the renal functional parameters compared to the WT group due to the lack of intrarenal 
calcium oxalate crystal deposition, in spite of elevated plasma and urine oxalate levels. Contrary to 
the acute oxalate nephropathy model [64], mutant mouse strains were unable to develop 
nephrocalcinosis in a chronic oxalate model of CKD.  
According to Knauf et al. the increased intrarenal crystal deposition observed in WT mice upon a 
high-soluble oxalate diet is a product of a vicious cycle between oxalate-induced systemic 
inflammation and progression of kidney disease. They argue that reduced GFR in WT mice (product 
of a systemic inflammation due to elevated plasma-oxalate levels) impedes oxalate excretion, thus 
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leading to accumulation of plasma-oxalate and further progression of CKD [164, 200]. Our findings 
showed no relevant differences in the plasma oxalate concentration between the groups, but did show 
differences in the urinary oxalate concentrations, which were higher in Nlrp-3- and Asc-deficient 
mice compared to the WT mice.  More importantly, our findings show that Nlrp-3- and Asc-deficient 
mice did not develop nephrocalcinosis despite hyperoxaluria, and hence no nephrocalcinosis-induced 
renal inflammation, fibrosis and thus no CKD. The lack of intrarenal calcium deposition in Nlpr-3- 
and Asc-null mice precludes the assessment of the role of these proteins in hyperoxaluria and 
nephrocalcinosis-induced CKD.  
One possible explanation for this phenomenon involves the presence of passenger mutations in 
genetically modified congenic mice, which confound the interpretation of experiments performed in 
these knockout mice [201]. Most genetically modified mouse strains are generated by germline 
transmission competent embryonic stem cells derived from the 129 mouse strain. In order to avoid 
passenger mutations flanking the gene, these mice are backcrossed to another particular mouse strain 
such as C57BL/6J, which reduces the probability of passenger mutations, although not excluding 
them completely [201]. A study performed by Kayagaki et al. demonstrated that the profound 
protection observed in Casp-1-deficient mice against lethal LPS challenge was due to an inactivating 
passenger mutation in the Casp-11 gene [202]. Whether this is also the case for Nlrp-3- and Asc-
deficient mice is not known. Certainly, both mutant mouse strains are not appropriate for the study of 
hyperoxaluria and nephrocalcinosis-induced CKD and thus an inflammasome-dependent or 
independent function of the NLRP3 cannot be assessed in this model. 
In order to overcome this genetic issue, C57BL/6N mice with nephrocalcinosis were treated with the 
IL-1 receptor antagonist anakinra or a vehicle. Surprisingly, anakinra-treated mice with 
nephrocalcinosis showed a significant elevation of plasma BUN (similar to the vehicle-treated mice) 
but decreased plasma creatinine levels compared to the vehicle-treated mice, whereby intrarenal 
crystal deposition revealed no significant differences between both groups. It is important to note 
that the reduced urine oxalate concentrations observed in anakinra-treated mice correlated with 
increased accumulation of crystals in the renal parenchyma compared to vehicle-treated mice. No 
convincing explanation could be given to this finding. In contrast, mice deficient in IL-1 receptor 
were protected from acute calcium oxalate-induced kidney injury [64], indicating that the IL-1 
receptor-mediated inflammatory response is crucial in AKI.  
Furthermore, assessment of renal injury revealed no significant differences between anakinra- and 
vehicle-treated mice, whereas the inflammatory response associated with macrophage infiltration and 
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Th-cell infiltration into the kidneys was significantly less in anakinra-treated mice implying a certain 
degree of protection. Surprisingly, anakinra treatment did not protect mice from renal interstitial 
fibrosis. Although histological analysis revealed a reduction in the intrarenal α-SMA expression in 
anakinra-treated mice compared to the vehicle group, collagen I deposition was significantly higher 
in the anakinra group compared to vehicle-treated mice. An explanation for this difference has not 
yet been found, as both parameters are known to positively correlate with the degree of renal 
interstitial fibrosis [203]. Consequently, assessment of the TGF-β receptor signaling pathway in 
hyperoxaluric mice upon anakinra treatment revealed no significant difference compared to the 
vehicle-treated mice, ruling out a link between the IL-1 receptor and the TGF-β receptor signaling 
pathway. Interestingly, the reduced inflammatory response observed upon anakinra treatment did not 
influence the profibrotic mechanisms induced by chronic hyperoxaluria. Taken together, these 
findings suggest that the NLRP3 inflammasome-IL-1-axis is not involved in hyperoxaluria and 
nephrocalcinosis-induced CKD. Unfortunately, differentiating whether these results are a product of 
an inflammasome-dependent or independent mechanism is currently impossible.  
Recently, a novel NLRP3 inflammasome inhibitor called CP-456,773 was tested in crystal-induced 
CKD animal models [204]. Ludwig-Portugall et al. demonstrated that early application of CP-
456,773 in mice upon adenine- or oxalate-induced nephropathy results in significant protection from 
renal interstitial fibrosis and progressive CKD. Unfortunately, the delayed application of the 
compound, which was associated with a significant reduction of IL-1 concentrations, could not 
resolve renal interstitial fibrosis [204]. The in vivo data indicated a novel approach in preventing 
crystal-induced nephropathy and its complications by using CP-456,773. Also, the results from this 
study suggest that NLRP3 and ASC can mediate crystal-induced chronic kidney injury and 
interstitial fibrosis through mechanisms, which do not imply inflammasome-dependent, i.e. Casp-1-
mediated IL-1β release and modulation of TGF-β downstream signaling.  
 
4.3 Fibroblasts and the NLRP3 inflammasome  
The presence of NLRP3 in non-immune cells has been extensively reported [140, 173 [138, 205], but 
its role in these cells is not completely understood as most of them do not secrete IL-1β. Wang et al. 
reported that tubular epithelial cells from humans and mice express NLRP3 and that its expression 
was induced upon TGF-β1 stimulation [138]. This was surprising as TGF-β is known for inducing 
epithelial cell apoptosis and exerting potent anti-inflammatory functions [131]. Interestingly, the 
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increased expression of NLRP3 correlated with the degree of phenotypical differentiation of TECs. 
Based on these findings, we investigated whether fibroblasts as main protagonists of fibrogenic 
processes needed the NLRP3 inflammasome for their function and proliferation. LPS-primed NIH-
3t3 cells and pMEFs revealed that NLRP3 expression was inducible in fibroblasts and that this 
correlated with increased fibroblast activation and expression of profibrotic markers. Proliferation of 
pMEFs was dependent on NLRP3 and ASC. The degree of myofibroblast activation and expression 
of ECM components upon TGF-β1 stimulation was decreased in cells lacking NLRP3, supporting 
previous studies performed in other fibroblasts including gingival and cardiac fibroblasts, where the 
latter also enhanced NLRP3 expression upon stimulation with TGF-β1 [143, 180]. Stimulation of 
pMEFs with the inflammasome complex activator ATP did not influence the activation and function 
of fibroblasts. Consequently, caspase inhibition had no effect on the proliferative ability of NIH-3t3 
cells, excluding an inflammasome-dependent effect on the proliferative ability of fibroblasts. This 
was further corroborated by the non-detectable production of IL-1β in NIH-3t3 cells and pMEFs 
when compared to BMDCs. Other studies performed in cardiac fibroblasts claim that these cells can 
produce IL-1β [206], although further studies on cardiac fibroblasts revealed that these cells produce 
negligible amounts of this cytokine compared to other inflammatory cells such as macrophages or 
DCs [180]. These results suggest that fibroblasts may produce small amounts of IL-1β in a rather 
secondary manner. Several fibroblast subsets have been described previously where functional 
differences should not be ignored [103, 207] due to the tissue- and environment-specific activity of 
these cells. It is important to note that while our studies were ongoing, Bracey N. et al. published 
similar results in the heart [180]. They show in both in vitro and in vivo studies the involvement of 
the NLRP3 inflammasome in cardiac fibrosis and refer to the inflammasome-independent signaling 
pathway of NLRP3. Using cardiac fibroblasts, in vitro experiments demonstrate that NLRP3 
regulates their differentiation into myofibroblasts in a Casp-1-independent manner [180].  
In conclusion, we show that the inflammasome component NLRP3 is pivotal for fibroblast 
activation, function and proliferation, and that this effect relies mainly on the regulation of TGF-β1 
signaling and not on the caspase-1-mediated interleukin release. 
 
Further research supported this theory and found an inflammasome-independent, non-canonical role 
for NLRP3. Recently, Wang H. et al. revealed that NLRP3 is required for EMT in colon cancer cells, 
a response that is independent of Casp-1-mediated IL-1β secretion [208]. They also reported that this 
effect was dependent on the activation of NF-κB signaling and regulated the expression of Snail 
[208]. Additionally, caspase-11 (equivalent in mice to caspase-4 and caspase-5 in humans) induces 
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NLRP3 inflammasome activation [186], whereby intracellular LPS binds to caspase-11 via 
Guanylate-binding proteins (GBPs) for the activation and cleavage of Gasdermine D, leading to 
pyroptotic cell death. Caspase-11-induced non-canonical NLRP3 activation has shown to be related 
to K+ efflux [202]. Furthermore, Chung H. et al. reported a novel non-canonical pathway for NLRP3 
involving the regulation of a non-canonical platform for caspase-8 activation during epithelial cell 
apoptosis [209]. They propose that NLRP3 and ASC form a platform for activating caspase-8 
mediated type II apoptosis in tubular epithelial cells. These effects vary from cell type to cell type 
and the localization of the NLRP3 in the cell might also be pivotal, e.g. NLRP3 localizes mostly to 
the cytosol in macrophages, but mainly to the mitochondria in TECs. Thus suggesting that NLRP3 
acts in a cell-context-specific manner balancing between inflammation and cell death [209].   
 
4.4 Study limitations 
The limitations of the current thesis are among others that most of the in vitro studies were 
performed in pMEFs instead of using renal fibroblasts. Whether renal fibroblasts behave in a similar 
manner like pMEFs is not addressed in this thesis. Also, the possible effects of IL-18 could not be 
evaluated in these cells.  
Furthermore, using zVAD for in vivo studies is rather unspecific for the inhibition of caspases, i.e. 
other caspase-specific functions such as regulation of apoptosis were probably also influenced in this 
study, but could not be directly assessed. Another limitation involving the use of anakinra as IL-1 
receptor inhibitor was the limited quantification of the inhibitory effect on the IL-1 receptor, which 
could not be directly assessed in this thesis. The reduced inflammatory responses observed in the 
study already suggest an effect of anakinra, although a direct quantification was not possible. A 
study using a dose-dependent anakinra application in vivo could be supportive in this manner. 
Nevertheless, the assessment of this was beyond the aims of this study.  
As described before the lack of intrarenal calcium oxalate crystal deposition in hyperoxaluric Nlrp-3- 
and Asc-deficient mice made it impossible to assess the role of these proteins in mice with 
nephrocalcinosis.  
Finally, experiments performed in mice only reflect to a limited extent human disease, due to the 
genetic and pathophysiological differences between both species.  
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4.5 Conclusion and further perspectives 
The results of this thesis identify NLRP3-TGF-β receptor signaling as a novel pathomechanism 
involved in renal fibrogenesis and CKD progression. From a therapeutic perspective, blocking 
NLRP3 is a potential target that can abrogate the inflammasome-dependent as well as -independent 
functions, and thus preventing the inflammatory and fibrotic response in CKD.  
Figure 42 shows a schematic representation of the proposed mechanism involving the regulation of 
the TGF-β receptor signaling pathway by NLRP3. Hence, the novel NLRP3 inflammasome 
inhibitors viz. β-hydroxybutyrate [210], glyburide[211], parthenolide, Bay11_7082 [212] and 
MCC950 (or CP-456773) [213] could be used as potential therapeutic approaches for CKD.  
 
 
Figure 42: Schematic representation of the modulation of NLRP3-mediated TGF-β receptor signaling. Stimulation with 
PAMPs, DAMPs and TGF-β induces NLRP3 activation. Increased expression of NLRP3 enhances Smad2/3 
phosphorylation augmenting TGF-β signaling and thus the production of profibrotic proteins (Collagen I, -III, 
Fibronectin) and other profibrotic growth factors.  
Abb.: ASC: Apoptosis-associated speck-like protein containing a CARD  NLRP3: Nod-like receptor protein 3, TGF-β: 
transforming growth factor beta 1, PAMP: pathogen-associated molecular patterns, DAMP: damage-associated 
molecular patterns, Smad 2/3/4: Mothers Against Decapentaplegic Homolog 2,3 and 4, P: phosphor group, TGF R 1/2: 
transforming growth factor beta receptor 1 and 2. 
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5. Abbreviations 
AKI Acute kidney injury 
AP Alkali phosphatase 
APC Antigen presenting cell 
ASC Apoptosis-associated speck-like protein containing a CARD 
ATP Adenosine triphosphate 
BMP Bone morphogenic protein 
BUN Blood urea nitrogen 
C57Bl6 C57 black 6 
CAPS Cryopyrin associated periodic syndromes 
Casp-1 Caspase 1 
CCL2 chemokine (C-C motif) ligand 2 
CD3 Cluster of differentiation 3 
CKD Chronic kidney disease 
CTGF Connecting tissue growth factor 
CXCL2 Chemokine (C-X-C motif) ligand 2 
DAMPs Danger associated molecular patterns 
DCs Dendritic cells 
ECM Extracellular matrix 
ECS Extracellular space 
ED-A FN ED-A Fibronectin 
EMT Epithelial to mesenchymal transition 
EndMT Endothelial to mesenchymal transition 
EPO Erythropoietin 
ERK Extra-cellular signal regulated kinases 
ESRD End stage renal disease 
GFR Glomerular filtration rate 
H2O2 Hydrogen peroxide 
IL-(1, 6, 8,18) Interleukin (1, 6, 8, 18) 
INF Interferon 
IRI Ischemia reperfusion injury 
KDIGO Kidney Disease: Improving Global Outcomes (KDIGO) 
KDOQI Kidney Disease Outcomes Quality Initiative 
KIM 1 Kidney injury molecule 1 
LPS Lipopolysaccharide 
LTA Lipoteichoic acid 
LTBP Latent TGF-β Binding Protein 
MCP-1 Monocyte chemotactic protein 1 
mRNA Messenger Ribonucleic acid 
NLR NOD like receptor 
NLRP3 NOD like receptor binding PYD 3 
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NOD nucleotide-binding oligomerization domain 
P2X7 P2X Purigenic receptor 7  
PAMPs Pattern associated molecular patterns 
PAS Periodic acid shiff 
PDGF Platelet derived growth factor 
pMEFs Primary Mouse embryonic fibroblasts 
PRRs Pattern recognition receptors 
PTH Parathormon 
RAAS Rennin-Angiotensine-aldosteron-system 
SMAD Mothers Against Decapentaplegic Homolog  
STZ Streptozotocin 
TECs Tubular epithelial cells 
TGF-β Transforming growth factor β 
TIMPs Tissue inhibitor metalloproteinases 
TNF-α Tumor necrosis factor α 
UTI Urinary tract infection 
UTO Urinary tract obstruction 
UTP Uridine triphosphate 
UUO Unilateral ureteral model 
VEGF Vascular endothelial growth factor 
zVAD 
Pan caspase inhibitor: carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]- fluoromethylketone 
α/Π-GST α/π – Gluthation-S-transferase 
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